primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
129222712,12922271,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Hypoglycaemia,,2018,Q1,2,F,20161023.0,20180110.0,20161108,20180110,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-071266",BOEHRINGER INGELHEIM,,41.0,YR,,M,Y,101.0,KG,20180110.0,,MD,CA,CA,2018,Q1,Adult
130111942,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Albumin urine present,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Hypertension,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Red blood cell count increased,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Albumin urine present,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Hypertension,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Red blood cell count increased,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130111942,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,2,F,20160810.0,20180209.0,20161208,20180216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20180216.0,,MD,JP,JP,2018,Q1,Adult
130681783,13068178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body,,2018,Q1,3,F,20160624.0,20180313.0,20161228,20180320,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001679",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,80.6,KG,20180320.0,,MD,JP,JP,2018,Q1,Adult
130681783,13068178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,3,F,20160624.0,20180313.0,20161228,20180320,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001679",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,80.6,KG,20180320.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Blood ketone body increased,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Blood uric acid increased,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Red blood cell count increased,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Blood ketone body increased,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Blood uric acid increased,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Red blood cell count increased,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
133797573,13379757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,3,F,20160701.0,20180316.0,20170328,20180327,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-44874NB",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,83.6,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
138071954,13807195,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"250 MG, QD",,,,,,,,250.0,MG,,QD,2018,Q1,Asthenia,,2018,Q1,4,F,201707.0,20170718.0,20170728,20180125,PER,,US-AMGEN-USASL2017101365,AMGEN,,62.0,YR,A,M,Y,98.87,KG,20180125.0,,MD,US,US,2018,Q1,Adult
138071954,13807195,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"250 MG, QD",,,,,,,,250.0,MG,,QD,2018,Q1,Dehydration,,2018,Q1,4,F,201707.0,20170718.0,20170728,20180125,PER,,US-AMGEN-USASL2017101365,AMGEN,,62.0,YR,A,M,Y,98.87,KG,20180125.0,,MD,US,US,2018,Q1,Adult
138071954,13807195,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"250 MG, QD",,,,,,,,250.0,MG,,QD,2018,Q1,Dizziness,,2018,Q1,4,F,201707.0,20170718.0,20170728,20180125,PER,,US-AMGEN-USASL2017101365,AMGEN,,62.0,YR,A,M,Y,98.87,KG,20180125.0,,MD,US,US,2018,Q1,Adult
138071954,13807195,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"250 MG, QD",,,,,,,,250.0,MG,,QD,2018,Q1,Headache,,2018,Q1,4,F,201707.0,20170718.0,20170728,20180125,PER,,US-AMGEN-USASL2017101365,AMGEN,,62.0,YR,A,M,Y,98.87,KG,20180125.0,,MD,US,US,2018,Q1,Adult
138071954,13807195,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"250 MG, QD",,,,,,,,250.0,MG,,QD,2018,Q1,Hyperhidrosis,,2018,Q1,4,F,201707.0,20170718.0,20170728,20180125,PER,,US-AMGEN-USASL2017101365,AMGEN,,62.0,YR,A,M,Y,98.87,KG,20180125.0,,MD,US,US,2018,Q1,Adult
139356712,13935671,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Silent myocardial infarction,,2018,Q1,2,F,20170315.0,20180104.0,20170905,20180105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004988",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,62.0,KG,20180105.0,,MD,JP,JP,2018,Q1,Adult
139963342,13996334,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body,,2018,Q1,2,F,20161025.0,20180322.0,20170921,20180328,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005393",BOEHRINGER INGELHEIM,,47.0,YR,,M,Y,85.4,KG,20180328.0,,MD,JP,JP,2018,Q1,Adult
140036662,14003666,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q1,Acute kidney injury,,2018,Q1,2,F,20150807.0,20180220.0,20170922,20180304,PER,,US-JNJFOC-20170913822,JANSSEN,,47.0,YR,A,F,Y,81.65,KG,20180304.0,,CN,US,US,2018,Q1,Adult
140476783,14047678,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Blood ketone body increased,,2018,Q1,3,F,20170805.0,20171228.0,20171005,20180103,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005598",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,73.2,KG,20180103.0,,MD,JP,JP,2018,Q1,Adult
140832182,14083218,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Myocardial ischaemia,,2018,Q1,2,F,20170704.0,20180206.0,20171012,20180209,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005392",BOEHRINGER INGELHEIM,,77.0,YR,,M,Y,55.4,KG,20180209.0,,MD,JP,JP,2018,Q1,Elderly
140886812,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Blood urea increased,,2018,Q1,2,F,20160620.0,20180223.0,20171013,20180302,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20180302.0,,MD,JP,JP,2018,Q1,Adult
140886812,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Haematocrit increased,,2018,Q1,2,F,20160620.0,20180223.0,20171013,20180302,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20180302.0,,MD,JP,JP,2018,Q1,Adult
140886812,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Low density lipoprotein increased,,2018,Q1,2,F,20160620.0,20180223.0,20171013,20180302,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20180302.0,,MD,JP,JP,2018,Q1,Adult
140886812,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Polyuria,,2018,Q1,2,F,20160620.0,20180223.0,20171013,20180302,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20180302.0,,MD,JP,JP,2018,Q1,Adult
140886812,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Red blood cell count increased,,2018,Q1,2,F,20160620.0,20180223.0,20171013,20180302,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20180302.0,,MD,JP,JP,2018,Q1,Adult
140886812,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,2,F,20160620.0,20180223.0,20171013,20180302,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20180302.0,,MD,JP,JP,2018,Q1,Adult
141135736,14113573,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2018,Q1,Bladder neoplasm,,2018,Q1,6,F,20171012.0,20180110.0,20171023,20180117,EXP,,DE-ROCHE-2009932,ROCHE,,69.0,YR,,M,Y,112.0,KG,20180117.0,,MD,DE,DE,2018,Q1,Elderly
141135736,14113573,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2018,Q1,Monoparesis,,2018,Q1,6,F,20171012.0,20180110.0,20171023,20180117,EXP,,DE-ROCHE-2009932,ROCHE,,69.0,YR,,M,Y,112.0,KG,20180117.0,,MD,DE,DE,2018,Q1,Elderly
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Asthenia,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Blood glucose increased,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Blood pressure inadequately controlled,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Cardiac failure,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Contraindicated product administered,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Feeling cold,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Hypotension,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Malaise,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Pain in extremity,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Psychiatric symptom,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Sleep disorder,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
142942047,14294204,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Testicular pain,,2018,Q1,7,F,201710.0,20180307.0,20171217,20180312,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180312.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q1,Adult
143137985,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q1,Angina unstable,,2018,Q1,5,F,20171203.0,20180221.0,20171221,20180307,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20180307.0,,OT,DE,DE,2018,Q1,Elderly
143137985,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q1,Cholecystitis,,2018,Q1,5,F,20171203.0,20180221.0,20171221,20180307,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20180307.0,,OT,DE,DE,2018,Q1,Elderly
143137985,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q1,Infection,,2018,Q1,5,F,20171203.0,20180221.0,20171221,20180307,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20180307.0,,OT,DE,DE,2018,Q1,Elderly
143137985,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q1,Multiple organ dysfunction syndrome,,2018,Q1,5,F,20171203.0,20180221.0,20171221,20180307,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20180307.0,,OT,DE,DE,2018,Q1,Elderly
143137985,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q1,Urosepsis,,2018,Q1,5,F,20171203.0,20180221.0,20171221,20180307,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20180307.0,,OT,DE,DE,2018,Q1,Elderly
143176982,14317698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Gastric cancer,,2018,Q1,2,F,2017.0,20180121.0,20171222,20180126,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007398",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.0,KG,20180126.0,,MD,JP,JP,2018,Q1,Elderly
143176982,14317698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Hypoglycaemia,,2018,Q1,2,F,2017.0,20180121.0,20171222,20180126,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007398",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.0,KG,20180126.0,,MD,JP,JP,2018,Q1,Elderly
143252112,14325211,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2018,Q1,Cardiac failure congestive,,2018,Q1,2,F,20170316.0,20180121.0,20171226,20180124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007517",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,68.0,KG,20180124.0,,MD,JP,JP,2018,Q1,Elderly
143252112,14325211,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,TABLET,QD,2018,Q1,Sinus node dysfunction,,2018,Q1,2,F,20170316.0,20180121.0,20171226,20180124,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007517",BOEHRINGER INGELHEIM,,79.0,YR,,M,Y,68.0,KG,20180124.0,,MD,JP,JP,2018,Q1,Elderly
143288382,14328838,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q1,Inappropriate schedule of drug administration,,2018,Q1,2,F,20161123.0,20180228.0,20171227,20180313,EXP,,PHHY2017GB194284,NOVARTIS,,56.0,YR,,M,Y,93.0,KG,20180313.0,,OT,GB,GB,2018,Q1,Adult
143288382,14328838,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q1,Prostate cancer,,2018,Q1,2,F,20161123.0,20180228.0,20171227,20180313,EXP,,PHHY2017GB194284,NOVARTIS,,56.0,YR,,M,Y,93.0,KG,20180313.0,,OT,GB,GB,2018,Q1,Adult
143396002,14339600,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2018,Q1,Condition aggravated,,2018,Q1,2,F,2015.0,20171228.0,20171230,20180112,EXP,,CZ-AUROBINDO-AUR-APL-2017-48115,AUROBINDO,MAULE P.. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME?. KAZUISTIKY V DIABETOLOGII. 2017;15(3):20-2,51.0,YR,,M,Y,100.0,KG,20180112.0,,MD,CZ,CZ,2018,Q1,Adult
143396002,14339600,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2018,Q1,Diabetes mellitus,,2018,Q1,2,F,2015.0,20171228.0,20171230,20180112,EXP,,CZ-AUROBINDO-AUR-APL-2017-48115,AUROBINDO,MAULE P.. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME?. KAZUISTIKY V DIABETOLOGII. 2017;15(3):20-2,51.0,YR,,M,Y,100.0,KG,20180112.0,,MD,CZ,CZ,2018,Q1,Adult
143396002,14339600,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2018,Q1,Drug ineffective,,2018,Q1,2,F,2015.0,20171228.0,20171230,20180112,EXP,,CZ-AUROBINDO-AUR-APL-2017-48115,AUROBINDO,MAULE P.. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME?. KAZUISTIKY V DIABETOLOGII. 2017;15(3):20-2,51.0,YR,,M,Y,100.0,KG,20180112.0,,MD,CZ,CZ,2018,Q1,Adult
143396002,14339600,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2018,Q1,Treatment failure,,2018,Q1,2,F,2015.0,20171228.0,20171230,20180112,EXP,,CZ-AUROBINDO-AUR-APL-2017-48115,AUROBINDO,MAULE P.. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME?. KAZUISTIKY V DIABETOLOGII. 2017;15(3):20-2,51.0,YR,,M,Y,100.0,KG,20180112.0,,MD,CZ,CZ,2018,Q1,Adult
143414781,14341478,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,,2018,Q1,Diabetes mellitus inadequate control,,2018,Q1,1,I,2015.0,20171218.0,20180102,20180102,EXP,,CZ-IPCA LABORATORIES LIMITED-IPC-2017-CZ-004017,IPCA,MAULE P. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME?. KAZUISTIKY V DIABETOLOGII. 2017;15(3):20-22,51.0,YR,,M,Y,100.0,KG,20180102.0,,MD,CZ,CZ,2018,Q1,Adult
143414781,14341478,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,,,2018,Q1,Treatment failure,,2018,Q1,1,I,2015.0,20171218.0,20180102,20180102,EXP,,CZ-IPCA LABORATORIES LIMITED-IPC-2017-CZ-004017,IPCA,MAULE P. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME?. KAZUISTIKY V DIABETOLOGII. 2017;15(3):20-22,51.0,YR,,M,Y,100.0,KG,20180102.0,,MD,CZ,CZ,2018,Q1,Adult
143420773,14342077,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Carotid artery stenosis,,2018,Q1,3,F,20170815.0,20180307.0,20180102,20180312,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000003",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,64.4,KG,20180312.0,,MD,JP,JP,2018,Q1,Elderly
143420773,14342077,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Malignant neoplasm progression,,2018,Q1,3,F,20170815.0,20180307.0,20180102,20180312,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000003",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,64.4,KG,20180312.0,,MD,JP,JP,2018,Q1,Elderly
143420773,14342077,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Thrombotic cerebral infarction,,2018,Q1,3,F,20170815.0,20180307.0,20180102,20180312,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000003",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,64.4,KG,20180312.0,,MD,JP,JP,2018,Q1,Elderly
143469122,14346912,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,2,F,,20180119.0,20180103,20180201,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-119665,BRISTOL MYERS SQUIBB,KAWAI. A CASE OF DIABETIC KETOACIDOSIS (DKA) IN A PATIENT WHO WAS ON ORAL SODIUM-GLUCOSE LINKED TRANSPORTER (SGLT) 2 INHIBITOR AND EXPERIENCED DISTURBANCE OF CONSCIOUSNESS WHICH WAS NOT ACCOMPANIED BY ABNORMAL HYPERGLYCAEMIA.. THE JOURNAL OF JAPANESE ASSOCIATION FOR ACUTE MEDICINE. 2017;28(9):525,68.0,YR,,F,Y,,,20180201.0,,OT,JP,JP,2018,Q1,Elderly
143485001,14348500,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2018,Q1,Death,,2018,Q1,1,I,,20171220.0,20180103,20180103,EXP,,US-009507513-1801USA000499,MERCK,,60.0,YR,,M,Y,,,20180103.0,,MD,US,US,2018,Q1,Adult
143504061,14350406,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2018,Q1,Pollakiuria,,2018,Q1,1,I,20171219.0,,20180102,20180102,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20180102.0,N,PH,US,US,2018,Q1,Elderly
143558281,14355828,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,, UNKNOWN,,,,,,,2018,Q1,Completed suicide,,2018,Q1,1,I,,20180103.0,20180105,20180105,EXP,,US-ABBVIE-18P-163-2210736-00,ABBVIE,"GUMMIN D, MOWRY J, SPYKER D, ET AL. 2016 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS NATIONAL POISON DATA SYSTEM (NPDS): 34TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2017;1-181.",60.0,YR,,M,Y,,,20180105.0,,MD,COUNTRY NOT SPECIFIED,US,2018,Q1,Adult
143751041,14375104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Chest pain,,2018,Q1,1,I,201704.0,20180102.0,20180111,20180111,EXP,DE-BFARM-17414404,DE-009507513-1801DEU000567,MERCK,,70.0,YR,,F,Y,,,20180111.0,,MD,DE,DE,2018,Q1,Elderly
143751041,14375104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Gastrointestinal carcinoma,,2018,Q1,1,I,201704.0,20180102.0,20180111,20180111,EXP,DE-BFARM-17414404,DE-009507513-1801DEU000567,MERCK,,70.0,YR,,F,Y,,,20180111.0,,MD,DE,DE,2018,Q1,Elderly
143751041,14375104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Lymphadenopathy,,2018,Q1,1,I,201704.0,20180102.0,20180111,20180111,EXP,DE-BFARM-17414404,DE-009507513-1801DEU000567,MERCK,,70.0,YR,,F,Y,,,20180111.0,,MD,DE,DE,2018,Q1,Elderly
143751041,14375104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Neoplasm malignant,,2018,Q1,1,I,201704.0,20180102.0,20180111,20180111,EXP,DE-BFARM-17414404,DE-009507513-1801DEU000567,MERCK,,70.0,YR,,F,Y,,,20180111.0,,MD,DE,DE,2018,Q1,Elderly
143751041,14375104,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Pancreatic disorder,,2018,Q1,1,I,201704.0,20180102.0,20180111,20180111,EXP,DE-BFARM-17414404,DE-009507513-1801DEU000567,MERCK,,70.0,YR,,F,Y,,,20180111.0,,MD,DE,DE,2018,Q1,Elderly
143801461,14380146,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,D,,,,,10.0,MG,,,2018,Q1,Diabetes mellitus inadequate control,,2018,Q1,1,I,2015.0,20171218.0,20180112,20180112,EXP,,CZ-MYLANLABS-2017M1083795,MYLAN,MAULE P.. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME? KAZUISTIKY V DIABETOLOGII.. 2017;15(3):20-2,51.0,YR,,M,Y,100.0,KG,20180112.0,,MD,CZ,CZ,2018,Q1,Adult
143801461,14380146,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,D,,,,,10.0,MG,,,2018,Q1,Treatment failure,,2018,Q1,1,I,2015.0,20171218.0,20180112,20180112,EXP,,CZ-MYLANLABS-2017M1083795,MYLAN,MAULE P.. A FIXED COMBINATION OF A LONG-LASTING INSULIN AND GLP-1 ANALOGUE - A NEW OPTION BEFORE AN INTENSIFIED INSULIN REGIME? KAZUISTIKY V DIABETOLOGII.. 2017;15(3):20-2,51.0,YR,,M,Y,100.0,KG,20180112.0,,MD,CZ,CZ,2018,Q1,Adult
143812801,14381280,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Eye irritation,,2018,Q1,1,I,20170927.0,,20180111,20180111,DIR,,,FDA-CTU,,46.0,YR,,M,N,,,20171122.0,N,PH,US,US,2018,Q1,Adult
143812801,14381280,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Facial paralysis,,2018,Q1,1,I,20170927.0,,20180111,20180111,DIR,,,FDA-CTU,,46.0,YR,,M,N,,,20171122.0,N,PH,US,US,2018,Q1,Adult
143812801,14381280,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Hemiparesis,,2018,Q1,1,I,20170927.0,,20180111,20180111,DIR,,,FDA-CTU,,46.0,YR,,M,N,,,20171122.0,N,PH,US,US,2018,Q1,Adult
143817271,14381727,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Completed suicide,,2018,Q1,1,I,2016.0,20180102.0,20180112,20180112,EXP,,US-GENUS_LIFESCIENCES-USA-POI0580201800071,GENUS LIFESCIENCES,GUMMIN D. 2016 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS NATIONAL POISON DATA SYSTEM (NPDS): 34TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2017 DEC 01;55(10):1072-1254.,60.0,YR,,M,Y,,,20180111.0,,MD,US,US,2018,Q1,Adult
143817452,14381745,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Diabetic coma,,2018,Q1,2,F,20171222.0,20180125.0,20180112,20180129,EXP,,AU-ALLERGAN-1801078US,ALLERGAN,,84.0,YR,,F,Y,,,20180129.0,,CN,AU,AU,2018,Q1,Elderly
143817452,14381745,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Vision blurred,,2018,Q1,2,F,20171222.0,20180125.0,20180112,20180129,EXP,,AU-ALLERGAN-1801078US,ALLERGAN,,84.0,YR,,F,Y,,,20180129.0,,CN,AU,AU,2018,Q1,Elderly
144085581,14408558,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, UNKNOWN",,,D,,,,,,,,,2018,Q1,Completed suicide,,2018,Q1,1,I,,20180102.0,20180118,20180118,EXP,,US-ENDO PHARMACEUTICALS INC-2018-013349,ENDO,"GUMMIN D D, MOWRY J B, SPYKER D A, BROOKS D E, FRASER M O, BANNER W.. 2016 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS^ NATIONAL POISON DATA SYSTEM (NPDS): 34TH ANNUAL REPORT. CLINICAL TOXICOLOGY. 2017;55 (10):1072-1254",60.0,YR,,M,Y,,,20180119.0,,MD,US,US,2018,Q1,Adult
144256621,14425662,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20171223.0,,20180122,20180122,DIR,,,FDA-CTU,,53.0,YR,,F,N,97.7,KG,20180122.0,N,PH,US,US,2018,Q1,Adult
144256621,14425662,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Myalgia,,2018,Q1,1,I,20171223.0,,20180122,20180122,DIR,,,FDA-CTU,,53.0,YR,,F,N,97.7,KG,20180122.0,N,PH,US,US,2018,Q1,Adult
144256621,14425662,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Nausea,,2018,Q1,1,I,20171223.0,,20180122,20180122,DIR,,,FDA-CTU,,53.0,YR,,F,N,97.7,KG,20180122.0,N,PH,US,US,2018,Q1,Adult
144256621,14425662,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Urinary tract infection,,2018,Q1,1,I,20171223.0,,20180122,20180122,DIR,,,FDA-CTU,,53.0,YR,,F,N,97.7,KG,20180122.0,N,PH,US,US,2018,Q1,Adult
144256621,14425662,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q1,Vomiting,,2018,Q1,1,I,20171223.0,,20180122,20180122,DIR,,,FDA-CTU,,53.0,YR,,F,N,97.7,KG,20180122.0,N,PH,US,US,2018,Q1,Adult
144345721,14434572,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2018,Q1,Amnesia,,2018,Q1,1,I,20171110.0,20180112.0,20180124,20180124,EXP,,US-BAUSCH-BL-2018-001460,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20180124.0,,CN,US,US,2018,Q1,Adult
144345721,14434572,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2018,Q1,Chest pain,,2018,Q1,1,I,20171110.0,20180112.0,20180124,20180124,EXP,,US-BAUSCH-BL-2018-001460,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20180124.0,,CN,US,US,2018,Q1,Adult
144345721,14434572,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2018,Q1,Confusional state,,2018,Q1,1,I,20171110.0,20180112.0,20180124,20180124,EXP,,US-BAUSCH-BL-2018-001460,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20180124.0,,CN,US,US,2018,Q1,Adult
144345721,14434572,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,,,TABLET,,2018,Q1,Depression,,2018,Q1,1,I,20171110.0,20180112.0,20180124,20180124,EXP,,US-BAUSCH-BL-2018-001460,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20180124.0,,CN,US,US,2018,Q1,Adult
144532382,14453238,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Off label use,,2018,Q1,2,F,20171206.0,20180130.0,20180129,20180206,EXP,,US-GILEAD-2017-0311955,GILEAD,,67.0,YR,E,M,Y,126.53,KG,20180206.0,,CN,US,US,2018,Q1,Elderly
144532382,14453238,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Sepsis,,2018,Q1,2,F,20171206.0,20180130.0,20180129,20180206,EXP,,US-GILEAD-2017-0311955,GILEAD,,67.0,YR,E,M,Y,126.53,KG,20180206.0,,CN,US,US,2018,Q1,Elderly
144532382,14453238,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Septic shock,,2018,Q1,2,F,20171206.0,20180130.0,20180129,20180206,EXP,,US-GILEAD-2017-0311955,GILEAD,,67.0,YR,E,M,Y,126.53,KG,20180206.0,,CN,US,US,2018,Q1,Elderly
144573882,14457388,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Listless,,2018,Q1,2,F,201707.0,20180314.0,20180130,20180316,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006301",BOEHRINGER INGELHEIM,,57.0,YR,,F,Y,,,20180316.0,,MD,JP,JP,2018,Q1,Adult
144573882,14457388,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Parkinson's disease,,2018,Q1,2,F,201707.0,20180314.0,20180130,20180316,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006301",BOEHRINGER INGELHEIM,,57.0,YR,,F,Y,,,20180316.0,,MD,JP,JP,2018,Q1,Adult
144594814,14459481,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,131597.0,,,TABLET,,2018,Q1,Haemorrhage subcutaneous,,2018,Q1,4,F,20171210.0,20180209.0,20180130,20180214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-003797",BOEHRINGER INGELHEIM,,56.0,YR,,F,Y,69.0,KG,20180214.0,,MD,JP,JP,2018,Q1,Adult
144594814,14459481,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,131597.0,,,TABLET,,2018,Q1,Vomiting,,2018,Q1,4,F,20171210.0,20180209.0,20180130,20180214,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-003797",BOEHRINGER INGELHEIM,,56.0,YR,,F,Y,69.0,KG,20180214.0,,MD,JP,JP,2018,Q1,Adult
144947581,14494758,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNKNOWN",,,U,U,,,,25.0,MG,TABLET,,2018,Q1,Arteriosclerosis,,2018,Q1,1,I,,20180125.0,20180206,20180206,EXP,,IT-ELI_LILLY_AND_COMPANY-IT201801013286,ELI LILLY AND CO,,80.0,YR,,M,Y,,,20180206.0,,CN,IT,IT,2018,Q1,Elderly
144947581,14494758,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNKNOWN",,,U,U,,,,25.0,MG,TABLET,,2018,Q1,Blood glucose abnormal,,2018,Q1,1,I,,20180125.0,20180206,20180206,EXP,,IT-ELI_LILLY_AND_COMPANY-IT201801013286,ELI LILLY AND CO,,80.0,YR,,M,Y,,,20180206.0,,CN,IT,IT,2018,Q1,Elderly
144947581,14494758,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNKNOWN",,,U,U,,,,25.0,MG,TABLET,,2018,Q1,Blood glucose increased,,2018,Q1,1,I,,20180125.0,20180206,20180206,EXP,,IT-ELI_LILLY_AND_COMPANY-IT201801013286,ELI LILLY AND CO,,80.0,YR,,M,Y,,,20180206.0,,CN,IT,IT,2018,Q1,Elderly
144947581,14494758,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNKNOWN",,,U,U,,,,25.0,MG,TABLET,,2018,Q1,Diabetic foot,,2018,Q1,1,I,,20180125.0,20180206,20180206,EXP,,IT-ELI_LILLY_AND_COMPANY-IT201801013286,ELI LILLY AND CO,,80.0,YR,,M,Y,,,20180206.0,,CN,IT,IT,2018,Q1,Elderly
144947581,14494758,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNKNOWN",,,U,U,,,,25.0,MG,TABLET,,2018,Q1,Glycosylated haemoglobin increased,,2018,Q1,1,I,,20180125.0,20180206,20180206,EXP,,IT-ELI_LILLY_AND_COMPANY-IT201801013286,ELI LILLY AND CO,,80.0,YR,,M,Y,,,20180206.0,,CN,IT,IT,2018,Q1,Elderly
145068661,14506866,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Acute kidney injury,,2018,Q1,1,I,,20180125.0,20180208,20180208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-010897,BRISTOL MYERS SQUIBB,TADA.. TWO CASES OF ACUTE RENAL IMPAIRMENT CAUSED BY SODIUM-GLUCOSE LINKED TRANSPORTER 2 (SGLT2) INHIBITORS. 2017;68,58.0,YR,,F,Y,,,20180208.0,,OT,JP,JP,2018,Q1,Adult
145159932,14515993,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,TABLET,,2018,Q1,Sinus bradycardia,,2018,Q1,2,F,,20180215.0,20180211,20180226,PER,,US-TEVA-2018-US-856756,TEVA,,69.0,YR,,M,Y,,,20180226.0,,OT,US,US,2018,Q1,Elderly
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Atrial fibrillation,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Chest pain,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Influenza,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Ketoacidosis,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Lethargy,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Malaise,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Pleural effusion,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Pneumonia,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Refusal of treatment by patient,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Staphylococcal infection,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Therapy change,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145189411,14518941,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,1.0,DF,,QD,2018,Q1,Unresponsive to stimuli,,2018,Q1,1,I,20180118.0,,20180209,20180209,DIR,,,FDA-CTU,,55.0,YR,,F,N,67.6,KG,20180209.0,N,PH,US,US,2018,Q1,Adult
145232761,14523276,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2018,Q1,Completed suicide,,2018,Q1,1,I,2016.0,20180201.0,20180212,20180212,EXP,,"US-LANNETT COMPANY, INC.-US-2018LAN000387",LANNETT,"GUMMIN D, MOWRY J, SPYKER D, BROOKS D, FRASER MO, BANNER W. 2016 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS? NATIONAL POISON DATA SYSTEM (NPDS): 34TH ANNUAL REPORT.. CLINICAL TOXICOLOGY. 2017;55(10):1072-1254",60.0,YR,,M,Y,,,20180212.0,,MD,US,US,2018,Q1,Adult
145232761,14523276,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2018,Q1,Toxicity to various agents,,2018,Q1,1,I,2016.0,20180201.0,20180212,20180212,EXP,,"US-LANNETT COMPANY, INC.-US-2018LAN000387",LANNETT,"GUMMIN D, MOWRY J, SPYKER D, BROOKS D, FRASER MO, BANNER W. 2016 ANNUAL REPORT OF THE AMERICAN ASSOCIATION OF POISON CONTROL CENTERS? NATIONAL POISON DATA SYSTEM (NPDS): 34TH ANNUAL REPORT.. CLINICAL TOXICOLOGY. 2017;55(10):1072-1254",60.0,YR,,M,Y,,,20180212.0,,MD,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Asthenia,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Blood glucose increased,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Fatigue,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Feeling abnormal,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Glycosylated haemoglobin increased,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Malaise,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145234042,14523404,4,C,EMPAGLIFLOZIN W/LINAGLIPTIN,,2,Unknown,"UNK, EACH MORNING",,,U,,,,,,,,QD,2018,Q1,Thirst,,2018,Q1,2,F,20180101.0,20180216.0,20180212,20180222,PER,,US-ELI_LILLY_AND_COMPANY-US201802003903,ELI LILLY AND CO,,59.0,YR,,F,Y,,,20180222.0,,CN,US,US,2018,Q1,Adult
145312892,14531289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2018,Q1,Brain contusion,,2018,Q1,2,F,20171215.0,20180216.0,20180214,20180222,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-069235",BOEHRINGER INGELHEIM,,81.0,YR,,M,Y,63.4,KG,20180222.0,,MD,JP,JP,2018,Q1,Elderly
145312892,14531289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2018,Q1,Skull fractured base,,2018,Q1,2,F,20171215.0,20180216.0,20180214,20180222,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-069235",BOEHRINGER INGELHEIM,,81.0,YR,,M,Y,63.4,KG,20180222.0,,MD,JP,JP,2018,Q1,Elderly
145312892,14531289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2018,Q1,Subdural haematoma,,2018,Q1,2,F,20171215.0,20180216.0,20180214,20180222,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-069235",BOEHRINGER INGELHEIM,,81.0,YR,,M,Y,63.4,KG,20180222.0,,MD,JP,JP,2018,Q1,Elderly
145312892,14531289,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2018,Q1,Traumatic intracranial haemorrhage,,2018,Q1,2,F,20171215.0,20180216.0,20180214,20180222,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-069235",BOEHRINGER INGELHEIM,,81.0,YR,,M,Y,63.4,KG,20180222.0,,MD,JP,JP,2018,Q1,Elderly
145316683,14531668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Atrial fibrillation,,2018,Q1,3,F,20180204.0,20180220.0,20180214,20180228,EXP,,US-JNJFOC-20180218608,PHARMACYCLICS,,62.0,YR,A,F,Y,61.7,KG,20180228.0,,MD,US,US,2018,Q1,Adult
145316683,14531668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Coronary artery disease,,2018,Q1,3,F,20180204.0,20180220.0,20180214,20180228,EXP,,US-JNJFOC-20180218608,PHARMACYCLICS,,62.0,YR,A,F,Y,61.7,KG,20180228.0,,MD,US,US,2018,Q1,Adult
145316683,14531668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Hyperkalaemia,,2018,Q1,3,F,20180204.0,20180220.0,20180214,20180228,EXP,,US-JNJFOC-20180218608,PHARMACYCLICS,,62.0,YR,A,F,Y,61.7,KG,20180228.0,,MD,US,US,2018,Q1,Adult
145316683,14531668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Mitral valve incompetence,,2018,Q1,3,F,20180204.0,20180220.0,20180214,20180228,EXP,,US-JNJFOC-20180218608,PHARMACYCLICS,,62.0,YR,A,F,Y,61.7,KG,20180228.0,,MD,US,US,2018,Q1,Adult
145316683,14531668,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Myocardial infarction,,2018,Q1,3,F,20180204.0,20180220.0,20180214,20180228,EXP,,US-JNJFOC-20180218608,PHARMACYCLICS,,62.0,YR,A,F,Y,61.7,KG,20180228.0,,MD,US,US,2018,Q1,Adult
145361663,14536166,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2018,Q1,Pericarditis,,2018,Q1,3,F,20180207.0,20180220.0,20180215,20180222,EXP,,US-ASTRAZENECA-2018SE18575,ASTRAZENECA,,762.0,MON,,M,Y,124.3,KG,20180222.0,,MD,US,US,2018,Q1,Elderly
145419962,14541996,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,,,,,2018,Q1,Diabetes mellitus,,2018,Q1,2,F,20180208.0,20180222.0,20180216,20180227,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008583",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,64.6,KG,20180227.0,,MD,KR,KR,2018,Q1,Elderly
145448821,14544882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Dyslipidaemia,,2018,Q1,1,I,20170605.0,20180209.0,20180217,20180217,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20180217.0,,MD,JP,JP,2018,Q1,Young Adult
145448821,14544882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,1,I,20170605.0,20180209.0,20180217,20180217,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20180217.0,,MD,JP,JP,2018,Q1,Young Adult
145448821,14544882,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Dyslipidaemia,,2018,Q1,1,I,20170605.0,20180209.0,20180217,20180217,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20180217.0,,MD,JP,JP,2018,Q1,Young Adult
145448821,14544882,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,1,I,20170605.0,20180209.0,20180217,20180217,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20180217.0,,MD,JP,JP,2018,Q1,Young Adult
145551032,14555103,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,,,,,,,,,,2018,Q1,Breast cancer,,2018,Q1,2,F,,20180221.0,20180220,20180302,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201802004697,ELI LILLY AND CO,,74.0,YR,,F,Y,,,20180302.0,,CN,DE,DE,2018,Q1,Elderly
145578862,14557886,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2018,Q1,Circulatory collapse,,2018,Q1,2,F,,20180209.0,20180221,20180221,EXP,,PHHY2018AU025105,NOVARTIS,,78.0,YR,,M,Y,,,20180221.0,,OT,AU,AU,2018,Q1,Elderly
145578862,14557886,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,2,F,,20180209.0,20180221,20180221,EXP,,PHHY2018AU025105,NOVARTIS,,78.0,YR,,M,Y,,,20180221.0,,OT,AU,AU,2018,Q1,Elderly
145578862,14557886,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2018,Q1,Peripheral ischaemia,,2018,Q1,2,F,,20180209.0,20180221,20180221,EXP,,PHHY2018AU025105,NOVARTIS,,78.0,YR,,M,Y,,,20180221.0,,OT,AU,AU,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Chest discomfort,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Chest pain,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Coronary artery occlusion,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Dyspnoea,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Exposure to radiation,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Hyperhidrosis,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145599921,14559992,5,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,,,,,,,,,,,,,2018,Q1,Nausea,,2018,Q1,1,I,,20170420.0,20180221,20180221,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009597",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,,,20180222.0,,MD,DE,DE,2018,Q1,Elderly
145632272,14563227,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG,,,,,,,,,,,,2018,Q1,Pericardial effusion,,2018,Q1,2,F,20180219.0,20180221.0,20180222,20180226,EXP,,US-ASTRAZENECA-2018SE22665,ASTRAZENECA,,762.0,MON,,M,Y,128.5,KG,20180226.0,,MD,US,US,2018,Q1,Elderly
145632272,14563227,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG,,,,,,,,,,,,2018,Q1,Pericarditis,,2018,Q1,2,F,20180219.0,20180221.0,20180222,20180226,EXP,,US-ASTRAZENECA-2018SE22665,ASTRAZENECA,,762.0,MON,,M,Y,128.5,KG,20180226.0,,MD,US,US,2018,Q1,Elderly
145636962,14563696,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Blood creatine phosphokinase increased,,2018,Q1,2,F,20170523.0,20180315.0,20180222,20180322,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000746",BOEHRINGER INGELHEIM,,50.0,YR,,M,Y,86.2,KG,20180322.0,,MD,JP,JP,2018,Q1,Adult
145636962,14563696,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,2,F,20170523.0,20180315.0,20180222,20180322,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000746",BOEHRINGER INGELHEIM,,50.0,YR,,M,Y,86.2,KG,20180322.0,,MD,JP,JP,2018,Q1,Adult
145744331,14574433,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2018,Q1,Pulmonary embolism,,2018,Q1,1,I,20180207.0,20180221.0,20180226,20180226,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-010077",BOEHRINGER INGELHEIM,,42.0,YR,,M,Y,116.4,KG,20180227.0,,MD,GB,GB,2018,Q1,Adult
145830261,14583026,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q1,Euglycaemic diabetic ketoacidosis,,2018,Q1,1,I,,20180216.0,20180228,20180228,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-016617,BRISTOL MYERS SQUIBB,YOKOYAMA A. A CASE OF EUGLYCAEMIC DIABETIC KETOACIDOSIS WHICH DEVELOPED AFTER STARTING SODIUM-GLUCOSE LINKED TRANSPORTER (SGLT) 2 INHIBITORS.. FOLIA ENDOCRINOLOGICA JAPONICA. 2017;93(3):846,33.0,YR,,M,Y,,,20180228.0,,OT,JP,JP,2018,Q1,Young Adult
145883682,14588368,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Atrial flutter,,2018,Q1,2,F,20170330.0,20180307.0,20180301,20180309,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000884",BOEHRINGER INGELHEIM,,56.0,YR,,M,Y,95.1,KG,20180309.0,,MD,JP,JP,2018,Q1,Adult
145888811,14588881,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Diabetic retinal oedema,,2018,Q1,1,I,20170201.0,20180228.0,20180301,20180301,EXP,GB-MHRA-EYC 00174441,GB-BAUSCH-BL-2018-005689,BAUSCH AND LOMB,,40.0,YR,,M,Y,95.0,KG,20180301.0,,CN,GB,GB,2018,Q1,Adult
145888811,14588881,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Diarrhoea,,2018,Q1,1,I,20170201.0,20180228.0,20180301,20180301,EXP,GB-MHRA-EYC 00174441,GB-BAUSCH-BL-2018-005689,BAUSCH AND LOMB,,40.0,YR,,M,Y,95.0,KG,20180301.0,,CN,GB,GB,2018,Q1,Adult
146027301,14602730,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Fatigue,,2018,Q1,1,I,20171024.0,20180226.0,20180306,20180306,EXP,,GB-ASTRAZENECA-2018SE24920,ASTRAZENECA,,42.0,YR,,F,Y,123.8,KG,20180306.0,,,GB,GB,2018,Q1,Adult
146135691,14613569,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q1,Euglycaemic diabetic ketoacidosis,,2018,Q1,1,I,,20180222.0,20180308,20180308,EXP,,CA-MYLANLABS-2018M1014382,MYLAN,"LAU A, BRUCE S, WANG E, REE R, RONDI K, CHAU A. PERIOPERATIVE IMPLICATIONS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS: A CASE SERIES OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN THREE PATIENTS AFTER CARDIAC SURGERY. CAN-J-ANESTH 2018;65(2):188-193.",58.0,YR,,M,Y,71.0,KG,20180308.0,,MD,CA,CA,2018,Q1,Adult
146135691,14613569,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,,20180222.0,20180308,20180308,EXP,,CA-MYLANLABS-2018M1014382,MYLAN,"LAU A, BRUCE S, WANG E, REE R, RONDI K, CHAU A. PERIOPERATIVE IMPLICATIONS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS: A CASE SERIES OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN THREE PATIENTS AFTER CARDIAC SURGERY. CAN-J-ANESTH 2018;65(2):188-193.",58.0,YR,,M,Y,71.0,KG,20180308.0,,MD,CA,CA,2018,Q1,Adult
146135711,14613571,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q1,Euglycaemic diabetic ketoacidosis,,2018,Q1,1,I,,20180222.0,20180308,20180308,EXP,,CA-MYLANLABS-2018M1014375,MYLAN,"LAU A, BRUCE S, WANG E, REE R, RONDI K, CHAU A. PERIOPERATIVE IMPLICATIONS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS: A CASE SERIES OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN THREE PATIENTS AFTER CARDIAC SURGERY. CAN-J-ANESTH 2018;65(2):188-193.",54.0,YR,,M,Y,70.0,KG,20180308.0,,MD,CA,CA,2018,Q1,Adult
146135711,14613571,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,,20180222.0,20180308,20180308,EXP,,CA-MYLANLABS-2018M1014375,MYLAN,"LAU A, BRUCE S, WANG E, REE R, RONDI K, CHAU A. PERIOPERATIVE IMPLICATIONS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS: A CASE SERIES OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN THREE PATIENTS AFTER CARDIAC SURGERY. CAN-J-ANESTH 2018;65(2):188-193.",54.0,YR,,M,Y,70.0,KG,20180308.0,,MD,CA,CA,2018,Q1,Adult
146135711,14613571,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q1,Respiratory acidosis,,2018,Q1,1,I,,20180222.0,20180308,20180308,EXP,,CA-MYLANLABS-2018M1014375,MYLAN,"LAU A, BRUCE S, WANG E, REE R, RONDI K, CHAU A. PERIOPERATIVE IMPLICATIONS OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS: A CASE SERIES OF EUGLYCEMIC DIABETIC KETOACIDOSIS IN THREE PATIENTS AFTER CARDIAC SURGERY. CAN-J-ANESTH 2018;65(2):188-193.",54.0,YR,,M,Y,70.0,KG,20180308.0,,MD,CA,CA,2018,Q1,Adult
146191631,14619163,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Fatigue,,2018,Q1,1,I,20171024.0,20180222.0,20180309,20180309,EXP,GB-MHRA-EYC 00168633,GB-AUROBINDO-AUR-APL-2018-012106,AUROBINDO,,42.0,YR,,F,Y,124.0,KG,20180309.0,,CN,GB,GB,2018,Q1,Adult
146238911,14623891,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Blood ketone body present,,2018,Q1,1,I,20171104.0,20180301.0,20180312,20180312,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001080",BOEHRINGER INGELHEIM,,44.0,YR,,M,Y,111.8,KG,20180310.0,,MD,JP,JP,2018,Q1,Adult
146238911,14623891,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,1,I,20171104.0,20180301.0,20180312,20180312,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001080",BOEHRINGER INGELHEIM,,44.0,YR,,M,Y,111.8,KG,20180310.0,,MD,JP,JP,2018,Q1,Adult
146428471,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Iron deficiency anaemia,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Nasopharyngitis,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Uterine leiomyoma,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Iron deficiency anaemia,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Nasopharyngitis,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146428471,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Uterine leiomyoma,,2018,Q1,1,I,20170316.0,20180309.0,20180315,20180315,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20180315.0,,MD,US,JP,2018,Q1,Adult
146438411,14643841,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Diabetic retinal oedema,,2018,Q1,1,I,20170201.0,20180228.0,20180315,20180315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-023061,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,95.0,KG,20180315.0,,CN,GB,GB,2018,Q1,Adult
146438411,14643841,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Diarrhoea,,2018,Q1,1,I,20170201.0,20180228.0,20180315,20180315,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-023061,BRISTOL MYERS SQUIBB,,40.0,YR,,M,Y,95.0,KG,20180315.0,,CN,GB,GB,2018,Q1,Adult
146498161,14649816,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Bile duct cancer,,2018,Q1,1,I,20171117.0,20180315.0,20180316,20180316,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001282",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,58.2,KG,20180316.0,,MD,JP,JP,2018,Q1,Elderly
146499532,14649953,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2018,Q1,Pericarditis,,2018,Q1,2,F,20180312.0,20180315.0,20180316,20180319,EXP,,US-ASTRAZENECA-2018SE33011,ASTRAZENECA,,23222.0,DY,,M,Y,115.5,KG,20180319.0,,MD,US,US,2018,Q1,Elderly
146518671,14651867,2,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,,2018,Q1,Asthenia,,2018,Q1,1,I,201801.0,20180306.0,20180317,20180317,PER,,US-GRANULES INDIA LIMITED-2043980,GRANULES INDIA,,71.0,YR,,F,Y,58.18,KG,20180317.0,,MD,US,US,2018,Q1,Elderly
146518671,14651867,2,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,,2018,Q1,Dizziness,,2018,Q1,1,I,201801.0,20180306.0,20180317,20180317,PER,,US-GRANULES INDIA LIMITED-2043980,GRANULES INDIA,,71.0,YR,,F,Y,58.18,KG,20180317.0,,MD,US,US,2018,Q1,Elderly
146518671,14651867,2,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,,2018,Q1,Fatigue,,2018,Q1,1,I,201801.0,20180306.0,20180317,20180317,PER,,US-GRANULES INDIA LIMITED-2043980,GRANULES INDIA,,71.0,YR,,F,Y,58.18,KG,20180317.0,,MD,US,US,2018,Q1,Elderly
146626461,14662646,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q1,Anaemia,,2018,Q1,1,I,201802.0,20180315.0,20180321,20180321,PER,,US-BEH-2018088888,CSL BEHRING,,72.0,YR,,F,Y,79.37,KG,20180321.0,,OT,US,US,2018,Q1,Elderly
146627991,14662799,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q1,Pancreatitis,,2018,Q1,1,I,,20180307.0,20180321,20180321,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-023347,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,,,20180321.0,,MD,US,US,2018,Q1,Adult
146650651,14665065,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,25.0,MG,FORMULATION UNKNOWN,,2018,Q1,Cystitis interstitial,,2018,Q1,1,I,20171215.0,20180314.0,20180321,20180321,EXP,NO-NOMAADVRE-PASRAPP-2018-0003697,NO-ASTELLAS-2018US013275,ASTELLAS,,65.0,YR,,F,Y,115.0,KG,20180321.0,,OT,NO,NO,2018,Q1,Elderly
146654241,14665424,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q1,Abdominal pain upper,,2018,Q1,1,I,,20180307.0,20180321,20180321,EXP,,PHHY2018US039017,SANDOZ,"LIGHTBOURNE T,NAJAFIAN N,MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017;112:S710",52.0,YR,,F,Y,,,20180321.0,,OT,US,US,2018,Q1,Adult
146654241,14665424,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q1,Glycosylated haemoglobin increased,,2018,Q1,1,I,,20180307.0,20180321,20180321,EXP,,PHHY2018US039017,SANDOZ,"LIGHTBOURNE T,NAJAFIAN N,MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017;112:S710",52.0,YR,,F,Y,,,20180321.0,,OT,US,US,2018,Q1,Adult
146654241,14665424,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q1,Leukocytosis,,2018,Q1,1,I,,20180307.0,20180321,20180321,EXP,,PHHY2018US039017,SANDOZ,"LIGHTBOURNE T,NAJAFIAN N,MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017;112:S710",52.0,YR,,F,Y,,,20180321.0,,OT,US,US,2018,Q1,Adult
146654241,14665424,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q1,Pancreatitis,,2018,Q1,1,I,,20180307.0,20180321,20180321,EXP,,PHHY2018US039017,SANDOZ,"LIGHTBOURNE T,NAJAFIAN N,MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017;112:S710",52.0,YR,,F,Y,,,20180321.0,,OT,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Back injury,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Concussion,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Craniocerebral injury,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Glycosylated haemoglobin increased,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Headache,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Neck injury,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Product storage error,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146660021,14666002,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q1,Road traffic accident,,2018,Q1,1,I,20171221.0,20180223.0,20180321,20180321,PER,,US-ELI_LILLY_AND_COMPANY-US201802011192,ELI LILLY AND CO,,62.0,YR,,M,Y,,,20180321.0,,CN,US,US,2018,Q1,Adult
146672471,14667247,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,,,,,2018,Q1,Abdominal pain upper,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-ZYDUS-019310,ZYDUS PHARM,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017; 112 (SUPPL. 1)S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146672471,14667247,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,,,,,2018,Q1,Abdominal tenderness,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-ZYDUS-019310,ZYDUS PHARM,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017; 112 (SUPPL. 1)S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146672471,14667247,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,,,,,2018,Q1,Leukocytosis,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-ZYDUS-019310,ZYDUS PHARM,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017; 112 (SUPPL. 1)S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146672471,14667247,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,,,,,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-ZYDUS-019310,ZYDUS PHARM,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017; 112 (SUPPL. 1)S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146672471,14667247,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,,,,,2018,Q1,Nausea,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-ZYDUS-019310,ZYDUS PHARM,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017; 112 (SUPPL. 1)S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146672471,14667247,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,,,,,2018,Q1,Pancreatitis,,2018,Q1,1,I,,20180312.0,20180322,20180322,EXP,,US-ZYDUS-019310,ZYDUS PHARM,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017; 112 (SUPPL. 1)S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146683971,14668397,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,,20180307.0,20180322,20180322,EXP,,US-MYLANLABS-2018M1016953,MYLAN,,52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146683971,14668397,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2018,Q1,Pancreatitis,,2018,Q1,1,I,,20180307.0,20180322,20180322,EXP,,US-MYLANLABS-2018M1016953,MYLAN,,52.0,YR,,F,Y,,,20180322.0,,MD,US,US,2018,Q1,Adult
146688281,14668828,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Bronchitis,,2018,Q1,1,I,20180125.0,,20180321,20180321,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.9,KG,20180321.0,N,,US,US,2018,Q1,Adult
146688281,14668828,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Culture urine positive,,2018,Q1,1,I,20180125.0,,20180321,20180321,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.9,KG,20180321.0,N,,US,US,2018,Q1,Adult
146688281,14668828,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Escherichia test positive,,2018,Q1,1,I,20180125.0,,20180321,20180321,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.9,KG,20180321.0,N,,US,US,2018,Q1,Adult
146688281,14668828,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Hypotension,,2018,Q1,1,I,20180125.0,,20180321,20180321,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.9,KG,20180321.0,N,,US,US,2018,Q1,Adult
146688281,14668828,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,25.0,MG,,QD,2018,Q1,Urinary tract infection,,2018,Q1,1,I,20180125.0,,20180321,20180321,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.9,KG,20180321.0,N,,US,US,2018,Q1,Adult
146716551,14671655,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,, UNKNOWN,,,,,,,2018,Q1,Completed suicide,,2018,Q1,1,I,,20180309.0,20180323,20180323,EXP,,US-LUPIN PHARMACEUTICALS INC.-2018-02400,LUPIN,,60.0,YR,,M,Y,,,20180323.0,,MD,US,US,2018,Q1,Adult
146853861,14685386,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,131597.0,10.0,MG,,QD,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,,20180323.0,20180327,20180327,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-016547",BOEHRINGER INGELHEIM,"SHARMA P, JOBANPUTRA Y, LEWIN K, BAGATELL S, LICHTSTEIN D. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS - A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS. 2018;13:1-5.",63.0,YR,,F,Y,,,20180327.0,,OT,US,US,2018,Q1,Adult
146853861,14685386,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,131597.0,10.0,MG,,QD,2018,Q1,Enteritis,,2018,Q1,1,I,,20180323.0,20180327,20180327,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-016547",BOEHRINGER INGELHEIM,"SHARMA P, JOBANPUTRA Y, LEWIN K, BAGATELL S, LICHTSTEIN D. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS - A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS. 2018;13:1-5.",63.0,YR,,F,Y,,,20180327.0,,OT,US,US,2018,Q1,Adult
147005251,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Anaemia,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Diabetic gangrene,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Hypophosphataemia,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Renal artery stenosis,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Anaemia,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Diabetic gangrene,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Hypophosphataemia,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q1,Renal artery stenosis,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Anaemia,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Diabetic gangrene,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Hypophosphataemia,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147005251,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q1,Renal artery stenosis,,2018,Q1,1,I,20161201.0,20170309.0,20180330,20180330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180330.0,,MD,JP,JP,2018,Q1,Elderly
147019561,14701956,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q1,Abdominal pain upper,,2018,Q1,1,I,,20180319.0,20180331,20180331,EXP,,US-AUROBINDO-AUR-APL-2018-017792,AUROBINDO,"LIGHTBOURNE T, ET AL.. EMPAGLIFLOZIN/FUROSEMIDE/METFORMIN PANCREATITIS: CASE REPORT. REACTIONS WEEKLY. 2018;1693:194",52.0,YR,,F,Y,,,20180331.0,,OT,US,US,2018,Q1,Adult
147019561,14701956,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q1,Nausea,,2018,Q1,1,I,,20180319.0,20180331,20180331,EXP,,US-AUROBINDO-AUR-APL-2018-017792,AUROBINDO,"LIGHTBOURNE T, ET AL.. EMPAGLIFLOZIN/FUROSEMIDE/METFORMIN PANCREATITIS: CASE REPORT. REACTIONS WEEKLY. 2018;1693:194",52.0,YR,,F,Y,,,20180331.0,,OT,US,US,2018,Q1,Adult
147019561,14701956,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q1,Pancreatitis,,2018,Q1,1,I,,20180319.0,20180331,20180331,EXP,,US-AUROBINDO-AUR-APL-2018-017792,AUROBINDO,"LIGHTBOURNE T, ET AL.. EMPAGLIFLOZIN/FUROSEMIDE/METFORMIN PANCREATITIS: CASE REPORT. REACTIONS WEEKLY. 2018;1693:194",52.0,YR,,F,Y,,,20180331.0,,OT,US,US,2018,Q1,Adult
130078603,13007860,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Chest discomfort,,2018,Q2,3,F,20160621.0,20180517.0,20161207,20180518,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001102",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,71.0,KG,20180518.0,,MD,JP,JP,2018,Q2,Elderly
130681784,13068178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Urine ketone body,,2018,Q2,4,F,20160624.0,20180519.0,20161228,20180523,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001679",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,80.6,KG,20180523.0,,MD,JP,JP,2018,Q2,Adult
130681784,13068178,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Urine ketone body present,,2018,Q2,4,F,20160624.0,20180519.0,20161228,20180523,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001679",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,80.6,KG,20180523.0,,MD,JP,JP,2018,Q2,Adult
133475115,13347511,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Acute myocardial infarction,,2018,Q2,5,F,20170106.0,20180410.0,20170317,20180416,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001293",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,92.9,KG,20180416.0,,MD,JP,JP,2018,Q2,Adult
134179162,13417916,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Blood ketone body increased,,2018,Q2,2,F,20170113.0,20180331.0,20170406,20180406,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001692",BOEHRINGER INGELHEIM,,46.0,YR,,F,Y,74.1,KG,20180407.0,,MD,JP,JP,2018,Q2,Adult
134179162,13417916,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Blood ketone body increased,,2018,Q2,2,F,20170113.0,20180331.0,20170406,20180406,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001692",BOEHRINGER INGELHEIM,,46.0,YR,,F,Y,74.1,KG,20180407.0,,MD,JP,JP,2018,Q2,Adult
134179743,13417974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Blood ketone body increased,,2018,Q2,3,F,20161004.0,20180530.0,20170406,20180607,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20180608.0,,MD,JP,JP,2018,Q2,Young Adult
134179743,13417974,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Urine ketone body present,,2018,Q2,3,F,20161004.0,20180530.0,20170406,20180607,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20180608.0,,MD,JP,JP,2018,Q2,Young Adult
134179743,13417974,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Blood ketone body increased,,2018,Q2,3,F,20161004.0,20180530.0,20170406,20180607,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20180608.0,,MD,JP,JP,2018,Q2,Young Adult
134179743,13417974,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Urine ketone body present,,2018,Q2,3,F,20161004.0,20180530.0,20170406,20180607,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001675",BOEHRINGER INGELHEIM,,32.0,YR,,F,Y,89.9,KG,20180608.0,,MD,JP,JP,2018,Q2,Young Adult
135414732,13541473,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Blood ketone body increased,,2018,Q2,2,F,20170120.0,20180426.0,20170512,20180430,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002478",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,87.7,KG,20180430.0,,MD,JP,JP,2018,Q2,Adult
135414732,13541473,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Blood ketone body increased,,2018,Q2,2,F,20170120.0,20180426.0,20170512,20180430,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-002478",BOEHRINGER INGELHEIM,,59.0,YR,,M,Y,87.7,KG,20180430.0,,MD,JP,JP,2018,Q2,Adult
136486454,13648645,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Urine ketone body present,,2018,Q2,4,F,20161117.0,20180330.0,20170613,20180406,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003274",BOEHRINGER INGELHEIM,,51.0,YR,,M,Y,87.9,KG,20180406.0,,MD,JP,JP,2018,Q2,Adult
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Cholelithiasis,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Cystitis,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Diabetic neuropathy,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Hyperlipidaemia,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Pancreatitis acute,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Renal injury,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Urinary tract infection,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
136969055,13696905,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,JARDIANCE/GLYXAMBI/SYNJARDY,,,,,,,,,,,,2018,Q2,Urinary tract obstruction,,2018,Q2,5,F,20150123.0,20180327.0,20170628,20180403,EXP,,US-ASTRAZENECA-2017SE65198,ASTRAZENECA,,17729.0,DY,,F,Y,62.6,KG,20180403.0,,,US,US,2018,Q2,Elderly
140036663,14003666,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Acute kidney injury,,2018,Q2,3,F,20150807.0,20180511.0,20170922,20180526,PER,,US-JNJFOC-20170913822,JANSSEN,,47.0,YR,A,F,Y,81.65,KG,20180526.0,,CN,US,US,2018,Q2,Adult
140832184,14083218,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Myocardial ischaemia,,2018,Q2,4,F,20170704.0,20180625.0,20171012,20180628,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005392",BOEHRINGER INGELHEIM,,77.0,YR,,M,Y,55.4,KG,20180628.0,,MD,JP,JP,2018,Q2,Elderly
142319293,14231929,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Angina pectoris,,2018,Q2,3,F,20161022.0,20180516.0,20171128,20180518,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004133",BOEHRINGER INGELHEIM,,44.0,YR,,M,Y,72.8,KG,20180518.0,,MD,JP,JP,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Asthenia,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Blood glucose increased,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Blood pressure inadequately controlled,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Cardiac failure,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Contraindicated product administered,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Feeling cold,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Feeling of despair,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Hypotension,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Malaise,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Pain in extremity,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Psychiatric symptom,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Sleep disorder,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
142942048,14294204,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Testicular pain,,2018,Q2,8,F,201710.0,20180522.0,20171217,20180528,EXP,,PHHY2017CO185949,SANDOZ,,57.0,YR,,M,Y,88.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Aortic valve disease,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Death,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Hypotension,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Infarction,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Limb injury,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Medical device discomfort,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
145744096,14574409,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q2,Pyoderma gangrenosum,,2018,Q2,6,F,20180416.0,20180525.0,20180226,20180528,EXP,,PHHY2018CO028523,SANDOZ,,63.0,YR,,M,Y,67.0,KG,20180529.0,,CN,COUNTRY NOT SPECIFIED,CO,2018,Q2,Adult
146189074,14618907,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Urine ketone body present,,2018,Q2,4,F,20171003.0,20180621.0,20180309,20180626,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001131",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,69.6,KG,20180626.0,,MD,JP,JP,2018,Q2,Adult
146286114,14628611,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Constipation,,2018,Q2,4,F,20180215.0,20180504.0,20180313,20180519,PER,,US-JNJFOC-20180225706,JOHNSON AND JOHNSON,,54.0,YR,A,M,Y,95.26,KG,20180519.0,,CN,US,US,2018,Q2,Adult
146354113,14635411,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2018,Q2,Dizziness,,2018,Q2,3,F,20180308.0,20180418.0,20180314,20180420,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,,,20180420.0,,MD,DE,DE,2018,Q2,Elderly
146354113,14635411,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,,2018,Q2,Dizziness,,2018,Q2,3,F,20180308.0,20180418.0,20180314,20180420,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-013543",BOEHRINGER INGELHEIM,,81.0,YR,,F,Y,,,20180420.0,,MD,DE,DE,2018,Q2,Elderly
146380952,14638095,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869770,TEVA,"LAU A, BRUCE S, WANG E, REE R.",58.0,YR,,M,Y,71.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146380952,14638095,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Metabolic acidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869770,TEVA,"LAU A, BRUCE S, WANG E, REE R.",58.0,YR,,M,Y,71.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146380962,14638096,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869769,TEVA,"LAU A, BRUCE S, WANG E, REE R.",54.0,YR,,M,Y,70.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146380962,14638096,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Metabolic acidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869769,TEVA,"LAU A, BRUCE S, WANG E, REE R.",54.0,YR,,M,Y,70.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146380962,14638096,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Respiratory acidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869769,TEVA,"LAU A, BRUCE S, WANG E, REE R.",54.0,YR,,M,Y,70.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146381012,14638101,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869771,TEVA,"LAU A, BRUCE S, WANG E, REE R.",54.0,YR,,M,Y,97.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146381012,14638101,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Metabolic acidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869771,TEVA,"LAU A, BRUCE S, WANG E, REE R.",54.0,YR,,M,Y,97.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146381012,14638101,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG DAILY,,,D,,,,,,,,,2018,Q2,Respiratory acidosis,,2018,Q2,2,F,,20180327.0,20180314,20180409,EXP,,CA-TEVA-2018-CA-869771,TEVA,"LAU A, BRUCE S, WANG E, REE R.",54.0,YR,,M,Y,97.0,KG,20180409.0,,MD,CA,CA,2018,Q2,Adult
146402992,14640299,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2018,Q2,Diabetic retinal oedema,,2018,Q2,2,F,20170201.0,20180412.0,20180315,20180426,EXP,,GB-AUROBINDO-AUR-APL-2018-013592,AUROBINDO,,40.0,YR,,M,Y,95.0,KG,20180426.0,,CN,GB,GB,2018,Q2,Adult
146402992,14640299,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2018,Q2,Diarrhoea,,2018,Q2,2,F,20170201.0,20180412.0,20180315,20180426,EXP,,GB-AUROBINDO-AUR-APL-2018-013592,AUROBINDO,,40.0,YR,,M,Y,95.0,KG,20180426.0,,CN,GB,GB,2018,Q2,Adult
146402992,14640299,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(),,,,,,,,,,,,2018,Q2,Diabetic retinal oedema,,2018,Q2,2,F,20170201.0,20180412.0,20180315,20180426,EXP,,GB-AUROBINDO-AUR-APL-2018-013592,AUROBINDO,,40.0,YR,,M,Y,95.0,KG,20180426.0,,CN,GB,GB,2018,Q2,Adult
146402992,14640299,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(),,,,,,,,,,,,2018,Q2,Diarrhoea,,2018,Q2,2,F,20170201.0,20180412.0,20180315,20180426,EXP,,GB-AUROBINDO-AUR-APL-2018-013592,AUROBINDO,,40.0,YR,,M,Y,95.0,KG,20180426.0,,CN,GB,GB,2018,Q2,Adult
146498163,14649816,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Bile duct cancer,,2018,Q2,3,F,20171117.0,20180608.0,20180316,20180611,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001282",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,58.2,KG,20180611.0,,MD,JP,JP,2018,Q2,Elderly
146689753,14668975,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q2,Dysstasia,,2018,Q2,3,F,,20180612.0,20180322,20180619,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,,,20180619.0,,MD,BR,BR,2018,Q2,Elderly
146689753,14668975,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q2,Ischaemic stroke,,2018,Q2,3,F,,20180612.0,20180322,20180619,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,,,20180619.0,,MD,BR,BR,2018,Q2,Elderly
146689753,14668975,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q2,Speech disorder,,2018,Q2,3,F,,20180612.0,20180322,20180619,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,,,20180619.0,,MD,BR,BR,2018,Q2,Elderly
146702922,14670292,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q2,Metabolic acidosis,,2018,Q2,2,F,,20180327.0,20180322,20180409,EXP,,US-TEVA-2018-US-873048,TEVA,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017;112 (SUPPL. 1):S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180409.0,,MD,US,US,2018,Q2,Adult
146702922,14670292,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q2,Pancreatitis,,2018,Q2,2,F,,20180327.0,20180322,20180409,EXP,,US-TEVA-2018-US-873048,TEVA,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN-ASSOCIATED PANCREATITIS. AM-J-GASTROENTEROL 2017;112 (SUPPL. 1):S710 ABSTR. P77.",52.0,YR,,F,Y,,,20180409.0,,MD,US,US,2018,Q2,Adult
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Acute myocardial infarction,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Atrial fibrillation,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Benign prostatic hyperplasia,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Diabetic nephropathy,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Diabetic neuropathy,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Diabetic retinopathy,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
146829652,14682965,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Ventricular fibrillation,,2018,Q2,2,F,2012.0,20180403.0,20180327,20180416,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026885,BRISTOL MYERS SQUIBB,MURIN J. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES. 2018;17-8,67.0,YR,,M,Y,90.0,KG,20180416.0,,OT,SK,SK,2018,Q2,Elderly
147005252,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Anaemia,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Diabetic gangrene,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Hypophosphataemia,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Renal artery stenosis,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Anaemia,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Diabetic gangrene,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Hypophosphataemia,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Renal artery stenosis,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Anaemia,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Diabetic gangrene,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Hypophosphataemia,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147005252,14700525,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Renal artery stenosis,,2018,Q2,2,F,20161201.0,20180530.0,20180330,20180604,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-001330",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,80.1,KG,20180604.0,,MD,JP,JP,2018,Q2,Elderly
147009052,14700905,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Back pain,,2018,Q2,2,F,20160607.0,20180406.0,20180330,20180409,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003534",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,72.3,KG,20180409.0,,MD,JP,JP,2018,Q2,Elderly
147009052,14700905,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Cholecystitis,,2018,Q2,2,F,20160607.0,20180406.0,20180330,20180409,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003534",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,72.3,KG,20180409.0,,MD,JP,JP,2018,Q2,Elderly
147009052,14700905,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Diabetes mellitus,,2018,Q2,2,F,20160607.0,20180406.0,20180330,20180409,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003534",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,72.3,KG,20180409.0,,MD,JP,JP,2018,Q2,Elderly
147009052,14700905,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Back pain,,2018,Q2,2,F,20160607.0,20180406.0,20180330,20180409,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003534",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,72.3,KG,20180409.0,,MD,JP,JP,2018,Q2,Elderly
147009052,14700905,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Cholecystitis,,2018,Q2,2,F,20160607.0,20180406.0,20180330,20180409,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003534",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,72.3,KG,20180409.0,,MD,JP,JP,2018,Q2,Elderly
147009052,14700905,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q2,Diabetes mellitus,,2018,Q2,2,F,20160607.0,20180406.0,20180330,20180409,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003534",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,72.3,KG,20180409.0,,MD,JP,JP,2018,Q2,Elderly
147123191,14712319,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,U,,,,,,,,2018,Q2,Pancreatitis,,2018,Q2,1,I,,20180321.0,20180404,20180404,EXP,,"US-ATLAS PHARMACEUTICALS, LLC-2045060",ATLAS PHARMACEUTICALS,"TABER LIGHTBOURNE, NILOFAR NAJAFIAN AND THOMAS R. MCCARTY, CONSIDERATION FOR EMPAGLIFLOZIN ASSOCIATED PANCREATITIS, AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (1), S710",52.0,YR,,F,Y,,,20180404.0,,MD,US,US,2018,Q2,Adult
147198231,14719823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,380.0,MG,D,,,,204629.0,10.0,MG,TABLET,,2018,Q2,Hyponatraemia,,2018,Q2,1,I,20180315.0,20180402.0,20180405,20180405,EXP,GB-MHRA-WEB-RADR1001764,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001219",BOEHRINGER INGELHEIM,,63.0,YR,,,Y,,,20180405.0,,MD,GB,GB,2018,Q2,Adult
147198231,14719823,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,380.0,MG,D,,,,204629.0,10.0,MG,TABLET,,2018,Q2,Hypovolaemia,,2018,Q2,1,I,20180315.0,20180402.0,20180405,20180405,EXP,GB-MHRA-WEB-RADR1001764,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001219",BOEHRINGER INGELHEIM,,63.0,YR,,,Y,,,20180405.0,,MD,GB,GB,2018,Q2,Adult
147226911,14722691,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,D,,,,12.5,MG,,,2018,Q2,Renal impairment,,2018,Q2,1,I,20180309.0,,20180401,20180401,DIR,,,FDA-CTU,,68.0,YR,,M,N,108.32,KG,20180317.0,N,PH,US,US,2018,Q2,Elderly
147313102,14731310,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,,2018,Q2,Vomiting,,2018,Q2,2,F,20180325.0,20180419.0,20180407,20180430,EXP,,ES-ROCHE-2101371,ROCHE,,76.0,YR,,M,Y,80.0,KG,20180430.0,,MD,ES,ES,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Arthralgia,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Blood pressure diastolic increased,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Cardiac failure chronic,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Cardiac failure congestive,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Cough,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Dyspnoea,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Fatigue,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Fluid retention,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Gait disturbance,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Inappropriate schedule of drug administration,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Incorrect dose administered,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Localised oedema,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Nasopharyngitis,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Oedema peripheral,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Peripheral swelling,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Pollakiuria,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147403533,14740353,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q2,Weight increased,,2018,Q2,3,F,201708.0,20180502.0,20180410,20180515,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180515.0,,CN,DE,DE,2018,Q2,Elderly
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Abdominal pain,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Back pain,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Decreased appetite,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Deep vein thrombosis,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Haemodialysis,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Ketoacidosis,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Metabolic acidosis,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Nausea,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Vomiting,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147442311,14744231,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q2,Wound infection,,2018,Q2,1,I,20171108.0,,20180405,20180405,DIR,,,FDA-CTU,,61.0,YR,,F,N,145.2,KG,20180405.0,N,PH,US,US,2018,Q2,Adult
147700901,14770090,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2018,Q2,Benign prostatic hyperplasia,,2018,Q2,1,I,2012.0,20180403.0,20180417,20180417,EXP,,SK-BAUSCH-BL-2018-009669,BAUSCH AND LOMB,MURIN J. I INCLUDE CARDIOVASCULAR DISEASE I DIABETES. 2018;17-18.,67.0,YR,,M,Y,90.0,KG,20180417.0,,OT,SK,SK,2018,Q2,Elderly
147700901,14770090,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2018,Q2,Diabetic nephropathy,,2018,Q2,1,I,2012.0,20180403.0,20180417,20180417,EXP,,SK-BAUSCH-BL-2018-009669,BAUSCH AND LOMB,MURIN J. I INCLUDE CARDIOVASCULAR DISEASE I DIABETES. 2018;17-18.,67.0,YR,,M,Y,90.0,KG,20180417.0,,OT,SK,SK,2018,Q2,Elderly
147700901,14770090,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2018,Q2,Diabetic neuropathy,,2018,Q2,1,I,2012.0,20180403.0,20180417,20180417,EXP,,SK-BAUSCH-BL-2018-009669,BAUSCH AND LOMB,MURIN J. I INCLUDE CARDIOVASCULAR DISEASE I DIABETES. 2018;17-18.,67.0,YR,,M,Y,90.0,KG,20180417.0,,OT,SK,SK,2018,Q2,Elderly
147700901,14770090,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2018,Q2,Diabetic retinopathy,,2018,Q2,1,I,2012.0,20180403.0,20180417,20180417,EXP,,SK-BAUSCH-BL-2018-009669,BAUSCH AND LOMB,MURIN J. I INCLUDE CARDIOVASCULAR DISEASE I DIABETES. 2018;17-18.,67.0,YR,,M,Y,90.0,KG,20180417.0,,OT,SK,SK,2018,Q2,Elderly
147745411,14774541,5,C,METFORMIN HYDOCHLORIDE-EMPAGLIFLOZIN,,2,Unknown,UNKNOWN,,,D,U,,,,,,,,2018,Q2,Cardio-respiratory arrest,,2018,Q2,1,I,20180307.0,20180406.0,20180418,20180418,EXP,,ES-LPDUSPRD-20180579,LUITPOLD,,52.0,YR,,F,Y,,,20180418.0,,PH,ES,ES,2018,Q2,Adult
147821481,14782148,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Diabetic retinal oedema,,2018,Q2,1,I,20170201.0,20180416.0,20180420,20180420,EXP,GB-MHRA-EYC 00174441,GB-TEVA-2018-GB-883572,TEVA,,40.0,YR,,M,Y,95.0,KG,20180420.0,,CN,GB,GB,2018,Q2,Adult
147821481,14782148,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Diarrhoea,,2018,Q2,1,I,20170201.0,20180416.0,20180420,20180420,EXP,GB-MHRA-EYC 00174441,GB-TEVA-2018-GB-883572,TEVA,,40.0,YR,,M,Y,95.0,KG,20180420.0,,CN,GB,GB,2018,Q2,Adult
147840311,14784031,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Angina pectoris,,2018,Q2,1,I,20171027.0,20180329.0,20180420,20180420,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001616",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,65.9,KG,20180420.0,,MD,JP,JP,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Blood glucose abnormal,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Blood glucose increased,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Drug ineffective,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Fatigue,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Hot flush,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Nasopharyngitis,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147948003,14794800,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q2,Nausea,,2018,Q2,3,F,201803.0,20180615.0,20180423,20180625,EXP,,US-ASTELLAS-2018US018898,ASTELLAS,,70.0,YR,,M,Y,,,20180625.0,,CN,US,US,2018,Q2,Elderly
147982421,14798242,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,1,I,20180401.0,,20180415,20180415,DIR,,,FDA-CTU,,50.0,YR,,M,N,136.8,KG,20180415.0,N,PH,US,US,2018,Q2,Adult
147982421,14798242,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,,2018,Q2,Injury,,2018,Q2,1,I,20180401.0,,20180415,20180415,DIR,,,FDA-CTU,,50.0,YR,,M,N,136.8,KG,20180415.0,N,PH,US,US,2018,Q2,Adult
147982421,14798242,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,,2018,Q2,Metabolic acidosis,,2018,Q2,1,I,20180401.0,,20180415,20180415,DIR,,,FDA-CTU,,50.0,YR,,M,N,136.8,KG,20180415.0,N,PH,US,US,2018,Q2,Adult
147996202,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Calculus urinary,,2018,Q2,2,F,20160816.0,20180508.0,20180424,20180510,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20180510.0,,MD,JP,JP,2018,Q2,Adult
147996202,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Oropharyngeal discomfort,,2018,Q2,2,F,20160816.0,20180508.0,20180424,20180510,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20180510.0,,MD,JP,JP,2018,Q2,Adult
147996202,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Urinary tract infection,,2018,Q2,2,F,20160816.0,20180508.0,20180424,20180510,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20180510.0,,MD,JP,JP,2018,Q2,Adult
148254761,14825476,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1D",2450.0,MG,,, UNKNOWN,,,10.0,MG,,QD,2018,Q2,Gastritis erosive,,2018,Q2,1,I,20161030.0,20180415.0,20180430,20180430,EXP,,DE-AUROBINDO-AUR-APL-2018-022583,AUROBINDO,,64.0,YR,,M,Y,101.0,KG,20180430.0,,MD,DE,DE,2018,Q2,Adult
148254761,14825476,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1D",2450.0,MG,,, UNKNOWN,,,10.0,MG,,QD,2018,Q2,Melaena,,2018,Q2,1,I,20161030.0,20180415.0,20180430,20180430,EXP,,DE-AUROBINDO-AUR-APL-2018-022583,AUROBINDO,,64.0,YR,,M,Y,101.0,KG,20180430.0,,MD,DE,DE,2018,Q2,Adult
148262901,14826290,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,D,,,,,,,QD,2018,Q2,Transitional cell carcinoma,,2018,Q2,1,I,20180208.0,,20180404,20180404,DIR,,,FDA-CTU,,69.0,YR,,M,N,106.0,KG,20180404.0,N,PH,US,US,2018,Q2,Elderly
148277012,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2018,Q2,Atrial fibrillation,,2018,Q2,2,F,20171002.0,20180508.0,20180430,20180515,EXP,,JP-009507513-1803JPN000430J,MERCK,,76.0,YR,,M,Y,73.0,KG,20180515.0,,MD,JP,JP,2018,Q2,Elderly
148277012,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2018,Q2,Malignant neoplasm progression,,2018,Q2,2,F,20171002.0,20180508.0,20180430,20180515,EXP,,JP-009507513-1803JPN000430J,MERCK,,76.0,YR,,M,Y,73.0,KG,20180515.0,,MD,JP,JP,2018,Q2,Elderly
148277012,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2018,Q2,Thyroiditis,,2018,Q2,2,F,20171002.0,20180508.0,20180430,20180515,EXP,,JP-009507513-1803JPN000430J,MERCK,,76.0,YR,,M,Y,73.0,KG,20180515.0,,MD,JP,JP,2018,Q2,Elderly
148323271,14832327,5,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Angioedema,,2018,Q2,1,I,20180418.0,,20180418,20180418,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20180418.0,N,MD,US,US,2018,Q2,Adult
148323271,14832327,5,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Injection site mass,,2018,Q2,1,I,20180418.0,,20180418,20180418,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20180418.0,N,MD,US,US,2018,Q2,Adult
148323271,14832327,5,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Skin mass,,2018,Q2,1,I,20180418.0,,20180418,20180418,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20180418.0,N,MD,US,US,2018,Q2,Adult
148381701,14838170,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1D",,,D,,,,,10.0,MG,UNSPECIFIED,,2018,Q2,Gastritis erosive,,2018,Q2,1,I,20161030.0,20180418.0,20180502,20180502,EXP,,DE-JNJFOC-20180424146,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,101.0,KG,20180502.0,,MD,DE,DE,2018,Q2,Adult
148381701,14838170,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1D",,,D,,,,,10.0,MG,UNSPECIFIED,,2018,Q2,Melaena,,2018,Q2,1,I,20161030.0,20180418.0,20180502,20180502,EXP,,DE-JNJFOC-20180424146,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,101.0,KG,20180502.0,,MD,DE,DE,2018,Q2,Adult
148425441,14842544,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2018,Q2,Blood iron decreased,,2018,Q2,1,I,2018.0,20180430.0,20180503,20180503,PER,,US-BEH-2018090251,CSL BEHRING,,53.0,YR,A,F,Y,,,20180503.0,,OT,US,US,2018,Q2,Adult
148425441,14842544,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2018,Q2,Productive cough,,2018,Q2,1,I,2018.0,20180430.0,20180503,20180503,PER,,US-BEH-2018090251,CSL BEHRING,,53.0,YR,A,F,Y,,,20180503.0,,OT,US,US,2018,Q2,Adult
148425441,14842544,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2018,Q2,Upper respiratory tract infection,,2018,Q2,1,I,2018.0,20180430.0,20180503,20180503,PER,,US-BEH-2018090251,CSL BEHRING,,53.0,YR,A,F,Y,,,20180503.0,,OT,US,US,2018,Q2,Adult
148425441,14842544,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,,,,,,25.0,MG,TABLET,,2018,Q2,White blood cell count increased,,2018,Q2,1,I,2018.0,20180430.0,20180503,20180503,PER,,US-BEH-2018090251,CSL BEHRING,,53.0,YR,A,F,Y,,,20180503.0,,OT,US,US,2018,Q2,Adult
148930881,14893088,6,C,EMPAGLIFLOZINE,,2,,,,,,,,,,,,,,2018,Q2,Nephrolithiasis,,2018,Q2,1,I,20170920.0,20180503.0,20180514,20180514,EXP,,CA-BAUSCH-BL-2018-013768,BAUSCH AND LOMB,,56.0,YR,,M,Y,157.3,KG,20180514.0,,OT,CA,CA,2018,Q2,Adult
148930881,14893088,7,C,EMPAGLIFLOZINE,,2,,DIE (DAILY),,,,,,,,,,,,2018,Q2,Nephrolithiasis,,2018,Q2,1,I,20170920.0,20180503.0,20180514,20180514,EXP,,CA-BAUSCH-BL-2018-013768,BAUSCH AND LOMB,,56.0,YR,,M,Y,157.3,KG,20180514.0,,OT,CA,CA,2018,Q2,Adult
148934331,14893433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Abdominal distension,,2018,Q2,1,I,20160513.0,20170830.0,20180514,20180514,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005034",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,76.3,KG,20180514.0,,MD,JP,JP,2018,Q2,Adult
148934331,14893433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Blood triglycerides increased,,2018,Q2,1,I,20160513.0,20170830.0,20180514,20180514,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005034",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,76.3,KG,20180514.0,,MD,JP,JP,2018,Q2,Adult
148934331,14893433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Chest discomfort,,2018,Q2,1,I,20160513.0,20170830.0,20180514,20180514,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005034",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,76.3,KG,20180514.0,,MD,JP,JP,2018,Q2,Adult
148934331,14893433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Gastrooesophageal reflux disease,,2018,Q2,1,I,20160513.0,20170830.0,20180514,20180514,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005034",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,76.3,KG,20180514.0,,MD,JP,JP,2018,Q2,Adult
148934331,14893433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Hyperglycaemia,,2018,Q2,1,I,20160513.0,20170830.0,20180514,20180514,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005034",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,76.3,KG,20180514.0,,MD,JP,JP,2018,Q2,Adult
148934331,14893433,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Lymphadenitis,,2018,Q2,1,I,20160513.0,20170830.0,20180514,20180514,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005034",BOEHRINGER INGELHEIM,,44.0,YR,,F,Y,76.3,KG,20180514.0,,MD,JP,JP,2018,Q2,Adult
148942071,14894207,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2018,Q2,Alcohol interaction,,2018,Q2,1,I,,20180207.0,20180515,20180515,PER,GB-MHRA-EYC 00173305,GB-LUPIN PHARMACEUTICALS INC.-2018-01010,LUPIN,,51.0,YR,,F,Y,63.5,KG,20180515.0,,CN,GB,GB,2018,Q2,Adult
148942071,14894207,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2018,Q2,Palpitations,,2018,Q2,1,I,,20180207.0,20180515,20180515,PER,GB-MHRA-EYC 00173305,GB-LUPIN PHARMACEUTICALS INC.-2018-01010,LUPIN,,51.0,YR,,F,Y,63.5,KG,20180515.0,,CN,GB,GB,2018,Q2,Adult
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Cellulitis gangrenous,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Condition aggravated,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Erythema,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Escherichia test positive,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Foot deformity,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Hyperkeratosis,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Hyperthermia,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Induration,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Leukocytosis,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Purulence,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Tenderness,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Toe amputation,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Ulcer,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149183381,14918338,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q2,Wound,,2018,Q2,1,I,20180421.0,,20180502,20180502,DIR,,,FDA-CTU,,67.0,YR,,M,N,125.55,KG,20180502.0,N,PH,US,US,2018,Q2,Elderly
149190622,14919062,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",2450.0,MG,,,,,,10.0,MG,,QD,2018,Q2,Gastritis erosive,,2018,Q2,2,F,20161030.0,20180517.0,20180521,20180523,EXP,,DE-PFIZER INC-2018205861,PFIZER,,64.0,YR,,M,Y,101.0,KG,20180523.0,,MD,DE,DE,2018,Q2,Adult
149190622,14919062,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",2450.0,MG,,,,,,10.0,MG,,QD,2018,Q2,Melaena,,2018,Q2,2,F,20161030.0,20180517.0,20180521,20180523,EXP,,DE-PFIZER INC-2018205861,PFIZER,,64.0,YR,,M,Y,101.0,KG,20180523.0,,MD,DE,DE,2018,Q2,Adult
149245042,14924504,13,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,UNKNOWN,,2018,Q2,Back pain,,2018,Q2,2,F,20180414.0,20180517.0,20180522,20180530,EXP,,GB-CELGENEUS-GBR-20180406674,CELGENE,,69.0,YR,,M,Y,98.9,KG,20180530.0,,OT,GB,GB,2018,Q2,Elderly
149245042,14924504,13,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,UNKNOWN,,2018,Q2,Cerebrovascular accident,,2018,Q2,2,F,20180414.0,20180517.0,20180522,20180530,EXP,,GB-CELGENEUS-GBR-20180406674,CELGENE,,69.0,YR,,M,Y,98.9,KG,20180530.0,,OT,GB,GB,2018,Q2,Elderly
149245042,14924504,13,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,UNKNOWN,,2018,Q2,Dyspnoea,,2018,Q2,2,F,20180414.0,20180517.0,20180522,20180530,EXP,,GB-CELGENEUS-GBR-20180406674,CELGENE,,69.0,YR,,M,Y,98.9,KG,20180530.0,,OT,GB,GB,2018,Q2,Elderly
149245042,14924504,13,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,UNKNOWN,,2018,Q2,Fatigue,,2018,Q2,2,F,20180414.0,20180517.0,20180522,20180530,EXP,,GB-CELGENEUS-GBR-20180406674,CELGENE,,69.0,YR,,M,Y,98.9,KG,20180530.0,,OT,GB,GB,2018,Q2,Elderly
149245042,14924504,13,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,UNKNOWN,,2018,Q2,Hyperglycaemia,,2018,Q2,2,F,20180414.0,20180517.0,20180522,20180530,EXP,,GB-CELGENEUS-GBR-20180406674,CELGENE,,69.0,YR,,M,Y,98.9,KG,20180530.0,,OT,GB,GB,2018,Q2,Elderly
149245042,14924504,13,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,,,UNKNOWN,,2018,Q2,Nausea,,2018,Q2,2,F,20180414.0,20180517.0,20180522,20180530,EXP,,GB-CELGENEUS-GBR-20180406674,CELGENE,,69.0,YR,,M,Y,98.9,KG,20180530.0,,OT,GB,GB,2018,Q2,Elderly
149251811,14925181,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,204629.0,,,,,2018,Q2,Depressed mood,,2018,Q2,1,I,20180510.0,20180522.0,20180522,20180522,EXP,GB-MHRA-TPP32947525C656014YC1525947109601,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-001792",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,132.0,KG,20180522.0,,MD,GB,GB,2018,Q2,Adult
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Anaemia,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Blood cholesterol increased,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Blood glucose increased,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Blood pressure fluctuation,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Blood uric acid increased,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Cardiomegaly,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Carotid arteriosclerosis,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Chest discomfort,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Decreased ventricular preload,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Dyspnoea exertional,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Electrocardiogram abnormal,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Hepatic lesion,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Ischaemia,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Myocardial ischaemia,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Renal impairment,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149478932,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q2,Transient ischaemic attack,,2018,Q2,2,F,,20180607.0,20180529,20180615,EXP,,PHHY2018HU007083,SANDOZ,SZLADEK H. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-5,65.0,YR,,M,Y,,,20180615.0,,OT,HU,HU,2018,Q2,Elderly
149574851,14957485,4,C,EMPAGLIFLOZIN;METFORMIN,,2,Oral,MG BID 12.5/1000,,,,, UNKNOWN,,,,,,,2018,Q2,Blood glucose increased,,2018,Q2,1,I,20180421.0,20180424.0,20180531,20180531,EXP,,CO-NOVOPROD-598158,NOVO NORDISK,,65.0,YR,A,F,Y,52.0,KG,20180531.0,,CN,CO,CO,2018,Q2,Elderly
149574851,14957485,4,C,EMPAGLIFLOZIN;METFORMIN,,2,Oral,MG BID 12.5/1000,,,,, UNKNOWN,,,,,,,2018,Q2,Decreased appetite,,2018,Q2,1,I,20180421.0,20180424.0,20180531,20180531,EXP,,CO-NOVOPROD-598158,NOVO NORDISK,,65.0,YR,A,F,Y,52.0,KG,20180531.0,,CN,CO,CO,2018,Q2,Elderly
149574851,14957485,4,C,EMPAGLIFLOZIN;METFORMIN,,2,Oral,MG BID 12.5/1000,,,,, UNKNOWN,,,,,,,2018,Q2,Flatulence,,2018,Q2,1,I,20180421.0,20180424.0,20180531,20180531,EXP,,CO-NOVOPROD-598158,NOVO NORDISK,,65.0,YR,A,F,Y,52.0,KG,20180531.0,,CN,CO,CO,2018,Q2,Elderly
149574851,14957485,4,C,EMPAGLIFLOZIN;METFORMIN,,2,Oral,MG BID 12.5/1000,,,,, UNKNOWN,,,,,,,2018,Q2,Headache,,2018,Q2,1,I,20180421.0,20180424.0,20180531,20180531,EXP,,CO-NOVOPROD-598158,NOVO NORDISK,,65.0,YR,A,F,Y,52.0,KG,20180531.0,,CN,CO,CO,2018,Q2,Elderly
149574851,14957485,4,C,EMPAGLIFLOZIN;METFORMIN,,2,Oral,MG BID 12.5/1000,,,,, UNKNOWN,,,,,,,2018,Q2,Nausea,,2018,Q2,1,I,20180421.0,20180424.0,20180531,20180531,EXP,,CO-NOVOPROD-598158,NOVO NORDISK,,65.0,YR,A,F,Y,52.0,KG,20180531.0,,CN,CO,CO,2018,Q2,Elderly
149735121,14973512,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q2,Acute myocardial infarction,,2018,Q2,1,I,,20180529.0,20180605,20180605,EXP,,PHHY2018PT013867,NOVARTIS,,67.0,YR,,M,Y,,,20180605.0,,OT,PT,PT,2018,Q2,Elderly
149869162,14986916,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2018,Q2,Drug ineffective,,2018,Q2,2,F,201106.0,20180530.0,20180608,20180614,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-051506,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20180614.0,,MD,SK,SK,2018,Q2,Elderly
149869162,14986916,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2018,Q2,Myocardial infarction,,2018,Q2,2,F,201106.0,20180530.0,20180608,20180614,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-051506,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20180614.0,,MD,SK,SK,2018,Q2,Elderly
149869162,14986916,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2018,Q2,Weight increased,,2018,Q2,2,F,201106.0,20180530.0,20180608,20180614,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-051506,BRISTOL MYERS SQUIBB,,66.0,YR,,M,Y,,,20180614.0,,MD,SK,SK,2018,Q2,Elderly
149905111,14990511,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,20180517.0,,20180520,20180520,DIR,,,FDA-CTU,,53.0,YR,,F,N,63.5,KG,20180520.0,N,PH,US,US,2018,Q2,Adult
149960281,14996028,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,QD,2018,Q2,Ankle fracture,,2018,Q2,1,I,20180516.0,,20180522,20180522,DIR,,,FDA-CTU,,51.0,YR,,M,N,113.6,KG,20180522.0,N,OT,US,US,2018,Q2,Adult
149960281,14996028,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,QD,2018,Q2,Diarrhoea,,2018,Q2,1,I,20180516.0,,20180522,20180522,DIR,,,FDA-CTU,,51.0,YR,,M,N,113.6,KG,20180522.0,N,OT,US,US,2018,Q2,Adult
149960281,14996028,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,QD,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,1,I,20180516.0,,20180522,20180522,DIR,,,FDA-CTU,,51.0,YR,,M,N,113.6,KG,20180522.0,N,OT,US,US,2018,Q2,Adult
149960281,14996028,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,QD,2018,Q2,Metabolic acidosis,,2018,Q2,1,I,20180516.0,,20180522,20180522,DIR,,,FDA-CTU,,51.0,YR,,M,N,113.6,KG,20180522.0,N,OT,US,US,2018,Q2,Adult
149960281,14996028,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,QD,2018,Q2,Weight decreased,,2018,Q2,1,I,20180516.0,,20180522,20180522,DIR,,,FDA-CTU,,51.0,YR,,M,N,113.6,KG,20180522.0,N,OT,US,US,2018,Q2,Adult
149976072,14997607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Lung neoplasm malignant,,2018,Q2,2,F,20180221.0,20180619.0,20180611,20180620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003129",BOEHRINGER INGELHEIM,,72.0,YR,,F,Y,66.1,KG,20180620.0,,MD,JP,JP,2018,Q2,Elderly
149976072,14997607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Pneumonia bacterial,,2018,Q2,2,F,20180221.0,20180619.0,20180611,20180620,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003129",BOEHRINGER INGELHEIM,,72.0,YR,,F,Y,66.1,KG,20180620.0,,MD,JP,JP,2018,Q2,Elderly
149977581,14997758,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2018,Q2,Drug ineffective,,2018,Q2,1,I,201106.0,20180606.0,20180611,20180611,EXP,,SK-BAUSCH-BL-2018-016279,BAUSCH AND LOMB,POLKO J. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNALLY MEDICINE. 2018;10-11.,66.0,YR,,M,Y,,,20180611.0,,MD,SK,SK,2018,Q2,Elderly
149977581,14997758,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2018,Q2,Myocardial infarction,,2018,Q2,1,I,201106.0,20180606.0,20180611,20180611,EXP,,SK-BAUSCH-BL-2018-016279,BAUSCH AND LOMB,POLKO J. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNALLY MEDICINE. 2018;10-11.,66.0,YR,,M,Y,,,20180611.0,,MD,SK,SK,2018,Q2,Elderly
149977581,14997758,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2018,Q2,Weight increased,,2018,Q2,1,I,201106.0,20180606.0,20180611,20180611,EXP,,SK-BAUSCH-BL-2018-016279,BAUSCH AND LOMB,POLKO J. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNALLY MEDICINE. 2018;10-11.,66.0,YR,,M,Y,,,20180611.0,,MD,SK,SK,2018,Q2,Elderly
150289331,15028933,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG,QD",12050.0,MG,,,,,,25.0,MG,,QD,2018,Q2,Acute myocardial infarction,,2018,Q2,1,I,20180330.0,20180425.0,20180619,20180619,EXP,,US-SA-2018SA123412,SANOFI AVENTIS,,49.0,YR,A,M,Y,96.0,KG,20180619.0,,MD,US,US,2018,Q2,Adult
150289331,15028933,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG,QD",12050.0,MG,,,,,,25.0,MG,,QD,2018,Q2,Acute myocardial infarction,,2018,Q2,1,I,20180330.0,20180425.0,20180619,20180619,EXP,,US-SA-2018SA123412,SANOFI AVENTIS,,49.0,YR,A,M,Y,96.0,KG,20180619.0,,MD,US,US,2018,Q2,Adult
150289331,15028933,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,12050.0,MG,,,,,,,,,,2018,Q2,Acute myocardial infarction,,2018,Q2,1,I,20180330.0,20180425.0,20180619,20180619,EXP,,US-SA-2018SA123412,SANOFI AVENTIS,,49.0,YR,A,M,Y,96.0,KG,20180619.0,,MD,US,US,2018,Q2,Adult
150373121,15037312,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Acute myocardial infarction,,2018,Q2,1,I,20180521.0,20180613.0,20180620,20180620,EXP,,PT-ASTRAZENECA-2018SE77407,ASTRAZENECA,,77.0,YR,,M,Y,63.0,KG,20180620.0,,MD,PT,PT,2018,Q2,Elderly
150373121,15037312,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Lower gastrointestinal haemorrhage,,2018,Q2,1,I,20180521.0,20180613.0,20180620,20180620,EXP,,PT-ASTRAZENECA-2018SE77407,ASTRAZENECA,,77.0,YR,,M,Y,63.0,KG,20180620.0,,MD,PT,PT,2018,Q2,Elderly
150447801,15044780,3,SS,EMPAGLIFLOZIN + METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,BID,2018,Q2,Gastric disorder,,2018,Q2,1,I,,20180601.0,20180621,20180621,EXP,,AU-GLAXOSMITHKLINE-AU2018GSK103583,GLAXOSMITHKLINE,,71.0,YR,,M,Y,,,20180621.0,,CN,AU,AU,2018,Q2,Elderly
150447801,15044780,3,SS,EMPAGLIFLOZIN + METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,BID,2018,Q2,Myocardial infarction,,2018,Q2,1,I,,20180601.0,20180621,20180621,EXP,,AU-GLAXOSMITHKLINE-AU2018GSK103583,GLAXOSMITHKLINE,,71.0,YR,,M,Y,,,20180621.0,,CN,AU,AU,2018,Q2,Elderly
150447801,15044780,3,SS,EMPAGLIFLOZIN + METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"1 DF, BID",,,U,,,,,1.0,DF,,BID,2018,Q2,Wrong technique in product usage process,,2018,Q2,1,I,,20180601.0,20180621,20180621,EXP,,AU-GLAXOSMITHKLINE-AU2018GSK103583,GLAXOSMITHKLINE,,71.0,YR,,M,Y,,,20180621.0,,CN,AU,AU,2018,Q2,Elderly
150501912,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Hypertension,,2018,Q2,2,F,20160708.0,20180625.0,20180622,20180629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20180629.0,,MD,JP,JP,2018,Q2,Elderly
150501912,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Hyperuricaemia,,2018,Q2,2,F,20160708.0,20180625.0,20180622,20180629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20180629.0,,MD,JP,JP,2018,Q2,Elderly
150501912,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Lacunar infarction,,2018,Q2,2,F,20160708.0,20180625.0,20180622,20180629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20180629.0,,MD,JP,JP,2018,Q2,Elderly
150501912,15050191,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Nephropathy,,2018,Q2,2,F,20160708.0,20180625.0,20180622,20180629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000929",BOEHRINGER INGELHEIM,,67.0,YR,,M,Y,70.0,KG,20180629.0,,MD,JP,JP,2018,Q2,Elderly
150568451,15056845,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q2,Acute myocardial infarction,,2018,Q2,1,I,20180601.0,,20180604,20180604,DIR,,,FDA-CTU,,57.0,YR,,F,N,69.3,KG,20180604.0,N,OT,US,US,2018,Q2,Adult
150568451,15056845,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,20180601.0,,20180604,20180604,DIR,,,FDA-CTU,,57.0,YR,,F,N,69.3,KG,20180604.0,N,OT,US,US,2018,Q2,Adult
150568451,15056845,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q2,Lactic acidosis,,2018,Q2,1,I,20180601.0,,20180604,20180604,DIR,,,FDA-CTU,,57.0,YR,,F,N,69.3,KG,20180604.0,N,OT,US,US,2018,Q2,Adult
150667691,15066769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Asthenia,,2018,Q2,1,I,20180228.0,20180606.0,20180626,20180626,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003161",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,94.2,KG,20180626.0,,MD,JP,JP,2018,Q2,Adult
150667691,15066769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q2,Loss of consciousness,,2018,Q2,1,I,20180228.0,20180606.0,20180626,20180626,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003161",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,94.2,KG,20180626.0,,MD,JP,JP,2018,Q2,Adult
150897941,15089794,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q2,Diabetic retinal oedema,,2018,Q2,1,I,20170201.0,20180624.0,20180629,20180629,EXP,,PHHY2018GB031838,SANDOZ,,40.0,YR,,M,Y,95.0,KG,20180629.0,,OT,GB,GB,2018,Q2,Adult
150897941,15089794,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q2,Diarrhoea,,2018,Q2,1,I,20170201.0,20180624.0,20180629,20180629,EXP,,PHHY2018GB031838,SANDOZ,,40.0,YR,,M,Y,95.0,KG,20180629.0,,OT,GB,GB,2018,Q2,Adult
129721114,12972111,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Ureterolithiasis,,2018,Q3,4,F,20160914.0,20180702.0,20161124,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-000946",BOEHRINGER INGELHEIM,,40.0,YR,,F,Y,89.5,KG,20180705.0,,MD,JP,JP,2018,Q3,Adult
129721114,12972111,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Ureterolithiasis,,2018,Q3,4,F,20160914.0,20180702.0,20161124,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-000946",BOEHRINGER INGELHEIM,,40.0,YR,,F,Y,89.5,KG,20180705.0,,MD,JP,JP,2018,Q3,Adult
137825373,13782537,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Angina pectoris,,2018,Q3,3,F,201610.0,20180808.0,20170724,20180814,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20180814.0,,MD,JP,JP,2018,Q3,Adult
137825373,13782537,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Angina pectoris,,2018,Q3,3,F,201610.0,20180808.0,20170724,20180814,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20180814.0,,MD,JP,JP,2018,Q3,Adult
137825373,13782537,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Angina pectoris,,2018,Q3,3,F,201610.0,20180808.0,20170724,20180814,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-003360",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,87.4,KG,20180814.0,,MD,JP,JP,2018,Q3,Adult
138768764,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Dizziness,,2018,Q3,4,F,20161213.0,20180702.0,20170817,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
138768764,13876876,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Ventricular extrasystoles,,2018,Q3,4,F,20161213.0,20180702.0,20170817,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004697",BOEHRINGER INGELHEIM,,74.0,YR,,M,Y,69.2,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
139356713,13935671,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Interstitial lung disease,,2018,Q3,3,F,20170315.0,20180807.0,20170905,20180808,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004988",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,62.0,KG,20180808.0,,MD,JP,JP,2018,Q3,Adult
139356713,13935671,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Silent myocardial infarction,,2018,Q3,3,F,20170315.0,20180807.0,20170905,20180808,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004988",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,62.0,KG,20180808.0,,MD,JP,JP,2018,Q3,Adult
140476853,14047685,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,3,F,20170214.0,20180626.0,20171005,20180702,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005642",BOEHRINGER INGELHEIM,,35.0,YR,,F,Y,90.5,KG,20180702.0,,MD,JP,JP,2018,Q3,Adult
140476853,14047685,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,3,F,20170214.0,20180626.0,20171005,20180702,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005642",BOEHRINGER INGELHEIM,,35.0,YR,,F,Y,90.5,KG,20180702.0,,MD,JP,JP,2018,Q3,Adult
141135737,14113573,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2018,Q3,Bladder neoplasm,,2018,Q3,7,F,20171012.0,20180912.0,20171023,20180917,EXP,,DE-ROCHE-2009932,ROCHE,,69.0,YR,,M,Y,112.0,KG,20180917.0,,MD,DE,DE,2018,Q3,Elderly
141135737,14113573,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2018,Q3,Intervertebral disc protrusion,,2018,Q3,7,F,20171012.0,20180912.0,20171023,20180917,EXP,,DE-ROCHE-2009932,ROCHE,,69.0,YR,,M,Y,112.0,KG,20180917.0,,MD,DE,DE,2018,Q3,Elderly
143176983,14317698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,5.0,MG,TABLET,QD,2018,Q3,Gastric cancer,,2018,Q3,3,F,2017.0,20180710.0,20171222,20180716,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007398",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.0,KG,20180716.0,,MD,JP,JP,2018,Q3,Elderly
143176983,14317698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,5.0,MG,TABLET,QD,2018,Q3,Hypoglycaemia,,2018,Q3,3,F,2017.0,20180710.0,20171222,20180716,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007398",BOEHRINGER INGELHEIM,,70.0,YR,,M,Y,69.0,KG,20180716.0,,MD,JP,JP,2018,Q3,Elderly
145318433,14531843,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Fall,,2018,Q3,3,F,20161011.0,20180910.0,20180214,20180917,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000619",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,64.5,KG,20180917.0,,MD,JP,JP,2018,Q3,Elderly
145318433,14531843,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Spinal compression fracture,,2018,Q3,3,F,20161011.0,20180910.0,20180214,20180917,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000619",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,64.5,KG,20180917.0,,MD,JP,JP,2018,Q3,Elderly
145551033,14555103,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,,,,,,,,,,2018,Q3,Breast cancer,,2018,Q3,3,F,,20180917.0,20180220,20180924,EXP,,DE-ELI_LILLY_AND_COMPANY-DE201802004697,ELI LILLY AND CO,,74.0,YR,,F,Y,,,20180924.0,,CN,DE,DE,2018,Q3,Elderly
145937639,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2018,Q3,Acute kidney injury,,2018,Q3,9,F,20170822.0,20180905.0,20180302,20180910,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.0,KG,20180910.0,,MD,US,US,2018,Q3,Elderly
145937639,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2018,Q3,Ascites,,2018,Q3,9,F,20170822.0,20180905.0,20180302,20180910,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.0,KG,20180910.0,,MD,US,US,2018,Q3,Elderly
145937639,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2018,Q3,Cardiac failure,,2018,Q3,9,F,20170822.0,20180905.0,20180302,20180910,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.0,KG,20180910.0,,MD,US,US,2018,Q3,Elderly
145937639,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2018,Q3,Fall,,2018,Q3,9,F,20170822.0,20180905.0,20180302,20180910,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.0,KG,20180910.0,,MD,US,US,2018,Q3,Elderly
145937639,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2018,Q3,Renal impairment,,2018,Q3,9,F,20170822.0,20180905.0,20180302,20180910,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.0,KG,20180910.0,,MD,US,US,2018,Q3,Elderly
145937639,14593763,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,TABLET,QD,2018,Q3,Subdural haematoma,,2018,Q3,9,F,20170822.0,20180905.0,20180302,20180910,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-001564",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.0,KG,20180910.0,,MD,US,US,2018,Q3,Elderly
146189075,14618907,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,5,F,20171003.0,20180721.0,20180309,20180727,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001131",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,69.6,KG,20180727.0,,MD,JP,JP,2018,Q3,Adult
146689754,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q3,Aortic thrombosis,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q3,Drug ineffective,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q3,Dysarthria,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q3,Dysstasia,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,QD,2018,Q3,Ischaemic stroke,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Aortic thrombosis,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Drug ineffective,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Dysarthria,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Dysstasia,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
146689754,14668975,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Ischaemic stroke,,2018,Q3,4,F,20180318.0,20180821.0,20180322,20180828,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-015601",BOEHRINGER INGELHEIM,,79.0,YR,,F,Y,80.0,KG,20180828.0,,MD,BR,BR,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Acute kidney injury,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Aortic valve calcification,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Aortic valve incompetence,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Aortic valve stenosis,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Arthralgia,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Balanoposthitis,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Blood pressure diastolic increased,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Cardiac failure,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Cardiac failure chronic,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Chest pain,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Contusion,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Cough,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Dizziness,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Dyspnoea,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Dyspnoea at rest,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Ejection fraction decreased,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Fatigue,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Fluid retention,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Gait disturbance,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Gout,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Hypochromic anaemia,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Inappropriate schedule of drug administration,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Incorrect dose administered,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Infection,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Left ventricular dysfunction,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Localised oedema,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Mitral valve calcification,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Mitral valve incompetence,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Nasopharyngitis,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Oedema peripheral,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Peripheral swelling,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Phimosis,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Pollakiuria,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Pulmonary congestion,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Stenosis,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Tricuspid valve incompetence,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Urinary retention,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147403534,14740353,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,Y,,,,,10.0,MG,,QD,2018,Q3,Weight increased,,2018,Q3,4,F,201708.0,20180720.0,20180410,20180801,EXP,,PHHY2018DE025219,NOVARTIS,,67.0,YR,,M,Y,120.4,KG,20180801.0,,CN,DE,DE,2018,Q3,Elderly
147517314,14751731,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cerebellar infarction,,2018,Q3,4,F,20170530.0,20180705.0,20180412,20180710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001602",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,81.2,KG,20180710.0,,MD,JP,JP,2018,Q3,Adult
147517314,14751731,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cerebral infarction,,2018,Q3,4,F,20170530.0,20180705.0,20180412,20180710,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001602",BOEHRINGER INGELHEIM,,55.0,YR,,M,Y,81.2,KG,20180710.0,,MD,JP,JP,2018,Q3,Adult
147958092,14795809,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2018,Q3,Injection site swelling,,2018,Q3,2,F,2018.0,20180523.0,20180423,20180719,PER,,US-AMGEN-USASL2018019004,AMGEN,,55.0,YR,A,M,Y,118.37,KG,20180719.0,,CN,US,US,2018,Q3,Adult
147958092,14795809,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2018,Q3,Joint stiffness,,2018,Q3,2,F,2018.0,20180523.0,20180423,20180719,PER,,US-AMGEN-USASL2018019004,AMGEN,,55.0,YR,A,M,Y,118.37,KG,20180719.0,,CN,US,US,2018,Q3,Adult
147958092,14795809,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2018,Q3,Skin reaction,,2018,Q3,2,F,2018.0,20180523.0,20180423,20180719,PER,,US-AMGEN-USASL2018019004,AMGEN,,55.0,YR,A,M,Y,118.37,KG,20180719.0,,CN,US,US,2018,Q3,Adult
148277013,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2018,Q3,Atrial fibrillation,,2018,Q3,3,F,20171002.0,20180508.0,20180430,20180719,EXP,,JP-009507513-1803JPN000430J,MERCK,,76.0,YR,,M,Y,73.0,KG,20180719.0,,MD,JP,JP,2018,Q3,Elderly
148277013,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2018,Q3,Malignant neoplasm progression,,2018,Q3,3,F,20171002.0,20180508.0,20180430,20180719,EXP,,JP-009507513-1803JPN000430J,MERCK,,76.0,YR,,M,Y,73.0,KG,20180719.0,,MD,JP,JP,2018,Q3,Elderly
148277013,14827701,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"20 MG, QD",,,D,,,,,20.0,MG,TABLET,QD,2018,Q3,Thyroiditis,,2018,Q3,3,F,20171002.0,20180508.0,20180430,20180719,EXP,,JP-009507513-1803JPN000430J,MERCK,,76.0,YR,,M,Y,73.0,KG,20180719.0,,MD,JP,JP,2018,Q3,Elderly
148381703,14838170,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1D",2450.0,MG,D,,,,,10.0,MG,UNSPECIFIED,,2018,Q3,Gastritis erosive,,2018,Q3,3,F,20161030.0,20180807.0,20180502,20180820,EXP,,DE-JNJFOC-20180424146,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,100.7,KG,20180820.0,,MD,DE,DE,2018,Q3,Adult
148381703,14838170,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1D",2450.0,MG,D,,,,,10.0,MG,UNSPECIFIED,,2018,Q3,Melaena,,2018,Q3,3,F,20161030.0,20180807.0,20180502,20180820,EXP,,DE-JNJFOC-20180424146,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,100.7,KG,20180820.0,,MD,DE,DE,2018,Q3,Adult
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Blood glucose fluctuation,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Blood glucose increased,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Drug ineffective,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Fatigue,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Hot flush,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Nasopharyngitis,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
148713922,14871392,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Nausea,,2018,Q3,2,F,201803.0,20180625.0,20180509,20180702,EXP,,US-ABBVIE-18S-163-2343061-00,ABBVIE,,70.0,YR,,M,Y,,,20180702.0,,CN,US,US,2018,Q3,Elderly
149190623,14919062,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",2450.0,MG,,,,,,10.0,MG,,QD,2018,Q3,Gastritis erosive,,2018,Q3,3,F,20161030.0,20180823.0,20180521,20180828,EXP,,DE-PFIZER INC-2018205861,PFIZER,,64.0,YR,,M,Y,101.0,KG,20180828.0,,MD,DE,DE,2018,Q3,Adult
149190623,14919062,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",2450.0,MG,,,,,,10.0,MG,,QD,2018,Q3,Melaena,,2018,Q3,3,F,20161030.0,20180823.0,20180521,20180828,EXP,,DE-PFIZER INC-2018205861,PFIZER,,64.0,YR,,M,Y,101.0,KG,20180828.0,,MD,DE,DE,2018,Q3,Adult
149731282,14973128,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Hepatocellular carcinoma,,2018,Q3,2,F,20180214.0,20180630.0,20180605,20180703,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001965",BOEHRINGER INGELHEIM,,75.0,YR,,M,Y,71.0,KG,20180703.0,,MD,JP,JP,2018,Q3,Elderly
149956163,14995616,13,C,METFORMIN HYDROCHLORIDE?EMPAGLIFLOZIN,,2,Unknown,MET.1000MG/EMPAG.5MG 1 IN 12H,,,U,U,,,,,,,,2018,Q3,Acute pulmonary oedema,,2018,Q3,3,F,20180524.0,20180623.0,20180611,20180806,EXP,,ES-LPDUSPRD-20180984,LUITPOLD,,65.0,YR,,M,Y,74.8,KG,20180803.0,,MD,ES,ES,2018,Q3,Elderly
150220122,15022012,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Pharyngeal cancer,,2018,Q3,2,F,20171211.0,20180628.0,20180618,20180703,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003309",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,65.1,KG,20180703.0,,MD,JP,JP,2018,Q3,Elderly
150373122,15037312,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2018,Q3,Acute myocardial infarction,,2018,Q3,2,F,20180521.0,20180718.0,20180620,20180724,EXP,,PT-ASTRAZENECA-2018SE77407,ASTRAZENECA,,77.0,YR,,M,Y,63.0,KG,20180724.0,,MD,PT,PT,2018,Q3,Elderly
150373122,15037312,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2018,Q3,Lower gastrointestinal haemorrhage,,2018,Q3,2,F,20180521.0,20180718.0,20180620,20180724,EXP,,PT-ASTRAZENECA-2018SE77407,ASTRAZENECA,,77.0,YR,,M,Y,63.0,KG,20180724.0,,MD,PT,PT,2018,Q3,Elderly
150667693,15066769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Presyncope,,2018,Q3,3,F,20180228.0,20180711.0,20180626,20180724,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003161",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,94.2,KG,20180724.0,,MD,JP,JP,2018,Q3,Adult
150934972,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,TABLET,,2018,Q3,Renal impairment,,2018,Q3,2,F,20180202.0,20180709.0,20180629,20180710,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20180710.0,,MD,DE,DE,2018,Q3,Elderly
150934972,15093497,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,TABLET,,2018,Q3,Systemic inflammatory response syndrome,,2018,Q3,2,F,20180202.0,20180709.0,20180629,20180710,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-008515",BOEHRINGER INGELHEIM,,78.0,YR,,F,Y,60.0,KG,20180710.0,,MD,DE,DE,2018,Q3,Elderly
151071272,15107127,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Angina pectoris,,2018,Q3,2,F,20171030.0,20180809.0,20180704,20180810,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003313",BOEHRINGER INGELHEIM,,50.0,YR,,F,Y,61.0,KG,20180810.0,,MD,JP,JP,2018,Q3,Adult
151093201,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Arthritis bacterial,,2018,Q3,1,I,20161017.0,20180314.0,20180705,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
151093201,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cardiac arrest,,2018,Q3,1,I,20161017.0,20180314.0,20180705,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
151093201,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cellulitis,,2018,Q3,1,I,20161017.0,20180314.0,20180705,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
151093201,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Infection,,2018,Q3,1,I,20161017.0,20180314.0,20180705,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
151093201,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Multiple organ dysfunction syndrome,,2018,Q3,1,I,20161017.0,20180314.0,20180705,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
151093201,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Skin ulcer,,2018,Q3,1,I,20161017.0,20180314.0,20180705,20180705,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20180705.0,,MD,JP,JP,2018,Q3,Elderly
151132782,15113278,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,10.0,MG,TABLET,,2018,Q3,Diarrhoea,,2018,Q3,2,F,201806.0,20180711.0,20180706,20180717,EXP,,US-ASTELLAS-2018US030122,ASTELLAS,,66.0,YR,,M,Y,,,20180717.0,,CN,US,US,2018,Q3,Elderly
151132782,15113278,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,U,,,,10.0,MG,TABLET,,2018,Q3,Pain,,2018,Q3,2,F,201806.0,20180711.0,20180706,20180717,EXP,,US-ASTELLAS-2018US030122,ASTELLAS,,66.0,YR,,M,Y,,,20180717.0,,CN,US,US,2018,Q3,Elderly
151134031,15113403,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,204629.0,1.0,DF,TABLET,QD,2018,Q3,Pancreatitis,,2018,Q3,1,I,,20180629.0,20180706,20180706,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-033965",BOEHRINGER INGELHEIM,SZLADEK H. GYAKORLATI TAPASZTALATOK KOMBINALT KEZELES TERAPIABA ILLESZTESEVEL. METABOLIZMUS 2018/2. 164?166.,65.0,YR,,M,Y,,,20180706.0,,MD,HU,HU,2018,Q3,Elderly
151140731,15114073,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Ketosis,,2018,Q3,1,I,201708.0,20180630.0,20180706,20180706,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003721",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,74.9,KG,20180706.0,,MD,JP,JP,2018,Q3,Adult
151267741,15126774,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2018,Q3,Renal impairment,,2018,Q3,1,I,20180613.0,,20180614,20180614,DIR,,,FDA-CTU,,60.0,YR,,M,N,137.7,KG,20180614.0,N,PH,US,US,2018,Q3,Adult
151290341,15129034,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Angina pectoris,,2018,Q3,1,I,20171013.0,20180222.0,20180711,20180711,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000847",BOEHRINGER INGELHEIM,,75.0,YR,,F,Y,77.4,KG,20180711.0,,MD,JP,JP,2018,Q3,Elderly
151332762,15133276,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Lip and/or oral cavity cancer,,2018,Q3,2,F,20170921.0,20180905.0,20180712,20180907,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003865",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,75.8,KG,20180907.0,,MD,JP,JP,2018,Q3,Elderly
151332762,15133276,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Lip and/or oral cavity cancer,,2018,Q3,2,F,20170921.0,20180905.0,20180712,20180907,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-003865",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,75.8,KG,20180907.0,,MD,JP,JP,2018,Q3,Elderly
151346752,15134675,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",4290.0,MG,Y,,,,,10.0,MG,,QD,2018,Q3,Lower respiratory tract infection,,2018,Q3,2,F,20180102.0,20180911.0,20180712,20180917,EXP,,PHHO2018GB000903,NOVARTIS,,62.0,YR,,M,Y,99.1,KG,20180917.0,,OT,GB,GB,2018,Q3,Adult
151346752,15134675,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",4290.0,MG,Y,,,,,10.0,MG,,QD,2018,Q3,Pancreatitis acute,,2018,Q3,2,F,20180102.0,20180911.0,20180712,20180917,EXP,,PHHO2018GB000903,NOVARTIS,,62.0,YR,,M,Y,99.1,KG,20180917.0,,OT,GB,GB,2018,Q3,Adult
151447827,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cardiac arrest,,2018,Q3,7,F,20180704.0,20180814.0,20180713,20180815,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20180815.0,,MD,DE,DE,2018,Q3,Adult
151447827,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Hypoglycaemia,,2018,Q3,7,F,20180704.0,20180814.0,20180713,20180815,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20180815.0,,MD,DE,DE,2018,Q3,Adult
151447827,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Hyponatraemia,,2018,Q3,7,F,20180704.0,20180814.0,20180713,20180815,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20180815.0,,MD,DE,DE,2018,Q3,Adult
151447827,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Hypotension,,2018,Q3,7,F,20180704.0,20180814.0,20180713,20180815,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20180815.0,,MD,DE,DE,2018,Q3,Adult
151447827,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Neurological symptom,,2018,Q3,7,F,20180704.0,20180814.0,20180713,20180815,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20180815.0,,MD,DE,DE,2018,Q3,Adult
151447827,15144782,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Pulmonary embolism,,2018,Q3,7,F,20180704.0,20180814.0,20180713,20180815,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-035148",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,94.0,KG,20180815.0,,MD,DE,DE,2018,Q3,Adult
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Atrial pressure increased,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Cardiac failure,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Choking,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Ejection fraction decreased,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Hypomagnesaemia,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Inflammation,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Intracardiac thrombus,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Pneumonia aspiration,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Pyrexia,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Tachycardia,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Ventricular fibrillation,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Atrial pressure increased,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Cardiac failure,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Choking,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Ejection fraction decreased,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Hypomagnesaemia,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Inflammation,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Intracardiac thrombus,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Pneumonia aspiration,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Pyrexia,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Tachycardia,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151448712,15144871,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q3,Ventricular fibrillation,,2018,Q3,2,F,20180413.0,20180822.0,20180713,20180824,EXP,,JP-BEH-2018092353,CSL BEHRING,,73.0,YR,E,M,Y,63.7,KG,20180824.0,,MD,JP,JP,2018,Q3,Elderly
151484522,15148452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Back pain,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Blood uric acid increased,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Diabetes mellitus inadequate control,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Hypertension,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Miliaria,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Back pain,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Blood uric acid increased,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Diabetes mellitus inadequate control,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Hypertension,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Miliaria,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151484522,15148452,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,2,F,201608.0,20180801.0,20180716,20180807,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004658",BOEHRINGER INGELHEIM,,25.0,YR,,M,Y,,,20180807.0,,MD,JP,JP,2018,Q3,Young Adult
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Acute myocardial infarction,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Atrial fibrillation,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Benign prostatic hyperplasia,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Diabetic nephropathy,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Diabetic neuropathy,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Diabetic retinopathy,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151674981,15167498,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,D,,,,,10.0,MG,TABLET,QD,2018,Q3,Ventricular fibrillation,,2018,Q3,1,I,2012.0,20180709.0,20180719,20180719,EXP,,SK-MYLANLABS-2018M1052172,MYLAN,MURIN J.. ZAHRNAJU KARDIOVASKULARNE OCHORENIA I DIABETES.. 2018?17?8,67.0,YR,,M,Y,90.0,KG,20180718.0,,OT,SK,SK,2018,Q3,Elderly
151780941,15178094,2,SS,EMPAGLIFLOZIN W/METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12,5/850 MG 1 X1 (1)",,,D,, UNK,,,,,FILM COATED TABLET,,2018,Q3,Cardiovascular insufficiency,,2018,Q3,1,I,20180701.0,20180707.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036467,AUROBINDO,,71.0,YR,,F,Y,,,20180721.0,,MD,SE,SE,2018,Q3,Elderly
151780941,15178094,2,SS,EMPAGLIFLOZIN W/METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12,5/850 MG 1 X1 (1)",,,D,, UNK,,,,,FILM COATED TABLET,,2018,Q3,Lactic acidosis,,2018,Q3,1,I,20180701.0,20180707.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036467,AUROBINDO,,71.0,YR,,F,Y,,,20180721.0,,MD,SE,SE,2018,Q3,Elderly
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Abdominal discomfort,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Abdominal pain,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Hyperglycaemia,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Ketoacidosis,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Kussmaul respiration,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Nausea,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Polydipsia,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Polyuria,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151782101,15178210,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Vomiting,,2018,Q3,1,I,,20180706.0,20180721,20180721,EXP,,SE-AUROBINDO-AUR-APL-2018-036016,AUROBINDO,,43.0,YR,,M,Y,,,20180721.0,,OT,SE,SE,2018,Q3,Adult
151798453,15179845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12 MG, UNK",,,U,U,,,,12.0,MG,,,2018,Q3,Erysipelas,,2018,Q3,3,F,20180409.0,20180821.0,20180723,20180827,EXP,,PHHO2018SE008264,NOVARTIS,,72.0,YR,,M,Y,105.0,KG,20180827.0,,MD,SE,SE,2018,Q3,Elderly
151798453,15179845,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12 MG, UNK",,,U,U,,,,12.0,MG,,,2018,Q3,Sepsis,,2018,Q3,3,F,20180409.0,20180821.0,20180723,20180827,EXP,,PHHO2018SE008264,NOVARTIS,,72.0,YR,,M,Y,105.0,KG,20180827.0,,MD,SE,SE,2018,Q3,Elderly
151832393,15183239,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q3,Pyelonephritis acute,,2018,Q3,3,F,20180228.0,20180813.0,20180723,20180816,EXP,,"CZ-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037658",BOEHRINGER INGELHEIM,,70.0,YR,,F,Y,80.0,KG,20180816.0,,MD,CZ,CZ,2018,Q3,Elderly
152013891,15201389,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,UNKNOWN,,,D,U, UNKNOWN,,,,,,,2018,Q3,Completed suicide,,2018,Q3,1,I,,20180718.0,20180726,20180726,EXP,,US-TORRENT-00006532,TORRENT,,60.0,YR,,M,Y,,,20180726.0,,MD,US,US,2018,Q3,Adult
152013891,15201389,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,UNKNOWN,,,D,U, UNKNOWN,,,,,,,2018,Q3,Toxicity to various agents,,2018,Q3,1,I,,20180718.0,20180726,20180726,EXP,,US-TORRENT-00006532,TORRENT,,60.0,YR,,M,Y,,,20180726.0,,MD,US,US,2018,Q3,Adult
152018193,15201819,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Brain stem haemorrhage,,2018,Q3,3,F,20180720.0,20180825.0,20180726,20180827,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004062",BOEHRINGER INGELHEIM,,46.0,YR,,M,Y,101.1,KG,20180827.0,,MD,JP,JP,2018,Q3,Adult
152022973,15202297,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK,UNK",,,U,,,,,,,,,2018,Q3,Deep vein thrombosis,,2018,Q3,3,F,20180312.0,20180726.0,20180726,20180810,EXP,,US-SA-2018SA091169,SANOFI AVENTIS,,71.0,YR,E,M,Y,93.7,KG,20180810.0,,MD,US,US,2018,Q3,Elderly
152022973,15202297,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK,UNK",,,U,,,,,,,,,2018,Q3,Hepatic cancer,,2018,Q3,3,F,20180312.0,20180726.0,20180726,20180810,EXP,,US-SA-2018SA091169,SANOFI AVENTIS,,71.0,YR,E,M,Y,93.7,KG,20180810.0,,MD,US,US,2018,Q3,Elderly
152022973,15202297,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK,UNK",,,U,,,,,,,,,2018,Q3,Pancreatic carcinoma,,2018,Q3,3,F,20180312.0,20180726.0,20180726,20180810,EXP,,US-SA-2018SA091169,SANOFI AVENTIS,,71.0,YR,E,M,Y,93.7,KG,20180810.0,,MD,US,US,2018,Q3,Elderly
152022973,15202297,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK,UNK",,,U,,,,,,,,,2018,Q3,Pulmonary embolism,,2018,Q3,3,F,20180312.0,20180726.0,20180726,20180810,EXP,,US-SA-2018SA091169,SANOFI AVENTIS,,71.0,YR,E,M,Y,93.7,KG,20180810.0,,MD,US,US,2018,Q3,Elderly
152031011,15203101,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 DF,QD",,,,,,,,10.0,DF,,QD,2018,Q3,Transient ischaemic attack,,2018,Q3,1,I,20180108.0,20180315.0,20180726,20180726,EXP,,US-SA-2018SA082951,SANOFI AVENTIS,,59.0,YR,A,M,Y,103.9,KG,20180726.0,,MD,US,US,2018,Q3,Adult
152070931,15207093,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,Y,,,,10.0,MG,,QD,2018,Q3,Hypoaesthesia,,2018,Q3,1,I,20180130.0,,20180628,20180628,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20180618.0,N,PH,US,US,2018,Q3,Elderly
152155122,15215512,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Lacunar stroke,,2018,Q3,2,F,20180706.0,20180824.0,20180730,20180829,EXP,,GB-ELI_LILLY_AND_COMPANY-GB201807008913,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20180829.0,,CN,GB,GB,2018,Q3,Adult
152187433,15218743,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,,,FILM-COATED TABLET,,2018,Q3,Hemiparesis,,2018,Q3,3,F,20180620.0,20180810.0,20180731,20180815,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-037662",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,100.8,KG,20180815.0,,MD,BR,BR,2018,Q3,Elderly
152235881,15223588,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,1,I,20170816.0,20180724.0,20180731,20180731,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004150",BOEHRINGER INGELHEIM,,50.0,YR,,M,Y,90.4,KG,20180731.0,,MD,JP,JP,2018,Q3,Adult
152255891,15225589,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2018,Q3,Rash,,2018,Q3,1,I,20180212.0,,20180705,20180705,DIR,,,FDA-CTU,,64.0,YR,,M,N,92.0,KG,20180417.0,N,PH,US,US,2018,Q3,Adult
152303931,15230393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2018,Q3,Dehydration,,2018,Q3,1,I,20180305.0,,20180706,20180706,DIR,,,FDA-CTU,,62.0,YR,,F,N,,,20180521.0,N,PH,US,US,2018,Q3,Adult
152303931,15230393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2018,Q3,Hypotension,,2018,Q3,1,I,20180305.0,,20180706,20180706,DIR,,,FDA-CTU,,62.0,YR,,F,N,,,20180521.0,N,PH,US,US,2018,Q3,Adult
152303931,15230393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2018,Q3,Syncope,,2018,Q3,1,I,20180305.0,,20180706,20180706,DIR,,,FDA-CTU,,62.0,YR,,F,N,,,20180521.0,N,PH,US,US,2018,Q3,Adult
152352581,15235258,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,1,I,20180330.0,20180728.0,20180803,20180803,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004215",BOEHRINGER INGELHEIM,,61.0,YR,,F,Y,51.0,KG,20180803.0,,MD,JP,JP,2018,Q3,Adult
152374581,15237458,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,D,,,,,25.0,MG,,,2018,Q3,Caesarean section,,2018,Q3,1,I,,20180720.0,20180803,20180803,EXP,,IT-AUROBINDO-AUR-APL-2018-038678,AUROBINDO,,31.0,YR,,F,Y,98.0,KG,20180803.0,,OT,IT,IT,2018,Q3,Young Adult
152374581,15237458,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,D,,,,,25.0,MG,,,2018,Q3,Maternal exposure during pregnancy,,2018,Q3,1,I,,20180720.0,20180803,20180803,EXP,,IT-AUROBINDO-AUR-APL-2018-038678,AUROBINDO,,31.0,YR,,F,Y,98.0,KG,20180803.0,,OT,IT,IT,2018,Q3,Young Adult
152374581,15237458,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,D,,,,,25.0,MG,,,2018,Q3,Normal newborn,,2018,Q3,1,I,,20180720.0,20180803,20180803,EXP,,IT-AUROBINDO-AUR-APL-2018-038678,AUROBINDO,,31.0,YR,,F,Y,98.0,KG,20180803.0,,OT,IT,IT,2018,Q3,Young Adult
152374581,15237458,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,D,,,,,25.0,MG,,,2018,Q3,Off label use,,2018,Q3,1,I,,20180720.0,20180803,20180803,EXP,,IT-AUROBINDO-AUR-APL-2018-038678,AUROBINDO,,31.0,YR,,F,Y,98.0,KG,20180803.0,,OT,IT,IT,2018,Q3,Young Adult
152402002,15240200,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, DAILY",,,,, UNKNOWN,,,25.0,MG,,,2018,Q3,Colitis microscopic,,2018,Q3,2,F,20180414.0,20180803.0,20180804,20180818,EXP,,DE-AUROBINDO-AUR-APL-2018-038246,AUROBINDO,,77.0,YR,,F,Y,87.0,KG,20180818.0,,OT,DE,DE,2018,Q3,Elderly
152402002,15240200,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, DAILY",,,,, UNKNOWN,,,25.0,MG,,,2018,Q3,Gastrointestinal haemorrhage,,2018,Q3,2,F,20180414.0,20180803.0,20180804,20180818,EXP,,DE-AUROBINDO-AUR-APL-2018-038246,AUROBINDO,,77.0,YR,,F,Y,87.0,KG,20180818.0,,OT,DE,DE,2018,Q3,Elderly
152402002,15240200,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, DAILY",,,,, UNKNOWN,,,25.0,MG,,,2018,Q3,Pseudomonas test positive,,2018,Q3,2,F,20180414.0,20180803.0,20180804,20180818,EXP,,DE-AUROBINDO-AUR-APL-2018-038246,AUROBINDO,,77.0,YR,,F,Y,87.0,KG,20180818.0,,OT,DE,DE,2018,Q3,Elderly
152402002,15240200,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, DAILY",,,,, UNKNOWN,,,25.0,MG,,,2018,Q3,Spinal instability,,2018,Q3,2,F,20180414.0,20180803.0,20180804,20180818,EXP,,DE-AUROBINDO-AUR-APL-2018-038246,AUROBINDO,,77.0,YR,,F,Y,87.0,KG,20180818.0,,OT,DE,DE,2018,Q3,Elderly
152404049,15240404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,,,2018,Q3,Presyncope,,2018,Q3,9,F,20180723.0,20180924.0,20180804,20180926,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038855",BOEHRINGER INGELHEIM,,88.0,YR,,M,Y,73.0,KG,20180926.0,,MD,CA,CA,2018,Q3,Elderly
152404049,15240404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,,,2018,Q3,Subdural haematoma,,2018,Q3,9,F,20180723.0,20180924.0,20180804,20180926,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038855",BOEHRINGER INGELHEIM,,88.0,YR,,M,Y,73.0,KG,20180926.0,,MD,CA,CA,2018,Q3,Elderly
152455571,15245557,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2018,Q3,Drug ineffective,,2018,Q3,1,I,201106.0,20180724.0,20180806,20180806,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20180806.0,,OT,SK,SK,2018,Q3,Elderly
152455571,15245557,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2018,Q3,Myocardial infarction,,2018,Q3,1,I,201106.0,20180724.0,20180806,20180806,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20180806.0,,OT,SK,SK,2018,Q3,Elderly
152455571,15245557,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, UNK",,,U,,,,,10.0,MG,,,2018,Q3,Weight increased,,2018,Q3,1,I,201106.0,20180724.0,20180806,20180806,EXP,,PHHY2018SK058557,SANDOZ,,66.0,YR,,M,Y,,,20180806.0,,OT,SK,SK,2018,Q3,Elderly
152455741,15245574,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Gastrointestinal haemorrhage,,2018,Q3,1,I,,20180724.0,20180806,20180806,EXP,,PHHY2018DE057302,SANDOZ,,60.0,YR,,F,Y,,,20180806.0,,OT,DE,DE,2018,Q3,Adult
152622701,15262270,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,TID,2018,Q3,Abdominal pain,,2018,Q3,1,I,20180110.0,,20180720,20180720,DIR,,,FDA-CTU,,61.0,YR,,F,N,85.0,KG,20180720.0,N,PH,US,US,2018,Q3,Adult
152622701,15262270,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,TID,2018,Q3,Ketoacidosis,,2018,Q3,1,I,20180110.0,,20180720,20180720,DIR,,,FDA-CTU,,61.0,YR,,F,N,85.0,KG,20180720.0,N,PH,US,US,2018,Q3,Adult
152622701,15262270,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,TID,2018,Q3,Nausea,,2018,Q3,1,I,20180110.0,,20180720,20180720,DIR,,,FDA-CTU,,61.0,YR,,F,N,85.0,KG,20180720.0,N,PH,US,US,2018,Q3,Adult
152622701,15262270,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,TID,2018,Q3,Vomiting,,2018,Q3,1,I,20180110.0,,20180720,20180720,DIR,,,FDA-CTU,,61.0,YR,,F,N,85.0,KG,20180720.0,N,PH,US,US,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Bile duct stone,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cholangitis acute,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Device occlusion,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Jaundice cholestatic,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Liver abscess,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Pancreatic carcinoma,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152645432,15264543,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Vascular stent stenosis,,2018,Q3,2,F,20170301.0,20180903.0,20180810,20180906,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006641",BOEHRINGER INGELHEIM,,52.0,YR,,M,Y,114.5,KG,20180906.0,,MD,JP,JP,2018,Q3,Adult
152715371,15271537,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,,20180801.0,20180813,20180813,EXP,,US-GLENMARK PHARMACEUTICALS-2018GMK036947,GLENMARK,"ALHASSAN S, RUDONI M, JAUME J C.. PROLONGED GLUCOSURIA AFTER DISCONTINUATION SGLT2 INHIBITORS:IMPLICATIONS FOR WEEKLY DOSING AND EXTENDED RISK OF EUGLYCEMIC DIABETES KETO?ACIDOSIS.. ENDOCRINE REVIEWS. 2018?39 (2:1)",73.0,YR,,F,Y,,,20180813.0,,OT,US,US,2018,Q3,Elderly
152715471,15271547,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,,,,,25.0,MG,,,2018,Q3,Diabetes mellitus inadequate control,,2018,Q3,1,I,,20180801.0,20180813,20180813,EXP,,US-GLENMARK PHARMACEUTICALS-2018GMK036919,GLENMARK,"SACK PA, SMITH JJ. MIFEPRISTONE THERAPY PRIOR TO PITUITARY SURGERY IN CUSHING DISEASE PREVENTED NEED FOR LONG?TERM GLUCOCORTICOID REPLACEMENT.. 100TH ANNUAL MEETING OF THE ENDOCRINE SOCIETY, ENDO 2018. UNITED STATES. 2018?39(2 SUPP 1)",18.0,YR,,F,Y,,,20180813.0,,OT,US,US,2018,Q3,Youth
152728501,15272850,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DAILY DOSE: 10 MG MILLGRAM(S) EVERY DAYS,,,U,, UNKNOWN,,,10.0,MG,,QD,2018,Q3,Hepatic enzyme increased,,2018,Q3,1,I,20180321.0,20180808.0,20180813,20180813,EXP,,PHHY2018DE069984,NOVARTIS,,62.0,YR,,M,Y,,,20180813.0,,OT,DE,DE,2018,Q3,Adult
152737471,15273747,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",50.0,MG,Y,,,,,25.0,MG,TABLET,QD,2018,Q3,Decreased appetite,,2018,Q3,1,I,20171119.0,20180806.0,20180813,20180813,EXP,,AU-009507513-1808AUS003020,MERCK,,53.0,YR,,F,Y,,,20180813.0,,OT,AU,AU,2018,Q3,Adult
152737471,15273747,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",50.0,MG,Y,,,,,25.0,MG,TABLET,QD,2018,Q3,Dehydration,,2018,Q3,1,I,20171119.0,20180806.0,20180813,20180813,EXP,,AU-009507513-1808AUS003020,MERCK,,53.0,YR,,F,Y,,,20180813.0,,OT,AU,AU,2018,Q3,Adult
152737471,15273747,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",50.0,MG,Y,,,,,25.0,MG,TABLET,QD,2018,Q3,Hyperglycaemia,,2018,Q3,1,I,20171119.0,20180806.0,20180813,20180813,EXP,,AU-009507513-1808AUS003020,MERCK,,53.0,YR,,F,Y,,,20180813.0,,OT,AU,AU,2018,Q3,Adult
152737471,15273747,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",50.0,MG,Y,,,,,25.0,MG,TABLET,QD,2018,Q3,Ketoacidosis,,2018,Q3,1,I,20171119.0,20180806.0,20180813,20180813,EXP,,AU-009507513-1808AUS003020,MERCK,,53.0,YR,,F,Y,,,20180813.0,,OT,AU,AU,2018,Q3,Adult
152737471,15273747,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",50.0,MG,Y,,,,,25.0,MG,TABLET,QD,2018,Q3,Vomiting,,2018,Q3,1,I,20171119.0,20180806.0,20180813,20180813,EXP,,AU-009507513-1808AUS003020,MERCK,,53.0,YR,,F,Y,,,20180813.0,,OT,AU,AU,2018,Q3,Adult
152765742,15276574,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,2,F,,20180910.0,20180814,20180925,EXP,,ES-ALKEM LABORATORIES LIMITED-ES-ALKEM-2018-06206,ALKEM,"HERNANDEZ?QUILES C, RAMIREZ?DUQUE N AND ACOSTA?DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT. CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2018?14:1?3",52.0,YR,,M,Y,70.0,KG,20180925.0,,OT,ES,ES,2018,Q3,Adult
152765742,15276574,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2018,Q3,Hyperglycaemia,,2018,Q3,2,F,,20180910.0,20180814,20180925,EXP,,ES-ALKEM LABORATORIES LIMITED-ES-ALKEM-2018-06206,ALKEM,"HERNANDEZ?QUILES C, RAMIREZ?DUQUE N AND ACOSTA?DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT. CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2018?14:1?3",52.0,YR,,M,Y,70.0,KG,20180925.0,,OT,ES,ES,2018,Q3,Adult
152823822,15282382,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Gastric cancer,,2018,Q3,2,F,20180126.0,20180823.0,20180816,20180828,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004452",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.1,KG,20180828.0,,MD,JP,JP,2018,Q3,Adult
152823822,15282382,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Malignant neoplasm of unknown primary site,,2018,Q3,2,F,20180126.0,20180823.0,20180816,20180828,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004452",BOEHRINGER INGELHEIM,,63.0,YR,,M,Y,68.1,KG,20180828.0,,MD,JP,JP,2018,Q3,Adult
152969421,15296942,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,,,TABLET,,2018,Q3,Hypokalaemia,,2018,Q3,1,I,20180809.0,20180813.0,20180820,20180820,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-041179",BOEHRINGER INGELHEIM,,77.0,YR,,F,Y,77.6,KG,20180820.0,,MD,US,US,2018,Q3,Elderly
152971902,15297190,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2018,Q3,Renal impairment,,2018,Q3,2,F,20180325.0,20180821.0,20180820,20180827,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-017595",BOEHRINGER INGELHEIM,,77.0,YR,,M,Y,94.0,KG,20180827.0,,MD,NL,NL,2018,Q3,Elderly
153003901,15300390,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,Y,U, UNKNOWN,,,,,,,2018,Q3,Intestinal obstruction,,2018,Q3,1,I,20180706.0,20180813.0,20180821,20180821,EXP,GB-MHRA-EYC 00183532,GB-NOVOPROD-616659,NOVO NORDISK,,56.0,YR,A,F,Y,92.0,KG,20180821.0,,OT,GB,GB,2018,Q3,Adult
153135942,15313594,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Diabetes mellitus inadequate control,,2018,Q3,2,F,20180501.0,20180829.0,20180824,20180831,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004574",BOEHRINGER INGELHEIM,,81.0,YR,,M,Y,94.6,KG,20180831.0,,MD,JP,JP,2018,Q3,Elderly
153145422,15314542,28,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Malignant neoplasm progression,,2018,Q3,2,F,20180723.0,20180911.0,20180824,20180917,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-069849,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20180917.0,,OT,AU,AU,2018,Q3,Adult
153145422,15314542,28,C,EMPAGLIFLOZIN;METFORMIN,,2,Unknown,UNK,,,U,,,,,,,,,2018,Q3,Vomiting,,2018,Q3,2,F,20180723.0,20180911.0,20180824,20180917,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-069849,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20180917.0,,OT,AU,AU,2018,Q3,Adult
153177623,15317762,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2018,Q3,Cerebellar infarction,,2018,Q3,3,F,20170116.0,20180920.0,20180824,20180922,EXP,,JP-ABBVIE-18K-087-2284026-00,ABBVIE,,65.0,YR,,M,Y,88.2,KG,20180922.0,,MD,JP,JP,2018,Q3,Elderly
153177623,15317762,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2018,Q3,Lung adenocarcinoma,,2018,Q3,3,F,20170116.0,20180920.0,20180824,20180922,EXP,,JP-ABBVIE-18K-087-2284026-00,ABBVIE,,65.0,YR,,M,Y,88.2,KG,20180922.0,,MD,JP,JP,2018,Q3,Elderly
153320911,15332091,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2018,Q3,Colitis microscopic,,2018,Q3,1,I,20180414.0,20180819.0,20180829,20180829,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20180829.0,,OT,DE,DE,2018,Q3,Elderly
153320911,15332091,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2018,Q3,Gastrointestinal haemorrhage,,2018,Q3,1,I,20180414.0,20180819.0,20180829,20180829,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20180829.0,,OT,DE,DE,2018,Q3,Elderly
153320911,15332091,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2018,Q3,Pseudomonas test positive,,2018,Q3,1,I,20180414.0,20180819.0,20180829,20180829,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20180829.0,,OT,DE,DE,2018,Q3,Elderly
153320911,15332091,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD  (DAILY DOSE)",,,,,,,,25.0,MG,,QD,2018,Q3,Spinal instability,,2018,Q3,1,I,20180414.0,20180819.0,20180829,20180829,EXP,,PHHY2018DE079229,SANDOZ,,77.0,YR,,F,Y,87.0,KG,20180829.0,,OT,DE,DE,2018,Q3,Elderly
153338551,15333855,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Urine ketone body present,,2018,Q3,1,I,20171117.0,20180824.0,20180830,20180830,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004674",BOEHRINGER INGELHEIM,,46.0,YR,,M,Y,74.0,KG,20180830.0,,MD,JP,JP,2018,Q3,Adult
153353501,15335350,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,25.0,MG,,,2018,Q3,Maternal exposure during pregnancy,,2018,Q3,1,I,,20180819.0,20180830,20180830,EXP,,PHHY2018IT079863,SANDOZ,,31.0,YR,,F,Y,98.0,KG,20180830.0,,OT,IT,IT,2018,Q3,Young Adult
153353501,15335350,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,25.0,MG,,,2018,Q3,Normal newborn,,2018,Q3,1,I,,20180819.0,20180830,20180830,EXP,,PHHY2018IT079863,SANDOZ,,31.0,YR,,F,Y,98.0,KG,20180830.0,,OT,IT,IT,2018,Q3,Young Adult
153353501,15335350,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,25.0,MG,,,2018,Q3,Off label use,,2018,Q3,1,I,,20180819.0,20180830,20180830,EXP,,PHHY2018IT079863,SANDOZ,,31.0,YR,,F,Y,98.0,KG,20180830.0,,OT,IT,IT,2018,Q3,Young Adult
153381801,15338180,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Cognitive disorder,,2018,Q3,1,I,20180219.0,20180829.0,20180831,20180831,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004709",BOEHRINGER INGELHEIM,,86.0,YR,,F,Y,51.5,KG,20180831.0,,MD,JP,JP,2018,Q3,Elderly
153381801,15338180,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Hyperglycaemia,,2018,Q3,1,I,20180219.0,20180829.0,20180831,20180831,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004709",BOEHRINGER INGELHEIM,,86.0,YR,,F,Y,51.5,KG,20180831.0,,MD,JP,JP,2018,Q3,Elderly
153400431,15340043,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MG, QD",,,U,U,,,,20.0,MG,,QD,2018,Q3,Gamma-glutamyltransferase increased,,2018,Q3,1,I,20180709.0,20180828.0,20180831,20180831,EXP,,AT-ALLERGAN-1842071US,ALLERGAN,,75.0,YR,,M,Y,,,20180831.0,,CN,AT,AT,2018,Q3,Elderly
153400431,15340043,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MG, QD",,,U,U,,,,20.0,MG,,QD,2018,Q3,Insomnia,,2018,Q3,1,I,20180709.0,20180828.0,20180831,20180831,EXP,,AT-ALLERGAN-1842071US,ALLERGAN,,75.0,YR,,M,Y,,,20180831.0,,CN,AT,AT,2018,Q3,Elderly
153443761,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Emphysema,,2018,Q3,1,I,201805.0,20180829.0,20180903,20180903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20180903.0,,MD,JP,JP,2018,Q3,Adult
153443761,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Interstitial lung disease,,2018,Q3,1,I,201805.0,20180829.0,20180903,20180903,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20180903.0,,MD,JP,JP,2018,Q3,Adult
153578211,15357821,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q3,Pancreatitis,,2018,Q3,1,I,,20180828.0,20180906,20180906,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-02867",IMPAX,"LIGHTBOURNE T, NAJAFIAN N, MCCARTY TR. CONSIDERATION FOR EMPAGLIFLOZIN?ASSOCIATED PANCREATITIS. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2017?112(SUPPL 1):S710",52.0,YR,,F,Y,,,20180906.0,,OT,US,US,2018,Q3,Adult
153593771,15359377,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,,20180828.0,20180907,20180907,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-082583,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,,,20180907.0,,OT,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Eye swelling,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Hypersensitivity,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Nasal congestion,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Pain,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Penile odour,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Penile swelling,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Pharyngeal oedema,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Pollakiuria,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153666961,15366696,1,PS,EMPAGLIFLOZIN 25 MG,EMPAGLIFLOZIN,1,Oral,?          QUANTITY:1 TABLET(S);?,,,Y,D,,,99.0,,,TABLET,,2018,Q3,Swelling face,,2018,Q3,1,I,20180901.0,,20180902,20180902,DIR,,,FDA-CTU,,71.0,YR,,M,N,81.9,KG,20180902.0,N,CN,US,US,2018,Q3,Elderly
153704301,15370430,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 MG, UNK",,,Y,,,,,12.5,MG,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180823.0,20180906.0,20180911,20180911,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-083854,BRISTOL MYERS SQUIBB,,52.0,YR,,F,Y,,,20180911.0,,MD,GB,GB,2018,Q3,Adult
153785701,15378570,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,12.5,MG,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180823.0,20180908.0,20180913,20180913,EXP,GB-MHRA-EYC 00184687,GB-BAUSCH-BL-2018-025143,BAUSCH AND LOMB,,52.0,YR,,F,Y,,,20180913.0,,MD,GB,GB,2018,Q3,Adult
153804451,15380445,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q3,Epistaxis,,2018,Q3,1,I,201806.0,20180529.0,20180913,20180913,PER,,US-ASTELLAS-2018US024826,ASTELLAS,,74.0,YR,,M,Y,,,20180913.0,,CN,US,US,2018,Q3,Elderly
153804451,15380445,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN FREQ.",,,D,U,,,,,,FORMULATION UNKNOWN,,2018,Q3,Fatigue,,2018,Q3,1,I,201806.0,20180529.0,20180913,20180913,PER,,US-ASTELLAS-2018US024826,ASTELLAS,,74.0,YR,,M,Y,,,20180913.0,,CN,US,US,2018,Q3,Elderly
153863981,15386398,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 MG, UNK",162.0,MG,Y,,,,,12.5,MG,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180823.0,20180910.0,20180914,20180914,EXP,,PHHY2018GB096720,SANDOZ,,52.0,YR,,F,Y,,,20180914.0,,OT,GB,GB,2018,Q3,Adult
154011831,15401183,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Fall,,2018,Q3,1,I,20171020.0,20180912.0,20180919,20180919,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004957",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,62.0,KG,20180919.0,,MD,JP,JP,2018,Q3,Elderly
154011831,15401183,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Spinal compression fracture,,2018,Q3,1,I,20171020.0,20180912.0,20180919,20180919,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004957",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,62.0,KG,20180919.0,,MD,JP,JP,2018,Q3,Elderly
154011831,15401183,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q3,Subdural haematoma,,2018,Q3,1,I,20171020.0,20180912.0,20180919,20180919,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004957",BOEHRINGER INGELHEIM,,76.0,YR,,M,Y,62.0,KG,20180919.0,,MD,JP,JP,2018,Q3,Elderly
154077111,15407711,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180823.0,20180919.0,20180920,20180920,EXP,GB-MHRA-EYC 00184687,GB-TEVA-2018-GB-956494,TEVA,,52.0,YR,,F,Y,,,20180920.0,,MD,GB,GB,2018,Q3,Adult
154153251,15415325,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,131597.0,,,,,2018,Q3,Dizziness,,2018,Q3,1,I,,20180912.0,20180921,20180921,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-045496",BOEHRINGER INGELHEIM,"MCNEILL D, HERBST R. SPECIAL CONSIDERATIONS IN THE MANAGEMENT OF DIABETES IN WOMEN. JOURNAL OF WOMEN^S HEALTH. 2018?27:8:982?986.",52.0,YR,,F,Y,,,20180922.0,,MD,US,US,2018,Q3,Adult
154215811,15421581,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Abdominal distension,,2018,Q3,1,I,,20180529.0,20180924,20180924,PER,,US-ALLERGAN-1828390US,ALLERGAN,,85.0,YR,,M,Y,,,20180924.0,,CN,US,US,2018,Q3,Elderly
154215811,15421581,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q3,Abdominal symptom,,2018,Q3,1,I,,20180529.0,20180924,20180924,PER,,US-ALLERGAN-1828390US,ALLERGAN,,85.0,YR,,M,Y,,,20180924.0,,CN,US,US,2018,Q3,Elderly
154227701,15422770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q3,Acute kidney injury,,2018,Q3,1,I,,20180810.0,20180925,20180925,EXP,,ES-BAUSCH-BL-2018-022283,BAUSCH AND LOMB,"HERNANDEZ?QUILES C, RAMIRE?DUQUE N, ACOSTA?DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT. CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2018?14:1?3.",52.0,YR,,M,Y,70.0,KG,20180925.0,,OT,ES,ES,2018,Q3,Adult
154227701,15422770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,,20180810.0,20180925,20180925,EXP,,ES-BAUSCH-BL-2018-022283,BAUSCH AND LOMB,"HERNANDEZ?QUILES C, RAMIRE?DUQUE N, ACOSTA?DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT. CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2018?14:1?3.",52.0,YR,,M,Y,70.0,KG,20180925.0,,OT,ES,ES,2018,Q3,Adult
154227701,15422770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q3,Leukocytosis,,2018,Q3,1,I,,20180810.0,20180925,20180925,EXP,,ES-BAUSCH-BL-2018-022283,BAUSCH AND LOMB,"HERNANDEZ?QUILES C, RAMIRE?DUQUE N, ACOSTA?DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT. CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2018?14:1?3.",52.0,YR,,M,Y,70.0,KG,20180925.0,,OT,ES,ES,2018,Q3,Adult
154227701,15422770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q3,Neutrophilia,,2018,Q3,1,I,,20180810.0,20180925,20180925,EXP,,ES-BAUSCH-BL-2018-022283,BAUSCH AND LOMB,"HERNANDEZ?QUILES C, RAMIRE?DUQUE N, ACOSTA?DELGADO D. KETOACIDOSIS DUE TO EMPAGLIFLOZIN, A PARADIGM SHIFT. CASE REPORT AND REVIEW OF LITERATURE. CURRENT DIABETES REVIEWS. 2018?14:1?3.",52.0,YR,,M,Y,70.0,KG,20180925.0,,OT,ES,ES,2018,Q3,Adult
154328361,15432836,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,TABLET,,2018,Q3,Acute kidney injury,,2018,Q3,1,I,20180611.0,20180926.0,20180927,20180927,EXP,GB-MHRA-MIDB-5EE1CA43-82F8-4638-A982-6700FA27DF7A,GB-TEVA-2018-GB-958856,TEVA,,82.0,YR,,F,Y,,,20180927.0,,PH,GB,GB,2018,Q3,Elderly
154328361,15432836,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,TABLET,,2018,Q3,Hyperkalaemia,,2018,Q3,1,I,20180611.0,20180926.0,20180927,20180927,EXP,GB-MHRA-MIDB-5EE1CA43-82F8-4638-A982-6700FA27DF7A,GB-TEVA-2018-GB-958856,TEVA,,82.0,YR,,F,Y,,,20180927.0,,PH,GB,GB,2018,Q3,Elderly
154398811,15439881,10,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Off label use,,2018,Q3,1,I,,20180912.0,20180928,20180928,EXP,,AU-SUNOVION-2018DSP011209,SUNOVION,,59.0,YR,,F,Y,,,20180928.0,,CN,AU,AU,2018,Q3,Adult
154398811,15439881,10,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Pleurothotonus,,2018,Q3,1,I,,20180912.0,20180928,20180928,EXP,,AU-SUNOVION-2018DSP011209,SUNOVION,,59.0,YR,,F,Y,,,20180928.0,,CN,AU,AU,2018,Q3,Adult
154402601,15440260,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,5.0,MG,,BID,2018,Q3,Deep vein thrombosis,,2018,Q3,1,I,,20180917.0,20180928,20180928,EXP,,ES-NOVOPROD-623305,NOVO NORDISK,,74.0,YR,E,F,Y,,,20180928.0,,MD,ES,ES,2018,Q3,Elderly
154402601,15440260,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,5.0,MG,,BID,2018,Q3,Hypoglycaemia,,2018,Q3,1,I,,20180917.0,20180928,20180928,EXP,,ES-NOVOPROD-623305,NOVO NORDISK,,74.0,YR,E,F,Y,,,20180928.0,,MD,ES,ES,2018,Q3,Elderly
154402601,15440260,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,5.0,MG,,BID,2018,Q3,Weight decreased,,2018,Q3,1,I,,20180917.0,20180928,20180928,EXP,,ES-NOVOPROD-623305,NOVO NORDISK,,74.0,YR,E,F,Y,,,20180928.0,,MD,ES,ES,2018,Q3,Elderly
130111943,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Albumin urine present,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Hypertension,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Left ventricular hypertrophy,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Red blood cell count increased,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Albumin urine present,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Hypertension,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Left ventricular hypertrophy,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Red blood cell count increased,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130111943,13011194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,3,F,20160810.0,20181221.0,20161208,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001158",BOEHRINGER INGELHEIM,,38.0,YR,,F,Y,85.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
130432424,13043242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood creatine phosphokinase increased,,2018,Q4,4,F,20160917.0,20181210.0,20161219,20181218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001374",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.4,KG,20181218.0,,MD,JP,JP,2018,Q4,Elderly
130432424,13043242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood ketone body increased,,2018,Q4,4,F,20160917.0,20181210.0,20161219,20181218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001374",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.4,KG,20181218.0,,MD,JP,JP,2018,Q4,Elderly
130432424,13043242,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,4,F,20160917.0,20181210.0,20161219,20181218,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-NB-001374",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,60.4,KG,20181218.0,,MD,JP,JP,2018,Q4,Elderly
132580687,13258068,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Glycosylated haemoglobin increased,,2018,Q4,7,F,20170113.0,20181022.0,20170221,20181029,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000742",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,50.3,KG,20181029.0,,MD,JP,JP,2018,Q4,Elderly
132580687,13258068,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,7,F,20170113.0,20181022.0,20170221,20181029,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000742",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,50.3,KG,20181029.0,,MD,JP,JP,2018,Q4,Elderly
132580687,13258068,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Glycosylated haemoglobin increased,,2018,Q4,7,F,20170113.0,20181022.0,20170221,20181029,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000742",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,50.3,KG,20181029.0,,MD,JP,JP,2018,Q4,Elderly
132580687,13258068,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,7,F,20170113.0,20181022.0,20170221,20181029,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-000742",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,50.3,KG,20181029.0,,MD,JP,JP,2018,Q4,Elderly
138683894,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood ketone body increased,,2018,Q4,4,F,20170728.0,20181116.0,20170815,20181123,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20181123.0,,MD,JP,JP,2018,Q4,Adult
138683894,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Hypercholesterolaemia,,2018,Q4,4,F,20170728.0,20181116.0,20170815,20181123,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20181123.0,,MD,JP,JP,2018,Q4,Adult
138683894,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Hyperuricaemia,,2018,Q4,4,F,20170728.0,20181116.0,20170815,20181123,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20181123.0,,MD,JP,JP,2018,Q4,Adult
138683894,13868389,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Leukocytosis,,2018,Q4,4,F,20170728.0,20181116.0,20170815,20181123,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004602",BOEHRINGER INGELHEIM,,39.0,YR,,M,Y,89.6,KG,20181123.0,,MD,JP,JP,2018,Q4,Adult
139356714,13935671,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Interstitial lung disease,,2018,Q4,4,F,20170315.0,20181101.0,20170905,20181105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004988",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,62.0,KG,20181105.0,,MD,JP,JP,2018,Q4,Adult
139356714,13935671,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Silent myocardial infarction,,2018,Q4,4,F,20170315.0,20181101.0,20170905,20181105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-004988",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,62.0,KG,20181105.0,,MD,JP,JP,2018,Q4,Adult
140344573,14034457,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood ketone body increased,,2018,Q4,3,F,20170805.0,20180925.0,20171003,20181002,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005622",BOEHRINGER INGELHEIM,,60.0,YR,,M,Y,89.4,KG,20181002.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Asthma,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Back pain,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood urea increased,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Haematocrit increased,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Herpes zoster,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Ligament sprain,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Low density lipoprotein increased,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Polyuria,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Red blood cell count increased,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Road traffic accident,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Upper respiratory tract inflammation,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
140886815,14088681,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,5,F,20160620.0,20181224.0,20171013,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005889",BOEHRINGER INGELHEIM,,53.0,YR,,F,Y,67.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
143137986,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q4,Angina unstable,,2018,Q4,6,F,20171203.0,20181018.0,20171221,20181024,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20181024.0,,OT,DE,DE,2018,Q4,Elderly
143137986,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q4,Cholecystitis,,2018,Q4,6,F,20171203.0,20181018.0,20171221,20181024,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20181024.0,,OT,DE,DE,2018,Q4,Elderly
143137986,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q4,Infection,,2018,Q4,6,F,20171203.0,20181018.0,20171221,20181024,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20181024.0,,OT,DE,DE,2018,Q4,Elderly
143137986,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q4,Multiple organ dysfunction syndrome,,2018,Q4,6,F,20171203.0,20181018.0,20171221,20181024,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20181024.0,,OT,DE,DE,2018,Q4,Elderly
143137986,14313798,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 OTHER,,,,,,,,,,UNKNOWN,QD,2018,Q4,Urosepsis,,2018,Q4,6,F,20171203.0,20181018.0,20171221,20181024,EXP,,DE-CELGENEUS-DEU-20171204818,CELGENE,,77.0,YR,,F,Y,,,20181024.0,,OT,DE,DE,2018,Q4,Elderly
145068662,14506866,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,2,F,,20180928.0,20180208,20181010,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-010897,BRISTOL MYERS SQUIBB,TADA.. TWO CASES OF ACUTE RENAL IMPAIRMENT CAUSED BY SODIUM-GLUCOSE LINKED TRANSPORTER 2 (SGLT2) INHIBITORS. 2017;68,58.0,YR,,F,Y,,,20181010.0,,OT,JP,JP,2018,Q4,Adult
145318434,14531843,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Fall,,2018,Q4,4,F,20161011.0,20181110.0,20180214,20181116,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000619",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,64.5,KG,20181116.0,,MD,JP,JP,2018,Q4,Elderly
145318434,14531843,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Spinal compression fracture,,2018,Q4,4,F,20161011.0,20181110.0,20180214,20181116,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000619",BOEHRINGER INGELHEIM,,73.0,YR,,M,Y,64.5,KG,20181116.0,,MD,JP,JP,2018,Q4,Elderly
145448822,14544882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Dizziness,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Dyslipidaemia,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Musculoskeletal stiffness,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Dizziness,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Dyslipidaemia,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Musculoskeletal stiffness,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145448822,14544882,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,2,F,20170605.0,20181224.0,20180217,20181231,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000688",BOEHRINGER INGELHEIM,,34.0,YR,,F,Y,137.2,KG,20181231.0,,MD,JP,JP,2018,Q4,Young Adult
145744332,14574433,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2018,Q4,Pulmonary embolism,,2018,Q4,2,F,20180207.0,20181221.0,20180226,20181227,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-010077",BOEHRINGER INGELHEIM,,42.0,YR,,M,Y,116.4,KG,20181227.0,,MD,GB,GB,2018,Q4,Adult
146238912,14623891,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood ketone body present,,2018,Q4,2,F,20171104.0,20181219.0,20180312,20181226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001080",BOEHRINGER INGELHEIM,,44.0,YR,,M,Y,111.8,KG,20181226.0,,MD,JP,JP,2018,Q4,Adult
146238912,14623891,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,2,F,20171104.0,20181219.0,20180312,20181226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001080",BOEHRINGER INGELHEIM,,44.0,YR,,M,Y,111.8,KG,20181226.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Iron deficiency anaemia,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Lipids abnormal,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Nasopharyngitis,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Uterine leiomyoma,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Iron deficiency anaemia,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Lipids abnormal,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Nasopharyngitis,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
146428472,14642847,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Uterine leiomyoma,,2018,Q4,2,F,20170316.0,20181222.0,20180315,20181230,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001244",BOEHRINGER INGELHEIM,,43.0,YR,,F,Y,74.9,KG,20181231.0,,MD,JP,JP,2018,Q4,Adult
147996204,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Calculus urinary,,2018,Q4,4,F,20160816.0,20181112.0,20180424,20181119,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20181119.0,,MD,JP,JP,2018,Q4,Adult
147996204,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Oropharyngeal discomfort,,2018,Q4,4,F,20160816.0,20181112.0,20180424,20181119,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20181119.0,,MD,JP,JP,2018,Q4,Adult
147996204,14799620,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urinary tract infection,,2018,Q4,4,F,20160816.0,20181112.0,20180424,20181119,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-002148",BOEHRINGER INGELHEIM,,64.0,YR,,M,Y,87.4,KG,20181119.0,,MD,JP,JP,2018,Q4,Adult
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Anaemia,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood cholesterol increased,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood glucose increased,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood pressure fluctuation,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood uric acid increased,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Cardiomegaly,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Carotid arteriosclerosis,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Chest discomfort,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Decreased ventricular preload,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Dyspnoea exertional,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Electrocardiogram abnormal,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Hepatic lesion,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Ischaemia,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Myocardial ischaemia,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Renal impairment,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
149478933,14947893,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,TABLET,QD,2018,Q4,Transient ischaemic attack,,2018,Q4,3,F,,20181210.0,20180529,20181224,EXP,,PHHY2018HU007083,SANDOZ,,65.0,YR,,M,Y,,,20181224.0,,OT,HU,HU,2018,Q4,Elderly
151093202,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Arthritis bacterial,,2018,Q4,2,F,20161007.0,20181129.0,20180705,20181202,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20181203.0,,MD,JP,JP,2018,Q4,Elderly
151093202,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Cellulitis,,2018,Q4,2,F,20161007.0,20181129.0,20180705,20181202,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20181203.0,,MD,JP,JP,2018,Q4,Elderly
151093202,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Infection,,2018,Q4,2,F,20161007.0,20181129.0,20180705,20181202,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20181203.0,,MD,JP,JP,2018,Q4,Elderly
151093202,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Multiple organ dysfunction syndrome,,2018,Q4,2,F,20161007.0,20181129.0,20180705,20181202,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20181203.0,,MD,JP,JP,2018,Q4,Elderly
151093202,15109320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Skin ulcer,,2018,Q4,2,F,20161007.0,20181129.0,20180705,20181202,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-001258",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,76.9,KG,20181203.0,,MD,JP,JP,2018,Q4,Elderly
151290342,15129034,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Angina pectoris,,2018,Q4,2,F,20171013.0,20181024.0,20180711,20181030,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-000847",BOEHRINGER INGELHEIM,,75.0,YR,,F,Y,77.4,KG,20181030.0,,MD,JP,JP,2018,Q4,Elderly
151553392,15155339,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2018,Q4,Bradycardia,,2018,Q4,2,F,20180705.0,20180928.0,20180717,20181012,EXP,,PHHY2018GB041358,NOVARTIS,,65.0,YR,,M,Y,124.0,KG,20181012.0,,CN,GB,GB,2018,Q4,Elderly
152148371,15214837,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2018,Q4,Caesarean section,,2018,Q4,1,I,,20180722.0,20180730,20180730,EXP,,IT-BAUSCH-BL-2018-020111,BAUSCH AND LOMB,"FORMOSO G, GINESTRA F, DI DALMAZI G, CONSOLI A. EMPAGLIFLOZIN, METFORMIN AND INSULIN DEGLUDEC, DURING PREGNANCY: A CASE REPORT. ACTA DIABETOLOGICA. 2018;55(7):759-761.",31.0,YR,,F,Y,98.0,KG,20180730.0,,OT,IT,IT,2018,Q4,Young Adult
152148371,15214837,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2018,Q4,Maternal exposure during pregnancy,,2018,Q4,1,I,,20180722.0,20180730,20180730,EXP,,IT-BAUSCH-BL-2018-020111,BAUSCH AND LOMB,"FORMOSO G, GINESTRA F, DI DALMAZI G, CONSOLI A. EMPAGLIFLOZIN, METFORMIN AND INSULIN DEGLUDEC, DURING PREGNANCY: A CASE REPORT. ACTA DIABETOLOGICA. 2018;55(7):759-761.",31.0,YR,,F,Y,98.0,KG,20180730.0,,OT,IT,IT,2018,Q4,Young Adult
152148371,15214837,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2018,Q4,Normal newborn,,2018,Q4,1,I,,20180722.0,20180730,20180730,EXP,,IT-BAUSCH-BL-2018-020111,BAUSCH AND LOMB,"FORMOSO G, GINESTRA F, DI DALMAZI G, CONSOLI A. EMPAGLIFLOZIN, METFORMIN AND INSULIN DEGLUDEC, DURING PREGNANCY: A CASE REPORT. ACTA DIABETOLOGICA. 2018;55(7):759-761.",31.0,YR,,F,Y,98.0,KG,20180730.0,,OT,IT,IT,2018,Q4,Young Adult
152148371,15214837,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,,,2018,Q4,Off label use,,2018,Q4,1,I,,20180722.0,20180730,20180730,EXP,,IT-BAUSCH-BL-2018-020111,BAUSCH AND LOMB,"FORMOSO G, GINESTRA F, DI DALMAZI G, CONSOLI A. EMPAGLIFLOZIN, METFORMIN AND INSULIN DEGLUDEC, DURING PREGNANCY: A CASE REPORT. ACTA DIABETOLOGICA. 2018;55(7):759-761.",31.0,YR,,F,Y,98.0,KG,20180730.0,,OT,IT,IT,2018,Q4,Young Adult
153164991,15316499,3,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2018,Q4,Nail discolouration,,2018,Q4,1,I,20180730.0,20180816.0,20180824,20180824,EXP,ES-AEMPS-386625,ES-SA-2018SA229221,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20180824.0,,PH,ES,ES,2018,Q4,Elderly
153164991,15316499,3,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,,,,,,,,2018,Q4,Pigmentation disorder,,2018,Q4,1,I,20180730.0,20180816.0,20180824,20180824,EXP,ES-AEMPS-386625,ES-SA-2018SA229221,SANOFI AVENTIS,,73.0,YR,E,M,Y,,,20180824.0,,PH,ES,ES,2018,Q4,Elderly
153381802,15338180,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Cognitive disorder,,2018,Q4,2,F,20180219.0,20181116.0,20180831,20181120,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004709",BOEHRINGER INGELHEIM,,86.0,YR,,F,Y,51.5,KG,20181120.0,,MD,JP,JP,2018,Q4,Elderly
153381802,15338180,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Hyperglycaemia,,2018,Q4,2,F,20180219.0,20181116.0,20180831,20181120,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004709",BOEHRINGER INGELHEIM,,86.0,YR,,F,Y,51.5,KG,20181120.0,,MD,JP,JP,2018,Q4,Elderly
153381802,15338180,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Cognitive disorder,,2018,Q4,2,F,20180219.0,20181116.0,20180831,20181120,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004709",BOEHRINGER INGELHEIM,,86.0,YR,,F,Y,51.5,KG,20181120.0,,MD,JP,JP,2018,Q4,Elderly
153381802,15338180,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Hyperglycaemia,,2018,Q4,2,F,20180219.0,20181116.0,20180831,20181120,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004709",BOEHRINGER INGELHEIM,,86.0,YR,,F,Y,51.5,KG,20181120.0,,MD,JP,JP,2018,Q4,Elderly
153443762,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Emphysema,,2018,Q4,2,F,201805.0,20181116.0,20180903,20181122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20181122.0,,MD,JP,JP,2018,Q4,Adult
153443762,15344376,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Interstitial lung disease,,2018,Q4,2,F,201805.0,20181116.0,20180903,20181122,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004711",BOEHRINGER INGELHEIM,,62.0,YR,,M,Y,50.7,KG,20181122.0,,MD,JP,JP,2018,Q4,Adult
153467272,15346727,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Genital herpes,,2018,Q4,2,F,20170909.0,20181004.0,20180904,20181005,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004765",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,59.7,KG,20181005.0,,MD,JP,JP,2018,Q4,Adult
153467272,15346727,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Genital herpes,,2018,Q4,2,F,20170909.0,20181004.0,20180904,20181005,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004765",BOEHRINGER INGELHEIM,,49.0,YR,,F,Y,59.7,KG,20181005.0,,MD,JP,JP,2018,Q4,Adult
154183512,15418351,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,,2018,Q4,Cardiovascular disorder,,2018,Q4,2,F,,20181010.0,20180924,20181019,EXP,,US-PFIZER INC-2018380684,PFIZER,,75.0,YR,,F,Y,,,20181019.0,,CN,US,US,2018,Q4,Elderly
154183512,15418351,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,,2018,Q4,Chest pain,,2018,Q4,2,F,,20181010.0,20180924,20181019,EXP,,US-PFIZER INC-2018380684,PFIZER,,75.0,YR,,F,Y,,,20181019.0,,CN,US,US,2018,Q4,Elderly
154183512,15418351,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,,2018,Q4,Dysgeusia,,2018,Q4,2,F,,20181010.0,20180924,20181019,EXP,,US-PFIZER INC-2018380684,PFIZER,,75.0,YR,,F,Y,,,20181019.0,,CN,US,US,2018,Q4,Elderly
154183512,15418351,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,,2018,Q4,Haemorrhage,,2018,Q4,2,F,,20181010.0,20180924,20181019,EXP,,US-PFIZER INC-2018380684,PFIZER,,75.0,YR,,F,Y,,,20181019.0,,CN,US,US,2018,Q4,Elderly
154183512,15418351,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,TABLET,,2018,Q4,Nausea,,2018,Q4,2,F,,20181010.0,20180924,20181019,EXP,,US-PFIZER INC-2018380684,PFIZER,,75.0,YR,,F,Y,,,20181019.0,,CN,US,US,2018,Q4,Elderly
154577691,15457769,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,1,I,20180126.0,20180926.0,20181003,20181003,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-005183",BOEHRINGER INGELHEIM,,30.0,YR,,M,Y,91.0,KG,20181003.0,,MD,JP,JP,2018,Q4,Young Adult
154601561,15460156,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D, UNKNOWN,,,25.0,MG,,QD,2018,Q4,Fournier's gangrene,,2018,Q4,1,I,20180822.0,,20181001,20181001,DIR,,,FDA-CTU,,65.0,YR,,M,N,102.5,KG,20181001.0,N,PH,US,US,2018,Q4,Elderly
154601561,15460156,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D, UNKNOWN,,,25.0,MG,,QD,2018,Q4,Impaired quality of life,,2018,Q4,1,I,20180822.0,,20181001,20181001,DIR,,,FDA-CTU,,65.0,YR,,M,N,102.5,KG,20181001.0,N,PH,US,US,2018,Q4,Elderly
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Asthenia,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Blood glucose fluctuation,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Discomfort,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Drug ineffective,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Therapy non-responder,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Viral infection,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154613152,15461315,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2018,Q4,Weight increased,,2018,Q4,2,F,20120101.0,20181004.0,20181003,20181008,EXP,,CZ-MYLANLABS-2018M1071887,MYLAN,BURDOVA D.. THE EASIER REGIMEN LEADING TO THE BETTER COMPENSATION. CASE REPORTS IN DIABETOLOGY. 2017;15 (3):12-14,43.0,YR,,M,Y,,,20181008.0,,MD,CZ,CZ,2018,Q4,Adult
154619165,15461916,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Hepatic function abnormal,,2018,Q4,5,F,20180924.0,20181128.0,20181003,20181130,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-048431",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,73.0,KG,20181130.0,,MD,BR,BR,2018,Q4,Elderly
154619165,15461916,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,,,FILM-COATED TABLET,,2018,Q4,Hepatic function abnormal,,2018,Q4,5,F,20180924.0,20181128.0,20181003,20181130,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-048431",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,73.0,KG,20181130.0,,MD,BR,BR,2018,Q4,Elderly
154652612,15465261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q4,Cerebral infarction,,2018,Q4,2,F,201807.0,20181031.0,20181004,20181107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-005221",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,,,20181107.0,,MD,JP,JP,2018,Q4,Adult
154652612,15465261,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q4,Dehydration,,2018,Q4,2,F,201807.0,20181031.0,20181004,20181107,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-005221",BOEHRINGER INGELHEIM,,61.0,YR,,M,Y,,,20181107.0,,MD,JP,JP,2018,Q4,Adult
154695742,15469574,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Acute coronary syndrome,,2018,Q4,2,F,20180914.0,20180921.0,20181005,20181019,EXP,,GB-SA-2018SA264566,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20181019.0,,MD,GB,GB,2018,Q4,Elderly
154759751,15475975,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,10.0,MG,,BID,2018,Q4,Deep vein thrombosis,,2018,Q4,1,I,,20181001.0,20181009,20181009,EXP,,PHHY2018ES118084,SANDOZ,,74.0,YR,,F,Y,,,20181009.0,,OT,ES,ES,2018,Q4,Elderly
154759751,15475975,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,10.0,MG,,BID,2018,Q4,Hypoglycaemia,,2018,Q4,1,I,,20181001.0,20181009,20181009,EXP,,PHHY2018ES118084,SANDOZ,,74.0,YR,,F,Y,,,20181009.0,,OT,ES,ES,2018,Q4,Elderly
154759751,15475975,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,, UNKNOWN,,,10.0,MG,,BID,2018,Q4,Weight decreased,,2018,Q4,1,I,,20181001.0,20181009,20181009,EXP,,PHHY2018ES118084,SANDOZ,,74.0,YR,,F,Y,,,20181009.0,,OT,ES,ES,2018,Q4,Elderly
154792681,15479268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q4,Abdominal pain,,2018,Q4,1,I,20180826.0,,20181003,20181003,DIR,,,FDA-CTU,,82.0,YR,,M,N,77.6,KG,20180921.0,N,MD,US,US,2018,Q4,Elderly
154792681,15479268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q4,Cholecystitis acute,,2018,Q4,1,I,20180826.0,,20181003,20181003,DIR,,,FDA-CTU,,82.0,YR,,M,N,77.6,KG,20180921.0,N,MD,US,US,2018,Q4,Elderly
154792681,15479268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20180826.0,,20181003,20181003,DIR,,,FDA-CTU,,82.0,YR,,M,N,77.6,KG,20180921.0,N,MD,US,US,2018,Q4,Elderly
154822311,15482231,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,5.0,MG,,BID,2018,Q4,Deep vein thrombosis,,2018,Q4,1,I,,20180930.0,20181010,20181010,EXP,,ES-BAUSCH-BL-2018-027102,BAUSCH AND LOMB,,74.0,YR,,F,Y,,,20181010.0,,MD,ES,ES,2018,Q4,Elderly
154822311,15482231,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,5.0,MG,,BID,2018,Q4,Hypoglycaemia,,2018,Q4,1,I,,20180930.0,20181010,20181010,EXP,,ES-BAUSCH-BL-2018-027102,BAUSCH AND LOMB,,74.0,YR,,F,Y,,,20181010.0,,MD,ES,ES,2018,Q4,Elderly
154822311,15482231,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,5.0,MG,,BID,2018,Q4,Weight decreased,,2018,Q4,1,I,,20180930.0,20181010,20181010,EXP,,ES-BAUSCH-BL-2018-027102,BAUSCH AND LOMB,,74.0,YR,,F,Y,,,20181010.0,,MD,ES,ES,2018,Q4,Elderly
154838191,15483819,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2018,Q4,Genital infection fungal,,2018,Q4,1,I,20180806.0,,20181003,20181003,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20180911.0,N,PH,US,US,2018,Q4,Elderly
154858491,15485849,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2018,Q4,Deep vein thrombosis,,2018,Q4,1,I,,20180928.0,20181011,20181011,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092942,BRISTOL MYERS SQUIBB,,74.0,YR,,F,Y,,,20181010.0,,MD,ES,ES,2018,Q4,Elderly
154858491,15485849,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2018,Q4,Hypoglycaemia,,2018,Q4,1,I,,20180928.0,20181011,20181011,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092942,BRISTOL MYERS SQUIBB,,74.0,YR,,F,Y,,,20181010.0,,MD,ES,ES,2018,Q4,Elderly
154858491,15485849,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,,,,,,5.0,MG,,BID,2018,Q4,Weight decreased,,2018,Q4,1,I,,20180928.0,20181011,20181011,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092942,BRISTOL MYERS SQUIBB,,74.0,YR,,F,Y,,,20181010.0,,MD,ES,ES,2018,Q4,Elderly
154880581,15488058,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2018,Q4,Pollakiuria,,2018,Q4,1,I,20180824.0,,20181003,20181003,DIR,,,FDA-CTU,,91.0,YR,,M,N,,,20180914.0,N,PH,US,US,2018,Q4,Elderly
154881661,15488166,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2018,Q4,Nausea,,2018,Q4,1,I,20180904.0,,20181003,20181003,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20180924.0,N,PH,US,US,2018,Q4,Adult
154881661,15488166,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2018,Q4,Vomiting,,2018,Q4,1,I,20180904.0,,20181003,20181003,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20180924.0,N,PH,US,US,2018,Q4,Adult
154909241,15490924,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY,5 MG, TWO TIMES A DAY",,,,, UNKNOWN,,,10.0,MG,,,2018,Q4,Deep vein thrombosis,,2018,Q4,1,I,,20180928.0,20181012,20181012,EXP,,ES-AUROBINDO-AUR-APL-2018-049600,AUROBINDO,,74.0,YR,,F,Y,,,20181012.0,,MD,ES,ES,2018,Q4,Elderly
154909241,15490924,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY,5 MG, TWO TIMES A DAY",,,,, UNKNOWN,,,10.0,MG,,,2018,Q4,Hypoglycaemia,,2018,Q4,1,I,,20180928.0,20181012,20181012,EXP,,ES-AUROBINDO-AUR-APL-2018-049600,AUROBINDO,,74.0,YR,,F,Y,,,20181012.0,,MD,ES,ES,2018,Q4,Elderly
154909241,15490924,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY,5 MG, TWO TIMES A DAY",,,,, UNKNOWN,,,10.0,MG,,,2018,Q4,Weight decreased,,2018,Q4,1,I,,20180928.0,20181012,20181012,EXP,,ES-AUROBINDO-AUR-APL-2018-049600,AUROBINDO,,74.0,YR,,F,Y,,,20181012.0,,MD,ES,ES,2018,Q4,Elderly
154911931,15491193,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, DAILY",,,U,U,,,,10.0,MG,,,2018,Q4,Hypomagnesaemia,,2018,Q4,1,I,20180816.0,20180927.0,20181012,20181012,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-187358,RANBAXY,,33.0,YR,,M,Y,,,20181012.0,,OT,GB,GB,2018,Q4,Young Adult
154935671,15493567,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Abdominal sepsis,,2018,Q4,1,I,,20181008.0,20181012,20181012,EXP,,GB-JNJFOC-20181011231,JANSSEN,,55.0,YR,A,F,Y,125.0,KG,20181012.0,,MD,GB,GB,2018,Q4,Adult
154935671,15493567,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,,20181008.0,20181012,20181012,EXP,,GB-JNJFOC-20181011231,JANSSEN,,55.0,YR,A,F,Y,125.0,KG,20181012.0,,MD,GB,GB,2018,Q4,Adult
154935671,15493567,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Enterovesical fistula,,2018,Q4,1,I,,20181008.0,20181012,20181012,EXP,,GB-JNJFOC-20181011231,JANSSEN,,55.0,YR,A,F,Y,125.0,KG,20181012.0,,MD,GB,GB,2018,Q4,Adult
154935671,15493567,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q4,Hepatic cirrhosis,,2018,Q4,1,I,,20181008.0,20181012,20181012,EXP,,GB-JNJFOC-20181011231,JANSSEN,,55.0,YR,A,F,Y,125.0,KG,20181012.0,,MD,GB,GB,2018,Q4,Adult
154935961,15493596,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2018,Q4,Pruritus,,2018,Q4,1,I,20180821.0,,20181004,20181004,DIR,,,FDA-CTU,,80.0,YR,,M,N,102.06,KG,,N,PH,US,US,2018,Q4,Elderly
154935961,15493596,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2018,Q4,Rash,,2018,Q4,1,I,20180821.0,,20181004,20181004,DIR,,,FDA-CTU,,80.0,YR,,M,N,102.06,KG,,N,PH,US,US,2018,Q4,Elderly
154935961,15493596,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2018,Q4,Urticaria,,2018,Q4,1,I,20180821.0,,20181004,20181004,DIR,,,FDA-CTU,,80.0,YR,,M,N,102.06,KG,,N,PH,US,US,2018,Q4,Elderly
155026981,15502698,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q4,Anion gap increased,,2018,Q4,1,I,20181001.0,,20181008,20181008,DIR,,,FDA-CTU,,35.0,YR,,F,N,116.6,KG,20181008.0,N,PH,US,US,2018,Q4,Adult
155026981,15502698,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q4,Dizziness,,2018,Q4,1,I,20181001.0,,20181008,20181008,DIR,,,FDA-CTU,,35.0,YR,,F,N,116.6,KG,20181008.0,N,PH,US,US,2018,Q4,Adult
155026981,15502698,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q4,Dyspnoea,,2018,Q4,1,I,20181001.0,,20181008,20181008,DIR,,,FDA-CTU,,35.0,YR,,F,N,116.6,KG,20181008.0,N,PH,US,US,2018,Q4,Adult
155026981,15502698,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q4,Euglycaemic diabetic ketoacidosis,,2018,Q4,1,I,20181001.0,,20181008,20181008,DIR,,,FDA-CTU,,35.0,YR,,F,N,116.6,KG,20181008.0,N,PH,US,US,2018,Q4,Adult
155026981,15502698,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q4,Nausea,,2018,Q4,1,I,20181001.0,,20181008,20181008,DIR,,,FDA-CTU,,35.0,YR,,F,N,116.6,KG,20181008.0,N,PH,US,US,2018,Q4,Adult
155026981,15502698,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2018,Q4,Palpitations,,2018,Q4,1,I,20181001.0,,20181008,20181008,DIR,,,FDA-CTU,,35.0,YR,,F,N,116.6,KG,20181008.0,N,PH,US,US,2018,Q4,Adult
155218181,15521818,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q4,Arthralgia,,2018,Q4,1,I,20181011.0,,20181018,20181018,DIR,,,FDA-CTU,,59.0,YR,,M,N,110.25,KG,20181018.0,N,CN,US,US,2018,Q4,Adult
155218181,15521818,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q4,Pain in extremity,,2018,Q4,1,I,20181011.0,,20181018,20181018,DIR,,,FDA-CTU,,59.0,YR,,M,N,110.25,KG,20181018.0,N,CN,US,US,2018,Q4,Adult
155218181,15521818,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q4,Post procedural complication,,2018,Q4,1,I,20181011.0,,20181018,20181018,DIR,,,FDA-CTU,,59.0,YR,,M,N,110.25,KG,20181018.0,N,CN,US,US,2018,Q4,Adult
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Anaemia,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood cholesterol increased,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood glucose increased,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood pressure fluctuation,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Blood uric acid increased,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Cardiomegaly,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Carotid arteriosclerosis,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Chest discomfort,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Decreased ventricular preload,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Dyspnoea exertional,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Electrocardiogram abnormal,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Hepatic lesion,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Ischaemia,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Myocardial ischaemia,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Renal impairment,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155382761,15538276,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,D,,,,,1.0,DF,TABLET,QD,2018,Q4,Transient ischaemic attack,,2018,Q4,1,I,,20181017.0,20181022,20181022,EXP,,HU-MYLANLABS-2018M1078419,MYLAN,SZLADEK H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT.. HAZIORVOS TOVABBKEPZO SZEMLE.. 2018;23:243-5,65.0,YR,,M,Y,,,20181021.0,,OT,HU,HU,2018,Q4,Elderly
155430892,15543089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Chronic kidney disease,,2018,Q4,2,F,20180912.0,20181030.0,20181023,20181105,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-047249",BOEHRINGER INGELHEIM,,66.0,YR,,F,Y,80.3,KG,20181105.0,,MD,BR,BR,2018,Q4,Elderly
155430892,15543089,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Hypertensive encephalopathy,,2018,Q4,2,F,20180912.0,20181030.0,20181023,20181105,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-047249",BOEHRINGER INGELHEIM,,66.0,YR,,F,Y,80.3,KG,20181105.0,,MD,BR,BR,2018,Q4,Elderly
155504461,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Alanine aminotransferase increased,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Blood alkaline phosphatase increased,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Cystitis,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Alanine aminotransferase increased,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Blood alkaline phosphatase increased,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Cystitis,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155504461,15550446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,1,I,20170613.0,20171004.0,20181025,20181025,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005802",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,52.4,KG,20181025.0,,MD,JP,JP,2018,Q4,Elderly
155517341,15551734,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2018,Q4,Euglycaemic diabetic ketoacidosis,,2018,Q4,1,I,,20181011.0,20181025,20181025,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-03437",IMPAX,"IYER P, THOSANI SN. EUGLYCEMIC DKA AS AN INITIAL PRESENTATION OF IMMUNOTHERAPY-INDUCED INSULIN-DEPENDENT DIABETES. DIABETES. 2018;67(SUPPL 1):A321",68.0,YR,,M,Y,,,20181024.0,,OT,US,US,2018,Q4,Elderly
155519851,15551985,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,,QD,2018,Q4,Cholestasis,,2018,Q4,1,I,,20170818.0,20181025,20181025,EXP,,MY-ASTRAZENECA-2017SE84085,ASTRAZENECA,,33.0,YR,,M,Y,,,20181025.0,,OT,MY,MY,2018,Q4,Young Adult
155523671,15552367,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, ONCE DAILY",,,Y,U,,,,25.0,MG,,QD,2018,Q4,Euglycaemic diabetic ketoacidosis,,2018,Q4,1,I,,20181011.0,20181025,20181025,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-03431",IMPAX,"RAFIQ A, ALI Z, ABBAS H, ARIF Z, MCGRATH GA. DIABETIC KETOACIDOSIS WITHOUT HYPERGLYCEMIA IN A PATIENT TREATED WITH EMPAGLIFLOZIN-A KNOWN ADVERSE EFFECT WITH LESSER KNOWN ASSOCIATIONS. ENDOCR REV. 2018;39(2SUPPL 1)",55.0,YR,,M,Y,,,20181025.0,,OT,US,US,2018,Q4,Adult
155523671,15552367,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, ONCE DAILY",,,Y,U,,,,25.0,MG,,QD,2018,Q4,Wound infection,,2018,Q4,1,I,,20181011.0,20181025,20181025,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-03431",IMPAX,"RAFIQ A, ALI Z, ABBAS H, ARIF Z, MCGRATH GA. DIABETIC KETOACIDOSIS WITHOUT HYPERGLYCEMIA IN A PATIENT TREATED WITH EMPAGLIFLOZIN-A KNOWN ADVERSE EFFECT WITH LESSER KNOWN ASSOCIATIONS. ENDOCR REV. 2018;39(2SUPPL 1)",55.0,YR,,M,Y,,,20181025.0,,OT,US,US,2018,Q4,Adult
155557961,15555796,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,,20181011.0,20181026,20181026,EXP,,"IE-IMPAX LABORATORIES, INC-2018-IPXL-03451",IMPAX,"GARRAHY A, BYRNE MM. UNEXPECTED DIABETIC KETOACIDOSIS IN TWO PATIENTS WITH TYPE 2 DIABETES, CAUSE OR COINCIDENCE WITH USE OF SGLT2 INHIBITORS: A REPORT OF TWO CASES. IR J MED SCI. 2017;186(9 SUPPL 1):S365",70.0,YR,,F,Y,,,20181026.0,,OT,IE,IE,2018,Q4,Elderly
155557961,15555796,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2018,Q4,Renal impairment,,2018,Q4,1,I,,20181011.0,20181026,20181026,EXP,,"IE-IMPAX LABORATORIES, INC-2018-IPXL-03451",IMPAX,"GARRAHY A, BYRNE MM. UNEXPECTED DIABETIC KETOACIDOSIS IN TWO PATIENTS WITH TYPE 2 DIABETES, CAUSE OR COINCIDENCE WITH USE OF SGLT2 INHIBITORS: A REPORT OF TWO CASES. IR J MED SCI. 2017;186(9 SUPPL 1):S365",70.0,YR,,F,Y,,,20181026.0,,OT,IE,IE,2018,Q4,Elderly
155603241,15560324,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,TABLET,QD,2018,Q4,Hypotension,,2018,Q4,1,I,,20180823.0,20181029,20181029,EXP,,GB-NOVOPROD-618370,NOVO NORDISK,,55.0,YR,A,M,Y,86.0,KG,20181029.0,,CN,GB,GB,2018,Q4,Adult
155603241,15560324,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,TABLET,QD,2018,Q4,Incorrect dose administered by product,,2018,Q4,1,I,,20180823.0,20181029,20181029,EXP,,GB-NOVOPROD-618370,NOVO NORDISK,,55.0,YR,A,M,Y,86.0,KG,20181029.0,,CN,GB,GB,2018,Q4,Adult
155603241,15560324,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,TABLET,QD,2018,Q4,Myocardial infarction,,2018,Q4,1,I,,20180823.0,20181029,20181029,EXP,,GB-NOVOPROD-618370,NOVO NORDISK,,55.0,YR,A,M,Y,86.0,KG,20181029.0,,CN,GB,GB,2018,Q4,Adult
155603241,15560324,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,,,,,,10.0,MG,TABLET,QD,2018,Q4,Palpitations,,2018,Q4,1,I,,20180823.0,20181029,20181029,EXP,,GB-NOVOPROD-618370,NOVO NORDISK,,55.0,YR,A,M,Y,86.0,KG,20181029.0,,CN,GB,GB,2018,Q4,Adult
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Asthenia,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Emotional disorder,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Fatigue,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Headache,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Malaise,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Muscular weakness,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155610261,15561026,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2018,Q4,Weight increased,,2018,Q4,1,I,,20181023.0,20181029,20181029,PER,,US-PFIZER INC-2018436385,PFIZER,,67.0,YR,,M,Y,,,20181029.0,,CN,US,US,2018,Q4,Elderly
155628853,15562885,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Gastrointestinal haemorrhage,,2018,Q4,3,F,201708.0,20181107.0,20181029,20181114,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006649",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,63.6,KG,20181114.0,,MD,JP,JP,2018,Q4,Adult
155628853,15562885,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,BID,2018,Q4,Gastrointestinal haemorrhage,,2018,Q4,3,F,201708.0,20181107.0,20181029,20181114,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-006649",BOEHRINGER INGELHEIM,,57.0,YR,,M,Y,63.6,KG,20181114.0,,MD,JP,JP,2018,Q4,Adult
155630551,15563055,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2018,Q4,Anaemia,,2018,Q4,1,I,20181009.0,20181025.0,20181029,20181029,EXP,,DK-ASTRAZENECA-2018SF40742,ASTRAZENECA,,22204.0,DY,,F,Y,,,20181029.0,,MD,DK,DK,2018,Q4,Elderly
155656371,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Fibrous histiocytoma,,2018,Q4,1,I,20160727.0,20170925.0,20181030,20181030,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20181030.0,,MD,JP,JP,2018,Q4,Adult
155656371,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Peritonitis,,2018,Q4,1,I,20160727.0,20170925.0,20181030,20181030,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20181030.0,,MD,JP,JP,2018,Q4,Adult
155656371,15565637,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Vulvovaginal candidiasis,,2018,Q4,1,I,20160727.0,20170925.0,20181030,20181030,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-005581",BOEHRINGER INGELHEIM,,45.0,YR,,F,Y,76.0,KG,20181030.0,,MD,JP,JP,2018,Q4,Adult
155706441,15570644,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,,2018,Q4,Breast cancer,,2018,Q4,1,I,201712.0,20181022.0,20181031,20181031,EXP,,IT-BAUSCH-BL-2018-029289,BAUSCH AND LOMB,,64.0,YR,,F,Y,,,20181031.0,,CN,IT,IT,2018,Q4,Adult
155722442,15572244,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2018,Q4,Drug ineffective,,2018,Q4,2,F,201106.0,20181108.0,20181031,20181113,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20181113.0,,MD,SK,SK,2018,Q4,Elderly
155722442,15572244,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2018,Q4,Myocardial infarction,,2018,Q4,2,F,201106.0,20181108.0,20181031,20181113,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20181113.0,,MD,SK,SK,2018,Q4,Elderly
155722442,15572244,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, UNK",,,D,,,,,10.0,MG,,,2018,Q4,Weight increased,,2018,Q4,2,F,201106.0,20181108.0,20181031,20181113,EXP,,SK-MYLANLABS-2018M1081194,MYLAN,POLKO J.. GLYCEMIA COMPENSATION IN A PATIENT WITH TYPE 2. DIABETES MELLITUS AND CARDIAL PRIMORBIDITY. INTERNA MEDICINA. 2018;2:10-11,66.0,YR,,M,Y,,,20181113.0,,MD,SK,SK,2018,Q4,Elderly
155774612,15577461,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Malignant neoplasm of unknown primary site,,2018,Q4,2,F,20170221.0,20181102.0,20181102,20181105,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-005743",BOEHRINGER INGELHEIM,,80.0,YR,,F,Y,49.9,KG,20181105.0,,MD,JP,JP,2018,Q4,Elderly
155802841,15580284,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,QD,2018,Q4,Debridement,,2018,Q4,1,I,20181101.0,,20181102,20181102,DIR,,,FDA-CTU,,33.0,YR,,M,N,206.0,KG,20181102.0,Y,PH,US,US,2018,Q4,Young Adult
155802841,15580284,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,QD,2018,Q4,Fournier's gangrene,,2018,Q4,1,I,20181101.0,,20181102,20181102,DIR,,,FDA-CTU,,33.0,YR,,M,N,206.0,KG,20181102.0,Y,PH,US,US,2018,Q4,Young Adult
155802841,15580284,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,QD,2018,Q4,Leukocytosis,,2018,Q4,1,I,20181101.0,,20181102,20181102,DIR,,,FDA-CTU,,33.0,YR,,M,N,206.0,KG,20181102.0,Y,PH,US,US,2018,Q4,Young Adult
155873271,15587327,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2018,Q4,Urinary tract infection,,2018,Q4,1,I,20181018.0,,20181101,20181101,DIR,,,FDA-CTU,,78.0,YR,,M,N,83.46,KG,20181029.0,N,PH,US,US,2018,Q4,Elderly
156034203,15603420,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Cerebral infarction,,2018,Q4,3,F,20180110.0,20181208.0,20181109,20181216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004378",BOEHRINGER INGELHEIM,,43.0,YR,,M,Y,120.1,KG,20181217.0,,MD,JP,JP,2018,Q4,Adult
156034203,15603420,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Infarction,,2018,Q4,3,F,20180110.0,20181208.0,20181109,20181216,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004378",BOEHRINGER INGELHEIM,,43.0,YR,,M,Y,120.1,KG,20181217.0,,MD,JP,JP,2018,Q4,Adult
156038771,15603877,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,Y,,,,,25.0,MG,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,,20181106.0,20181109,20181109,EXP,,IL-ALLERGAN-1852591US,ALLERGAN,,66.0,YR,,M,Y,,,20181109.0,,MD,IL,IL,2018,Q4,Elderly
156038771,15603877,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,Y,,,,,25.0,MG,,,2018,Q4,Contraindicated product prescribed,,2018,Q4,1,I,,20181106.0,20181109,20181109,EXP,,IL-ALLERGAN-1852591US,ALLERGAN,,66.0,YR,,M,Y,,,20181109.0,,MD,IL,IL,2018,Q4,Elderly
156047721,15604772,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,D,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181110.0,,20181110,20181110,DIR,,,FDA-CTU,,47.0,YR,,M,N,93.8,KG,20181110.0,N,PH,US,US,2018,Q4,Adult
156130291,15613029,5,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2018,Q4,Blindness,,2018,Q4,1,I,,20181105.0,20181113,20181113,EXP,,ES-CELGENEUS-ESP-20181101555,CELGENE,,73.0,YR,,M,Y,,,20181113.0,,OT,ES,ES,2018,Q4,Elderly
156130291,15613029,5,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2018,Q4,Keratitis,,2018,Q4,1,I,,20181105.0,20181113,20181113,EXP,,ES-CELGENEUS-ESP-20181101555,CELGENE,,73.0,YR,,M,Y,,,20181113.0,,OT,ES,ES,2018,Q4,Elderly
156262411,15626241,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2018,Q4,Urinary incontinence,,2018,Q4,1,I,20180814.0,,20181112,20181112,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20180928.0,N,PH,US,US,2018,Q4,Elderly
156412952,15641295,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2018,Q4,Acute kidney injury,,2018,Q4,2,F,,20181112.0,20181120,20181120,EXP,,PHHY2018IL155029,NOVARTIS,,66.0,YR,,M,Y,,,20181121.0,,OT,IL,IL,2018,Q4,Elderly
156468761,15646876,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,175.042,DF,,,,,,1.0,DF,,QD,2018,Q4,Bradycardia,,2018,Q4,1,I,20181030.0,20181114.0,20181122,20181122,EXP,,GB-ASTRAZENECA-2018SF50425,ASTRAZENECA,,73.0,YR,,F,Y,79.0,KG,20181122.0,,MD,GB,GB,2018,Q4,Elderly
156468761,15646876,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,175.042,DF,,,,,,1.0,DF,,QD,2018,Q4,Flushing,,2018,Q4,1,I,20181030.0,20181114.0,20181122,20181122,EXP,,GB-ASTRAZENECA-2018SF50425,ASTRAZENECA,,73.0,YR,,F,Y,79.0,KG,20181122.0,,MD,GB,GB,2018,Q4,Elderly
156468761,15646876,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,175.042,DF,,,,,,1.0,DF,,QD,2018,Q4,Paraesthesia oral,,2018,Q4,1,I,20181030.0,20181114.0,20181122,20181122,EXP,,GB-ASTRAZENECA-2018SF50425,ASTRAZENECA,,73.0,YR,,F,Y,79.0,KG,20181122.0,,MD,GB,GB,2018,Q4,Elderly
156592721,15659272,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,25.0,MG,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,,20181119.0,20181127,20181127,EXP,,IL-TEVA-2018-IL-980107,TEVA,"PERLMAN A, HEYMAN SN, STOKAR J, DARMON D, MUSZKAT M, SZALAT A. CLINICAL SPECTRUM AND MECHANISM OF ACUTE KIDNEY INJURY IN PATIENTS WITH DIABETES MELLITUS ON SGLT-2 INHIBITORS. ISR-MED-ASSOC-J 2018;20(8):513-516.",61.0,YR,,M,Y,,,20181127.0,,MD,IL,IL,2018,Q4,Adult
156592771,15659277,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,,20181119.0,20181127,20181127,EXP,,IL-TEVA-2018-IL-980106,TEVA,"PERLMAN A, HEYMAN SN, STOKAR J, DARMON D, MUSZKAT M, SZALAT A. CLINICAL SPECTRUM AND MECHANISM OF ACUTE KIDNEY INJURY IN PATIENTS WITH DIABETES MELLITUS ON SGLT-2 INHIBITORS. ISR-MED-ASSOC-J 2018;20(8):513-516.",62.0,YR,,M,Y,,,20181127.0,,MD,IL,IL,2018,Q4,Adult
156592801,15659280,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,25.0,MG,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,,20181119.0,20181127,20181127,EXP,,IL-TEVA-2018-IL-980113,TEVA,"PERLMAN A, HEYMAN SN, STOKAR J, DARMON D, MUSZKAT M, SZALAT A. CLINICAL SPECTRUM AND MECHANISM OF ACUTE KIDNEY INJURY IN PATIENTS WITH DIABETES MELLITUS ON SGLT-2 INHIBITORS. ISR-MED-ASSOC-J 2018;20(8):513-516.",66.0,YR,,M,Y,,,20181127.0,,MD,IL,IL,2018,Q4,Elderly
156684341,15668434,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,Y,,,,,25.0,MG,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,,20181114.0,20181129,20181129,EXP,,IL-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-192267,RANBAXY,,66.0,YR,,M,Y,,,20181129.0,,MD,IL,IL,2018,Q4,Elderly
156684341,15668434,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,Y,,,,,25.0,MG,,,2018,Q4,Nephropathy toxic,,2018,Q4,1,I,,20181114.0,20181129,20181129,EXP,,IL-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-192267,RANBAXY,,66.0,YR,,M,Y,,,20181129.0,,MD,IL,IL,2018,Q4,Elderly
156684341,15668434,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,Y,,,,,25.0,MG,,,2018,Q4,Renal impairment,,2018,Q4,1,I,,20181114.0,20181129,20181129,EXP,,IL-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-192267,RANBAXY,,66.0,YR,,M,Y,,,20181129.0,,MD,IL,IL,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Chronic kidney disease,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Hyperglycaemia,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Hypovolaemia,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Peripheral ischaemia,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Polyuria,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156762351,15676235,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,FILM-COATED TABLET,,2018,Q4,Splenic infarction,,2018,Q4,1,I,20180518.0,20181119.0,20181130,20181130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-110621,BRISTOL MYERS SQUIBB,,76.0,YR,,M,Y,105.3,KG,20181130.0,,OT,US,US,2018,Q4,Elderly
156770111,15677011,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Cardiac failure,,2018,Q4,1,I,20181012.0,20181126.0,20181130,20181130,EXP,,"CO-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-057465",BOEHRINGER INGELHEIM,,69.0,YR,,F,Y,,,20181130.0,,MD,CO,CO,2018,Q4,Elderly
156855742,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Hyperkalaemia,,2018,Q4,2,F,20181018.0,20181205.0,20181204,20181210,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20181210.0,,MD,AU,AU,2018,Q4,Elderly
156855742,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Hypotension,,2018,Q4,2,F,20181018.0,20181205.0,20181204,20181210,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20181210.0,,MD,AU,AU,2018,Q4,Elderly
156855742,15685574,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,FILM-COATED TABLET,,2018,Q4,Renal impairment,,2018,Q4,2,F,20181018.0,20181205.0,20181204,20181210,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-051737",BOEHRINGER INGELHEIM,,69.0,YR,,M,Y,126.0,KG,20181210.0,,MD,AU,AU,2018,Q4,Elderly
156936531,15693653,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,FILM-COATED TABLET,,2018,Q4,Benign prostatic hyperplasia,,2018,Q4,1,I,,20181129.0,20181206,20181206,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113188,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,111.6,KG,20181206.0,,OT,US,US,2018,Q4,Elderly
156936531,15693653,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,FILM-COATED TABLET,,2018,Q4,Chronic kidney disease,,2018,Q4,1,I,,20181129.0,20181206,20181206,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113188,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,111.6,KG,20181206.0,,OT,US,US,2018,Q4,Elderly
156936531,15693653,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,FILM-COATED TABLET,,2018,Q4,Contraindicated product administered,,2018,Q4,1,I,,20181129.0,20181206,20181206,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113188,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,111.6,KG,20181206.0,,OT,US,US,2018,Q4,Elderly
156936531,15693653,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,FILM-COATED TABLET,,2018,Q4,Haematuria,,2018,Q4,1,I,,20181129.0,20181206,20181206,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113188,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,111.6,KG,20181206.0,,OT,US,US,2018,Q4,Elderly
156936531,15693653,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,FILM-COATED TABLET,,2018,Q4,Off label use,,2018,Q4,1,I,,20181129.0,20181206,20181206,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113188,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,111.6,KG,20181206.0,,OT,US,US,2018,Q4,Elderly
156936531,15693653,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,FILM-COATED TABLET,,2018,Q4,Product use in unapproved indication,,2018,Q4,1,I,,20181129.0,20181206,20181206,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113188,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,111.6,KG,20181206.0,,OT,US,US,2018,Q4,Elderly
156978321,15697832,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,,2018,Q4,Pyelitis,,2018,Q4,1,I,20181009.0,,20181126,20181126,DIR,,,FDA-CTU,,45.0,YR,,M,N,,,20181029.0,N,PH,US,US,2018,Q4,Adult
156978321,15697832,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,,2018,Q4,Sepsis,,2018,Q4,1,I,20181009.0,,20181126,20181126,DIR,,,FDA-CTU,,45.0,YR,,M,N,,,20181029.0,N,PH,US,US,2018,Q4,Adult
156978321,15697832,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,,2018,Q4,Systemic candida,,2018,Q4,1,I,20181009.0,,20181126,20181126,DIR,,,FDA-CTU,,45.0,YR,,M,N,,,20181029.0,N,PH,US,US,2018,Q4,Adult
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Abdominal pain,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Abdominal pain upper,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Asthenia,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Constipation,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Diarrhoea,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Dysuria,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Nausea,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Pollakiuria,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Pyrexia,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Urticaria,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157033391,15703339,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 MG;OTHER FREQUENCY:AM;?,,,Y,D,,,,,,,,2018,Q4,Vomiting,,2018,Q4,1,I,20181120.0,,20181127,20181127,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20181120.0,N,PH,US,US,2018,Q4,Elderly
157042871,15704287,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,1,I,20180908.0,,20181210,20181210,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20181210.0,N,,US,US,2018,Q4,Elderly
157042871,15704287,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20180908.0,,20181210,20181210,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20181210.0,N,,US,US,2018,Q4,Elderly
157201391,15720139,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Diabetic gangrene,,2018,Q4,1,I,20180220.0,20180726.0,20181213,20181213,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-004126",BOEHRINGER INGELHEIM,,68.0,YR,,M,Y,81.0,KG,20181213.0,,MD,JP,JP,2018,Q4,Elderly
157203632,15720363,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,204629.0,,,FILM-COATED TABLET,,2018,Q4,Hepatic function abnormal,,2018,Q4,2,F,20181121.0,20181214.0,20181213,20181219,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-057672",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,85.0,KG,20181219.0,,MD,CN,CN,2018,Q4,Adult
157234731,15723473,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,(1-0-0),,,,,,,,,,,,2018,Q4,Diabetes mellitus inadequate control,,2018,Q4,1,I,201810.0,20181206.0,20181214,20181214,EXP,,DE-ASTRAZENECA-2018SF61693,ASTRAZENECA,,74.0,YR,,F,Y,64.0,KG,20181214.0,,MD,DE,DE,2018,Q4,Elderly
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Cholestasis,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Discomfort,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Diverticulum,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Dysbacteriosis,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Gastrooesophageal reflux disease,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Helicobacter infection,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Pancreatitis acute,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Pleural effusion,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Surgery,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157241071,15724107,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,12.5 MG/DAY,,,,,,,,,,,QD,2018,Q4,Weight decreased,,2018,Q4,1,I,2018.0,20181115.0,20181214,20181214,EXP,,CL-009507513-1811CHL007471,MERCK,,58.0,YR,,M,Y,,,20181214.0,,OT,SI,CL,2018,Q4,Adult
157262511,15726251,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181121.0,20181210.0,20181216,20181216,EXP,GB-MHRA-EYC 00190646,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-12-004025",BOEHRINGER INGELHEIM,,71.0,YR,,M,Y,90.15,KG,20181217.0,,CN,GB,GB,2018,Q4,Elderly
157353311,15735331,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,D,, UNKNOWN,,,25.0,MG,,QD,2018,Q4,Exposure during pregnancy,,2018,Q4,1,I,,20180405.0,20181218,20181218,PER,,IT-ALKEM LABORATORIES LIMITED-IT-ALKEM-2018-02365,ALKEM,"FORMOSO G, GINESTRA F, DALMAZI GD AND CONSOLI A.. EMPAGLIFLOZIN, METFORMIN AND INSULIN DEGLUDEC, DURING PREGNANCY: A CASE REPORT. ACTA DIABETOLOGICA.. 2018;55(7):759-761",31.0,YR,,F,Y,,,20181218.0,,OT,IT,IT,2018,Q4,Young Adult
157412181,15741218,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,1.0,DF,,QD,2018,Q4,Fournier's gangrene,,2018,Q4,1,I,20181003.0,,20181204,20181204,DIR,,,FDA-CTU,,74.0,YR,,M,N,63.96,KG,20181203.0,N,PH,US,US,2018,Q4,Elderly
157458521,15745852,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q4,Liver abscess,,2018,Q4,1,I,20181109.0,20181114.0,20181220,20181220,EXP,,JP-PFIZER INC-2018470268,PFIZER,,71.0,YR,,M,Y,66.3,KG,20181220.0,,MD,JP,JP,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Abdominal distension,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Abdominal pain,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Blood glucose increased,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Blood pressure increased,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Blood sodium abnormal,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Blood urea abnormal,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Body temperature abnormal,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Bowel movement irregularity,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Complication associated with device,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Constipation,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Flatulence,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Gastrointestinal motility disorder,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Ileus,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Intestinal obstruction,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Nausea,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Pain,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Pulse abnormal,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,Retching,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157503941,15750394,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2018,Q4,White blood cell disorder,,2018,Q4,1,I,,20181212.0,20181221,20181221,EXP,,PHHY2018US188551,NOVARTIS,,76.0,YR,,M,Y,80.4,KG,20181221.0,,OT,US,US,2018,Q4,Elderly
157506131,15750613,19,C,EMPAGLIFLOZIN (JARDIANCE),,2,,,,,,,,,,,,,,2018,Q4,Penile discharge,,2018,Q4,1,I,20180810.0,,20181221,20181221,DIR,,,FDA-CTU,,76.0,YR,,M,N,114.75,KG,20181221.0,N,CN,US,US,2018,Q4,Elderly
157608381,15760838,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Seasonal allergy,,2018,Q4,1,I,20160531.0,20181219.0,20181226,20181226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006647",BOEHRINGER INGELHEIM,,54.0,YR,,F,Y,60.5,KG,20181226.0,,MD,JP,JP,2018,Q4,Adult
157608381,15760838,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,10.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,1,I,20160531.0,20181219.0,20181226,20181226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006647",BOEHRINGER INGELHEIM,,54.0,YR,,F,Y,60.5,KG,20181226.0,,MD,JP,JP,2018,Q4,Adult
157608381,15760838,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Seasonal allergy,,2018,Q4,1,I,20160531.0,20181219.0,20181226,20181226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006647",BOEHRINGER INGELHEIM,,54.0,YR,,F,Y,60.5,KG,20181226.0,,MD,JP,JP,2018,Q4,Adult
157608381,15760838,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,1,I,20160531.0,20181219.0,20181226,20181226,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-NB-006647",BOEHRINGER INGELHEIM,,54.0,YR,,F,Y,60.5,KG,20181226.0,,MD,JP,JP,2018,Q4,Adult
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Anaemia,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Blood cholesterol increased,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Blood glucose increased,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Blood pressure fluctuation,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Blood pressure increased,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Blood triglycerides increased,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Blood uric acid increased,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Cardiomegaly,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Carotid arteriosclerosis,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Chest discomfort,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Decreased ventricular preload,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Dyspnoea exertional,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,ECG signs of myocardial ischaemia,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Hepatic lesion,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Myocardial ischaemia,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157665812,15766581,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, UNK 1 TABLET, (IN THE MORNING)",,,U,,,,,1.0,DF,TABLET,,2018,Q4,Renal impairment,,2018,Q4,2,F,,20181220.0,20181227,20181231,EXP,,HU-PFIZER INC-2018523214,PFIZER,"SZLADEK, H.. PRACTICAL EXPERIENCES IN INTEGRATING COMBINATION THERAPY TO EXISTING TREATMENT. HAZIORVOS TOVABBKEPZO SZEMLE. 2018;23:243-245",65.0,YR,,M,Y,,,20181231.0,,MD,HU,HU,2018,Q4,Elderly
157689761,15768976,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,,,,,2018,Q4,Completed suicide,,2018,Q4,1,I,,20181214.0,20181228,20181228,EXP,,US-AUROBINDO-AUR-APL-2018-062130,AUROBINDO,,60.0,YR,,M,Y,,,20181228.0,,MD,US,US,2018,Q4,Adult
157718831,15771883,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Back pain,,2018,Q4,1,I,201704.0,20171130.0,20181228,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007028",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,91.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
157718831,15771883,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Blood triglycerides increased,,2018,Q4,1,I,201704.0,20171130.0,20181228,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007028",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,91.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
157718831,15771883,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Diabetes mellitus inadequate control,,2018,Q4,1,I,201704.0,20171130.0,20181228,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007028",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,91.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
157718831,15771883,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Musculoskeletal pain,,2018,Q4,1,I,201704.0,20171130.0,20181228,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007028",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,91.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
157718831,15771883,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Polycythaemia,,2018,Q4,1,I,201704.0,20171130.0,20181228,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007028",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,91.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
157718831,15771883,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,204629.0,25.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,1,I,201704.0,20171130.0,20181228,20181228,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-NB-007028",BOEHRINGER INGELHEIM,,48.0,YR,,M,Y,91.1,KG,20181228.0,,MD,JP,JP,2018,Q4,Adult
157723721,15772372,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2018,Q4,Anaphylactic reaction,,2018,Q4,1,I,20181204.0,20181219.0,20181228,20181228,EXP,SE-MPA-2018-007444,SE-FRESENIUS KABI-FK201813091,FRESENIUS KABI,,56.0,YR,,M,Y,,,20181228.0,,OT,GB,SE,2018,Q4,Adult
